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Toll-like receptors (TLR) are key pattern recognition receptors in the innate 
immune system. In particular, TLR4-mediated immune response has been 
implicated in ischaemia-induced tissue injury. Mounting evidence supports a 
detrimental role of the innate immune system in the pathophysiology of 
skeletal muscle damage in patients with critical limb ischaemia (CLI), in whom 
patient oriented functional outcomes are poor. The overall aim of this study 
was to investigate the potential role of TLR4 in skeletal muscle dysfunction 
and damage in CLI. 
The role of TLR4 in ischaemic muscle was studied with three aims: 1) To 
develop a biobank of human gastrocnemius muscle from stratified patients 
and to explore TLR4 expression and distribution in these biopsies 2) To 
investigate the TLR4 pathway and functional consequences of TLR4 
inhibition in myotubes derived from human muscle biopsies 3) To evaluate 
the therapeutic potential of modulating TLR4 signalling in ischaemic muscle 
using a relevant mouse hind-limb ischaemia model.  
TLR4 was found to be expressed in muscle biopsies, with significant 
upregulation in samples from patients with CLI. In vitro studies using cultured 
human myotubes demonstrated upregulation of TLR4 in ischaemia, with 
activation of the downstream signalling pathway. Inhibition of TLR4 prior to 
ischaemia was associated with reduced ischaemia-induced apoptosis. The 
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ischaemic muscle. Inhibition of TLR4 was associated with reduced 
inflammatory cell infiltration and diminished apoptosis in the ischaemic limb. 
In conclusion, work presented in this thesis demonstrated that TLR4 is 
upregulated and activated in ischaemic skeletal muscle in patients with CLI. 
Modulating TLR4 signalling in vitro and in vivo was associated with 
attenuation of ischaemia-induced skeletal muscle damage. This strategy 
























Peripheral arterial disease (PAD) is a progressive condition characterised by 
atherosclerotic narrowings and occlusions of the lower limb arteries. Its 
prevalence is growing predominantly due to an ageing population and it is a 
global health burden. The main treatment options in patients with critical limb 
ischaemia (CLI), the most severe form of PAD, remain limited to 
revascularisation or amputation. However, the poor functional outcomes have 
highlighted the importance of other contributory factors involved in the 
pathophysiology of the CLI.   
We have shown that in skeletal muscle of patients with CLI TLR4 activation 
occurs and contributes to inflammation and tissue damage which may in turn 
result in muscle dysfunction. Further we have successfully cultured human 
skeletal myotubes and demonstrated that TLR4 inhibition attenuates 
ischaemia-induced skeletal muscle. Finally, we have developed a murine 
model of hind-limb ischaemia which results in skeletal muscle changes that 
closely mimics those that occur in patients with CLI. Using this model, we 
were able to confirm in vivo the role of TLR4 in ischaemia induced muscle 
damage.  
Taken together, our findings suggest that pharmaceutical inhibition of the 
TLR4 pathway might be of clinical significance in patients with PAD where it 
could be used as an adjunctive treatment to improve outcomes of treatments 
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development for use in other areas, making translation to patient benefit 
feasible in a realistic timescale. 
Both the in vitro and in vivo models developed in this thesis would also be 
useful tools for further research into PAD. The in vitro myotube model would 
allow drug testing in cells from a relevant patient group whilst the in vivo 
model would facilitate evaluation of strategies targeting ischaemic muscle 
changes.  
The impact of the work performed in this thesis has so far been demonstrated 
by presentations at prestigious national and international scientific vascular 
meetings such as the Vascular Society for Great Britain and Ireland (VS), 
Society of Academic & Research Surgery (SARS), and Arteriosclerosis, 
Thrombosis and Vascular Biology (ATVB), and also publications in the 
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1.1. Peripheral Arterial Disease 
 
 1.1.1. Definition & epidemiology 
Peripheral arterial disease (PAD) is a progressive condition characterised by 
stenoses and occlusions of the peripheral arterial tree [Figure 1]. The 
prevalence of PAD is growing and is a global health burden (1). Sixteen 
percent (27million) of the population ≥55 years of age in Europe and North 
America have PAD. While up to 38% of these patients are asymptomatic, the 
rest experience some degree of symptoms ranging from mild intermittent 
claudication (IC) to the most severe form that is critical limb ischaemia (CLI). 
The European Consensus Document (1989) defined critical ischaemia of the 
limb as “persistently recurring rest pain requiring analgesia for more than 2 
weeks, or ulceration or gangrene of the foot in the presence of an ankle 
systolic pressure less than 50 mmHg (or a toe pressure less than 30 mmHg in 
diabetic patients)”. Patients with CLI who do not undergo revascularisation 
have one-year mortality and amputation rates as high as 54% and 46%, 
respectively (2, 3).  
A recent meta-analysis of 34 studies conducted by Fowkes et al. estimated 
that more than 200 million people are affected by PAD globally, with a relative 
increase in PAD prevalence of 23.5% during the first decade of the 21st 
century (4). The economic burden of PAD-related hospitalisation is high, 
especially as this debilitating condition often leads to multiple hospitalisations 
(5).  
 
 1.1.2. Management options & clinical outcomes 
Management options for patients with PAD, who suffer from mild to moderate 
IC, is mainly aimed at best medical therapy to reduce cardiovascular risk 
factors and to improve quality of life, whilst in patients with CLI 
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Despite in current treatments, the outcomes remain poor especially in 
patients with CLI (6). Outcome reports of lower limb amputations in patients 
with CLI between 2003 and 2008 in England showed an overall major 
amputation rate of 5.1 per 100,000 populations with a 16.8% in-hospital 
mortality rate. 53.3% of patients undergoing major amputation had a 
revascularisation procedure within the prior 3 years (7). Another population 
based observational cohort study between 2008 and 2013, showed that the 
cumulative incidence of major ipsilateral amputation or death in patients with 
CLI (n=10,617) was 48.8% at 36 months after their first revascularisation 
procedure (8).    
Further, increasing number of studies have demonstrated that functional 
outcomes of patients with CLI who undergo revascularisation procedures are 
poor (9, 10). Whilst limb salvage may improve quality of life in some patients, 
it does not equate to return to premorbid ambulatory or occupational status 
(11). This suggests that adjunctive treatments in addition to revascularisation 
are required to improve outcomes.  
Physician-oriented outcomes are mainly described as patency rates, limb 
salvage rates or ulcer healing rates, which do not necessarily translate into 
improvement from the patient’s point of view. Taylor et al. reported clinical 
success using patient-oriented outcome measured after lower limb 
revascularisation for ischaemic tissue loss. Revascularisation was considered 
to be clinically successful if each of the following occurred: reconstruction 
patency until wound healing, limb salvage for 1 year, maintenance of 
ambulation for 1 year, and survival for 6 months. This study showed only 
40.9% overall clinical success rate (n=277; clinical success was 44.3% and 
37% in open and endovascular revascularisation, respectively). This study 
showed that current surgical interventions for CLI are not associated with 
impressive outcomes (12).    
Cieri et al. conducted an observational retrospective cohort study to evaluate 
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infrainguinal arterial bypass or endovascular revascularisation. They recruited 
248 consecutive patients with CLI between 2006 and 2008. Only patients who 
survived the primary operation / procedure were included. The activities of 
daily living were measured using the Katz Index (9). The demographics in the 
sample group were representative of the general population of patients with 
CLI. During the study period, (mean follow up period of 16.9 +/- 10.75 months 
from revascularisation) 24 patients (9.7%) underwent major amputation, 46 
patients (11.2%) were still in rest pain and 35 patients (14.1%) showed no 
improvement in tissue loss. Fifty-nine patients (43.2%) required secondary 
procedures. Physician-orientated outcomes however were good, with 90% 
limb salvage rate and 82% patency rates at 24 months. The patency rates 
were higher in patients who had surgical bypasses than in those who had 
endovascular revascularisation (90% versus 77%, P=0.035). Despite good 
patency rates, the functional abilities failed to improve as expected [Figure 2]. 
These data suggest that successful revascularisation is not associated with 
improved functional abilities in patients with CLI (Evidence Level 1b) 
(Appendix 6).  
The impact of PAD on individuals and society is high and deserves greater 
research focus. Despite progress in vascular and endovascular techniques, 
outcomes of revascularisation remain poor. This suggests that adjunctive 
treatments in addition to revascularisation are required to improve outcomes. 
 
 1.1.3. Pathology: Atherosclerosis and skeletal muscle changes 
The risk factors associated with PAD are determined from large 
epidemiological studies and are very similar to the risk factors contributing to 
cerebrovascular disease and ischaemic heart disease. The major risk factors 
are sex, age, diabetes, hypertension and hyperlipidaemia (13). 
PAD is considered to be a set of syndromes resulting from the presence of 
occlusion or narrowing in the peripheral arterial tree. This is the result of 
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Endothelial dysfunction is a precursor to atherosclerosis and a key 
component of PAD. The endothelium actively participates in all stages of 
atherosclerotic lesion formation. Endothelial dysfunction describes changes in 
the normal homeostatic control mechanisms of the endothelium that can lead 
to the development and progression of atherosclerosis (14). In such 
situations, the endothelial function favours vasoconstriction, thrombus, 
platelet activation, migration and growth of smooth muscle cells, promotion of 
vascular inflammation, and oxidative stress. Oxidative stress, which is 
characterised by increased production of reactive oxygen species (ROS) 
[Figure 3] appears to be the common underlying factor of the risk factors of 
endothelial dysfunction and consequent PAD and other atherosclerotic 
diseases.   
Atherosclerosis is described in three stages: early, developing and mature 
lesions. Early lesions are characterised by areas of lipid deposition, which 
consist of lipid-filled macrophages and smooth muscle cells in focal areas of 
the intima. Developing lesions are fibrous plaques, which are firm and 
covered by a fibromuscular layer. Mature lesions are characterised by 
calcified fibrotic plaques, which are often symptomatic by either reducing the 
blood flow to the distal tissue, or by becoming ulcerated and causing 
thromboembolic events (15). Reduced blood supply in the lower limb results 
in arterial claudication when the balance between oxygen demand and supply 
is compromised during exercise. In patients with CLI, this balance is disrupted 
even at rest causing rest pain and tissue loss.  
In 1966, it was reported that patients with PAD who undertake regular 
exercise can improve their walking distance while mean arterial blood flow in 
the lower limb remains the same, suggesting mechanisms other than 
haemodynamic effects (16). Since then, it has been demonstrated that 
changes within the lower limb skeletal muscle occur in patients with PAD and 
contributes to the clinical manifestations and poor functional status of these 
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assessments of the skeletal muscle in patients with PAD described a 
myopathy with myofibre degeneration, alteration in the size and shape of the 
myofibres, shift of myofibre phenotype towards type I fibres, myofibre 
necrosis and fatty infiltration in patients with IC and CLI (20-22). Koutakis et 
al. quantified the morphological damage to myofibres by investigating 
gastrocnemius muscle biopsies from patients with PAD who suffered from IC, 
and showed that the morphological changes in gastrocnemius muscle of 
patients with PAD are closely linked to calf muscle strength and walking 
distance (23). 
A key element in the process of this myopathy appear to be faulty 
mitochondria that results in failure in energy regulation, ROS production and 
apoptosis. It has also been shown that PAD induces inflammation which play 
a key role in lower limb tissue damage (18). Thus, prevention and treatment 
of the muscle damage may enable us to improve the outcome of patients with 
PAD [Figure 4]. 
 
1.2. Toll-like Receptors (TLRs) 
 
 1.2.1. Innate immune system 
The innate immune system is the first line immune response to pathogens. 
The innate immune cells recognize damage-associated molecular patters 
(DAMPs) and pathogen-associated molecular patterns (PAMPs) via pattern 
recognition receptors (PRRs). DAMPs are upregulated in any injury or tissue 
damage. In case of chronic inflammation, DAMPs, such as high mobility 
group box 1 (HMGB1) and heat shock proteins (HSPs), play a vital role in the 
pathogenesis of the disease (24). HMGB1 and HSPs have been shown to be 
involved in different pathologies such as atherosclerosis and inflammatory 
bowel disease. HMGB1 has also been shown to play a significant role in 
ischaemia reperfusion injury in the liver [Table 1] (24). One of the well 
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Pathology DAMP Effect 
Atherosclerosis Apo CIII-
rich VLDL 
Stimulated TLR2 dependent monocyte 
activation and adhesion 
Brain injury HMGB1 Increased cytokines, taste aversion, fever, 




HMGB1 Increased ileal mucosal permeability and 
bacterial translocation to mesenteric 
lymph nodes 
Joint disease FNEDA 
HMGB1 
Tenascin-C 
Induced TLR4 dependent transient ankle 
swelling, cytokine synthesis, synovial 
inflammation, pannus formation, and 
induced TLR4 dependent joint 
inflammation and tissue erosion  
Liver injury  DNA 
HMGB1 
During acetaminophen induced cell death 
induced TLR9 dependent tissue injury, 
aggravated ischaemic reperfusion injury 
Lung injury HMGB1 Stimulated acute inflammatory injury, 




Induced TLR4 dependent lethality 
Table 1 – Piccinini et al. described the role of DAMPs in different pathologies 
(24) 
 
 1.2.2. TLR structure 
The mammalian TLRs can be categorized as cell membrane receptors 
(TLR1, TLR2, TLR4, TLR5, and TLR6) or intracellular receptors (TLR3, TLR7, 
TLR8, and TLR9). Both groups share a similar structure where the cell 
membrane receptors recognise ligands that are primarily present in the 
extracellular space whilst the intracellular receptors recognise the ligands that 
are primarily produced in the intracellular space.   
TLRs are type 1 transmembrane proteins with an ectodomain consisting of 
leucine-rich repeats required to recognize exogenous ligands (PAMPs or 
DAMPs); a transmembrane domain, which determines cellular localization; 
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It appears that homo-/hetero-dimerisation of TLRs and the involvement of 
different co-receptors and accessory molecules confer specificity to ligand 
detection and response (24). Most of the TLRs form homodimers, however 
TLR2 forms heterodimers with TLR1 or TLR6, and TLR4 heterodimerises with 
TLR6 (25). There is evidence that TLR4 forms a heterodimer with TLR5, and 
also with TLR1 (27, 28). Furthermore, TLR4 has been shown to form 
heterodimers with TLR1 in response to exogenous ligands such as 
lipopolysaccharide (27). Whilst the expression of TLR4 has been shown in 
skeletal muscle with its upregulation in inflammatory myopathies (29-31), its 
role in lower limb ischaemia secondary to PAD is unclear. Also, the link 
between TLR4 and TLR1 has not been investigated in CLI.  
 
 1.2.3. TLR ligands 
TLRs were initially shown to recognise and respond to conserved 
components of microbes (32). In addition to binding exogenous ligands 
derived from the pathogens, TLRs interact with endogenous molecules 
released from damaged tissues or dead cells and regulate many sterile 
inflammation processes (25, 26, 32). Endogenous TLR ligands include HSPs, 
HMGB1 and breakdown products of fibronectin, heparin sulphate and 
hyaluronic acid, which are exposed during cellular injury and death and 
extracellular matrix degradation (33). By responding to these DAMPs, TLRs 
have been implicated in a range of inflammatory and autoimmune conditions 
(34). Figure 5 shows some of the known exogenous and endogenous ligands 
of TLRs (25, 33).  
 1.2.4. TLR downstream signalling 
Downstream signalling starts upon the recognition of DAMPs or PAMPs by 
TLRs leading to the recruitment of adaptor proteins such as MyD88 and TRIF. 
Two downstream signalling pathways are involved: the MyD88-dependent 
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specific transcription factors such as NFkB, JNK and MAPK, which are 
required for inflammatory gene transcription. This in turn results in the release 
of a wide range of cytokines and inflammatory markers such as IL1, 6 and 8, 
TNFα, INFα and INFβ (25). Apart from TLR3, which only utilises the TRIF-
dependent pathway resulting in INFα secretion, all TLRs recruit MyD88. TLR4 
recruits both MyD88- and TRIF-dependent pathways. The specific TLR 
activated, its cellular localisation and the activating ligand involved all appear 
to determine which signalling pathway is activated. Heterodimerisation 
together with the involvement of accessory molecules and co-receptors such 
as MD-2 confer increasing specificity of these receptors to different ligands 
(35) [Figure 6]. 
 1.2.5. TLRs, chronic inflammation and autoimmunity 
The immune response mediated by TLRs is protective in most cases as 
pathogens are destroyed before they harm the host. However if inflammation 
becomes chronic, excessive tissue damage may occur (24, 34) [Figure 7]. 
There is increasing evidence that TLRs play a key role in developing 
inflammatory responses in conditions such as atherosclerosis and cardiac 
muscle ischaemia. TLRs have also been implicated in cerebral, renal, liver 
and myocardial ischaemia by contributing to the inflammatory process and 
the subsequent tissue injury in animal models (34, 36, 37). Previous work in 
our lab has shown that TLRs contribute to the inflammatory process in 
ischaemic muscle injury in vitro (38). 
 
 1.2.6. Therapeutic role of TLR modulation in cardiovascular dysfunction 
Whilst the role of TLRs in PAD has not been explored, there is increasing 
evidence that they play a role in cardiovascular diseases and suggesting that 
manipulation of TLR pathways may be of benefit (39). Understanding the 
molecular structure of TLRs, the downstream signalling pathways and the role 
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TLR agonists and antagonists for therapeutic purposes (40, 41). Both TLR 
activation and inhibition have been shown to be of benefit in various 
conditions by reducing the tissue inflammatory response. The effects of TLR 
agonists and antagonists appear to be dependent on the timing of 
administration of these modulators during the course of the pathology (42) 
[Figure 8]. 
 1.2.6.1. Cardiac dysfunction (Table 2) 
Ischaemic Heart Disease 
TLR2 and TLR4 are activated during myocardial ischaemia and result in 
NFkB activation with the subsequent release of inflammatory cytokines, which 
may cause injury to myocardium. TLR2 or TLR4 deficiency attenuates 
myocardial inflammation, reduces infarct size, and preserves ventricular 
function after transient ischemic injury (43-47). The potential benefits of TLR 
antagonists in myocardial ischaemia have therefore been explored.  
TLR antagonists: OPN-301 is a mouse IgG1 antibody that selectively inhibits 
TLR2 activity in mouse, pig, monkey, and humans. Arslan and colleagues 
showed that OPN-301 reduces myocardial I/R injury in a mouse model by 
downregulating NFkB signalling and therefore reducing leukocyte infiltration 
and apoptosis (43).  
The TLR4 antagonist, Eritoran, is an analogue of the lipid A portion of the 
bacterial derived LPS with long pharmacokinetics but short 
pharmacodynamics half-life. In a mouse model of myocardial ischaemia, 
Eritoran has been found to be protective by modifying the immune response 
and reducing infarct size (48). Emotional stress can contribute to the 
pathophysiology of coronary atherosclerosis by accelerating the plaque 
formation or causing an acute cardiac event in patients with advanced 
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Eritoran inhibited NFkB activity and reduced stress-related myocardial injury 
(51). 
TLR agonists: Interestingly, TLR agonists have also been found to be 
beneficial in models of myocardial ischaemia. Lipopolysaccharide (LPS) is a 
TLR4 agonist that is a major structural component of the outer wall of all 
Gram-negative bacteria. It has protective effects in cardiac ischaemia 
(Zacharowski et al., 2000, Ha et al., 2008) via TLR4-induced MyD88-
dependent pathway activation (52). The cardioprotective effect of LPS 
appears between 12-24 hours after LPS administration (53). TLR4 also has 
cardioprotective effects by enhancing the production of inducible nitric oxide 
synthase (iNOS) (54, 55). Wang and colleagues demonstrated that activation 
of the TLR4-mediated MyD88-signalling pathway by LPS led to increased 
production of iNOS and generation of nitric oxide with improved ventricular 
function (52). Administration of low doses of TLR2 or TLR4 ligands prior to 
myocardial I/R is also associated with reduced myocardial damage. In a 
mouse model, administrating the TLR2 agonist Pam3CSK4, a synthetic 
triacylated lipopeptide that mimics the acylated amino terminus of bacterial 
lipopeptides, prior to ischaemia rendered the myocardium less susceptible to 
subsequent I/R injury and reduced myocardial damage (56). The exact 
mechanism of this protective effect is unclear, but it is thought that stimulating 
TLR with a low dose of its ligand, may precondition or reprogramme the 
signalling pathway to attenuate the inflammatory response and subsequent 
tissue damage. Serial stimulation of TLRs is associated with differential 
regulation of the MyD88-dependent and MyD88-independent signalling 
pathways (57). The initial low dose TLR ligand promotes signalling via the 
MyD88 pathway, while the subsequent stimulation results in reduced MyD88-
dependent and enhanced MyD88-independent signalling and subsequently, 




Student Number: 110091643 
 
Heart failure 
Heart failure is associated with chronic inflammation (58) and upregulation of 
TLR4 in cardiac muscle (59, 60). Absence of TLR4 prevents the increase in 
myocyte and cardiac size following pressure overload (61). The acute 
activation of TLR signalling may be beneficial in the short term, but ongoing 
tissue damage which results in chronic activation of TLRs can lead to heart 
failure (62). Both TLR antagonists and agonists have been shown to be 
protective in heart failure.  
TLR antagonists: Eritoran has also been shown to reduce cardiac 
hypertrophy in a mouse model of aortic constriction by inhibiting a TLR4-
mediated inflammatory response (63). Thus, patients with pressure 
overloaded induced heart failure may benefit from the inhibition of TLR4 
signalling. However the pharmacodynamics of Eritoran requires 
administration by a continuous infusion that would not be practical for the 
treatment of patients with chronic heart failure.  
TLR agonists: Bacillus Calmette-Guerin (BCG) is a well-recognised 
immunotherapy against tuberculosis (64). BCG has also been used for the 
treatment of patients with bladder cancer by stimulating the immune response 
via activation of TLR4 (65). The stimulation of TLR4 by BCG also prevented 
the development of pressure-induced cardiac hypertrophy and fibrosis in a 
mouse model of abdominal aortic constriction induced hypertension (66). 
Myocarditis 
Myocarditis is an inflammatory process involving the cardiac muscle and can 
be caused by infection, autoimmune diseases or toxic chemicals. Up to 20% 
of sudden cardiovascular deaths amongst young individuals are caused by 
myocarditis (67, 68). 
TLR antagonists: Coxsackievirus B3 (CVB3) is the major cause of human 
myocarditis (69, 70). In CVB3-mediated autoimmune myocarditis, TLR4 plays 
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worsening of the condition and therefore TLR4 inhibition may have 
therapeutic applications.  
 
Other compounds found to be beneficial in cardiac dysfunction have been 
found to work via anti-TLR mechanisms (42) [Table 2]. 
 
Compound Mechanism Application Reference 
Pam3CSK4 TLR2 agonist Cardiac ischaemia Mersmann 2010 
OPN-301 TLR2 antagonist Cardiac ischaemia Arslan 2010 
LPS TLR4 agonist Cardiac ischaemia Wang 2011a 
BCG TLR4 agonist Cardiac 
hypertrophy 
Liu 2008 
Eritoran TLR4 antagonist Cardiac ischaemia Shimamoto 2006 
Valsartan TLR4 inhibitor Cardiac ischaemia Yang 2009 
Atorvastatin TLR4 inhibitor Cardiac ischaemia Chansrichavala 2009 
Losartan TLR4 inhibitor Cardiac failure Ogawa 2011 
Fluvastatin TLR4 inhibitor Cardiac failure Folden 2008 
Cinnamaldehyde TLR4 inhibitor Myocarditis Ding 2010 
Geldanamycin TLR4 inhibitor Myocardial 
inflammation 
Barber 2008 
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 1.2.6.2. Vascular dysfunction  
Cerebrovascular injury (Table 3) 
Cerebrovascular diseases refer to a group of brain dysfunctions induced by 
disease of the blood vessels supplying the brain and include ischaemic and 
haemorrhagic stroke. TLRs play a key role in the post-ischaemic inflammatory 
response (IL1, IL6, TNFα) in the brain. In particular, TLR2 and TLR4 activate 
the inflammatory response and apoptotic pathways (74). TLR2 is mainly 
expressed in microglia (75) and is activated by endogenous ligands such as 
HMGB1 and HSPs (76). Intracerebral haemorrhage is responsible for up to 
20% of all strokes (77). TLR4-mediated NFkB activation plays an important 
role in the inflammatory response and cell apoptosis in intracerebral 
haemorrhage (78, 79). By activating the acute inflammatory response, TLR4 
also contributes to the pathogenesis of early brain injury in subarachnoid 
haemorrhage, the most disabling feature of aneurysmal subarachnoid 
haemorrhage (80, 81). TLR antagonists may be of benefit in patients with 
stroke by reducing the inflammatory response in the brain tissue. 
TLR antagonists: T2.5, a monoclonal antibody against the extracellular 
domain of TLR2, has been shown to inhibit TLR2-mediated inflammatory 
responses in murine and human macrophages (82). In a mouse model of 
transient brain ischaemia, T2.5 reduced inflammatory cell accumulation and 
neural death with tendency towards a reduction in infarct size (83). 
The TLR4 antagonist, Eritoran, mimics the LPS structure and is therefore too 
large to pass through the normal blood-brain barrier. However, following a 
stroke, the blood-brain barrier is compromised which may allow the passage 
of larger molecules such as Eritoran and this may allow further studies to 
investigate the role of Eritoran in cerebral infarction. (84). 
TLR agonists: Despite the increasing number of studies indicating that TLR 
inhibition may have a potentially protective role in brain ischaemia there is 
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brain ischaemia is also neuroprotective in vivo (85). Thus, high risk patients 
may benefit from prophylactic TLR agonists prior to the potential brain 
ischaemia. During major cardiac surgery, patients are exposed to I/R injury of 
major organs such as the brain and kidneys (86-88). Further, up to 50% of 
patients undergoing coronary artery bypass graft, experience intra-operative 
focal or global brain ischaemia (89). 
Administration of Pam3CysSerLys4 (Pam3CSK4), a specific TLR2 agonist 
(90), prior to brain ischaemia resulted in significant reduction in infarct size 
and mortality rate in a mouse model of cerebral I/R injury (91). 
Unmethylated cytosine guanine rich DNA oligonucleotides (CpG ODNs) 
which are synthetic TLR9 agonists, have been shown to be safe in a number 
of human clinical trials  as a vaccine adjuvant (92). Administration of low dose 
CpG ODN or LPS prior to stroke in a mouse model of cerebral ischaemia, has 
protective effects against neuronal ischaemic damage (93). This protective 
effect is thought be the result of activation of TLR4 and TLR9 and the 
subsequent downstream signalling pathway that leads to activation of 
interferon regulatory transcription factor (IRF) (93). IRFs are key modulators 
of type I interferon gene regulation. Further, prophylactic LPS has also been 
shown to reduce ischaemic injury in hippocampal neurons in a pig model of 
cardiopulmonary bypass (94).  
 
Other compounds found to be beneficial in cerebrovascular dysfunction have 
been found to work via anti-TLR mechanisms (42) [Table 3]. 
 
Compound Mechanism Application Reference 
Pam3CSK4 TLR2 agonist Brain ischaemia Hua 2008 
T2.5 TLR2 antagonist Brain ischaemia Meng 2004 
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Oxymatrine TLR2 and TLR4 inhibitor Brain ischaemia Fan 2009 
LPS TLR4 agonist Brain ischaemia Stevens 2011 
Progesterone TLR4 inhibitor Brain ischaemia Wang 2011 
Ginkgobiloba TLR4inhibitor Brain ischaemia Hu 2011 
Picroside 2 TLR4 inhibitor Brain ischaemia Guo 2011 
CpG ODN 
1826 
TLR9 agonist Brain ischaemia Stevens 2011 
Table 3 - List of compounds shown to modify TLRs in cerebrovascular 
dysfunction 
 
Ischaemic reperfusion injury (Table 4) 
I/R injury is an antigen independent inflammatory process characterized by 
activation of the innate immune system (95). While the initial ischaemia 
causes tissue injury, reperfusion can further enhance the tissue response.  
Ischaemic reperfusion liver injury 
Liver ischaemia is common during hepatectomy and liver transplantation. The 
ischaemia-induced inflammatory response contributes to the liver damage.  
TLR3 and TLR4 have been found mediating the inflammatory response in 
liver ischaemia. TLR4 induces the inflammatory response in liver I/R injury by 
activating transcription factors such as NFkB, JNK and MAP kinases (96-
101).  
TLR agonists: Administration of TLR ligands prior to ischaemia, has been 
shown to be protective during the reperfusion period by suppressing and 
redirecting the tissue response (102, 103). The predictability of liver I/R injury 
during a liver transplant encourages the application of preventive strategies 
such as pre-treatment with TLR ligands prior to I/R injury to minimize the 
potential liver damage (104-107). In a mouse model of liver ischaemia, pre-
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signalling pathway during the pre-ischaemic period with subsequent 
suppression of NFkB and JNK during reperfusion (108). Further, LPS has 
also been shown to be protective in a mouse model of liver I/R injury by 
suppressing TLR4 signalling through early induction of suppressor of cytokine 
signalling 1 (SOCS-1), a negative regulator of cytokine signalling (109). 
Ischaemic reperfusion renal injury 
Peri-operative acute kidney injury is a well-recognized complication following 
major cardiothoracic and vascular surgeries (110-112). Changes in 
haemodynamics may cause renal tubular injury followed by activation of the 
immune system (113). Both innate and adaptive immune responses 
contribute in renal I/R injury, a well-recognised cause of acute kidney failure 
(114, 115). Activation of the immune system leads to endothelial and 
epithelial cell damage. The inflammatory process begins within minutes of 
reperfusion through innate immune response and is followed by a late 
adaptive response that manifests within a few days. (115, 116). TLR4 is 
normally expressed in the collecting ducts, loop of Henle, proximal and distal 
tubules (117). Considering that I/R injury is associated with upregulation of 
TLR4 in kidney epithelial cells where they contribute to acute kidney injury 
(118, 119), TLR4 antagonists may have therapeutic role in protecting the 
kidneys in renal I/R injury. 
TLR antagonist: Eritoran has been shown to have protective effects on the 
kidney in renal I/R injury. Liu and colleagues demonstrated that administration 
of Eritoran reduced the inflammatory gene expression and enhanced the 
morphological features in the kidney in a rat model of renal I/R injury (120).  
TLR agonists: Pre-treatment with TLR ligands, has also been shown to be 
protective in renal I/R injury. Polyinosinic polycytidylic acid (poly-IC), a TLR3 
agonist, is a synthetic double stranded RNA. In order to improve the 
pharmacokinetics of poly-IC, it is stabilized with poly-L-lysine and 
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been shown to be safe in humans in a number of conditions including viral 
infection, multiple sclerosis and cancer (121, 122). Pre-treatment with poly-
ICLC had a protective effect in mouse models of renal and cerebral I/R injury 
in vitro and in vivo, by reducing the release of inflammatory cytokines 
including IL1, IL6, IL12, TNFα and INF and also decreasing infarct size (123). 
Flagellin, a TLR5 agonist is a protein that arranges itself into a hollow cylinder 
to form the filament in bacterial flagellum. Pre-treatment with CBLB-502, a 
pharmacologically optimized Flagellin derivate has been shown to be 
protective in I/R injury by decreasing the accumulation of reactive oxygen 
species (ROS). In a mouse model of renal I/R injury, pre-treatment with 
CBLB502 inhibited neutrophil infiltration during the reperfusion period (124). 
In addition, administration of CBLB502 immediately after reperfusion was also 
protective in renal I/R injury. Thus, these protective properties can be of 
potential benefit during the reperfusion of transplanted organs.  
Ischaemic reperfusion lung injury 
Ischaemic reperfusion injury in the lung can be characterized by non-specific 
alveolar damage and lung oedema that is followed by systemic hypoxia (125). 
In particular, TLR4 plays a key role in the pathogenesis of I/R injury by 
increasing microvascular permeability, activating the NFkB signalling pathway 
and inducing apoptosis in lung tissue (48, 126, 127).  
 
Other compounds found to be beneficial in I/R injury have been found to work 
via anti-TLR mechanisms (42) [Table 4]. 
 
Compound Target Application Reference 
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Lipopolysaccharide TLR4 agonist Liver I/R injury Sano 2010 
Eritoran TLR4 antagonist Renal I/R injury Liu 2010 
Oestrogen TLR4 inhibitor Lung I/R injury Shih 2011 
Dexmedetomidine TLR4 inhibitor Renal ischaemia Gu 2011 
Melatonin TLR3&4 inhibitor Liver I/R injury Kang 2011 
CBLB502 TLR5 agonist Renal I/R injury Fukuzawa 2011 
Table 4 - List of compounds shown to modify TLRs in I/R injury 
 
Modulating TLRs by both stimulation and inhibition of TLR signalling has 
been shown to have therapeutic potential in various models of cardiovascular 
diseases. TLR antagonists have clearly been shown to be protective by 
directly inhibiting inflammatory gene transcription and reducing secretion of 
inflammatory cytokines in several conditions. However, preconditioning with 
low dose TLR agonists may also be an effective strategy to protect tissue 
against subsequent detrimental insults such as reperfusion injury. This 
underscores the importance of administering specific TLR agonists and 
antagonists during the relevant phase of the pathological process in order to 
achieve an optimal balance of TLR activation and inhibition. Further 
translational studies are required to improve the practicality of TLR 
modulation in cardiovascular diseases. 
 
 1.2.7. TLR4 and ischaemic-induced injury 
TLRs seem to be involved in a range of diseases associated with vascular 
dysfunction and ischaemic tissue damage, in particular TLR4, its involvement 
in PAD and resultant muscle damage is likely. 
TLR4 has been shown to be important in animal models of ischaemia: TLR4 
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(128), reduced myocardial infarct size and protected against focal cerebral 
ischemia (129). Preliminary work in our lab has shown that TLR4 is 
upregulated in gastrocnemius muscle biopsies obtained from patients with 
CLI compared to patients with no PAD (38). Discovering the role of TLR4 
stimulation in inflammation has led to the development of specific TLR4 
antagonists for therapeutic purposes. Eritoran, a TLR4 antagonist, has been 
trialled  to assess its efficacy in severe sepsis (40). In an animal model of 
myocardial ischaemia, Eritoran reduced ischaemic injury and inflammation 
(48). Pharmacological inhibition of TLR4 may therefore also be of benefit in 
CLI. Results from this study will increase our knowledge on the 
pathophysiology of PAD, in particular the mechanisms underlying ischaemic 
muscle damage. Further, the potential of targeting TLR4 signalling to reduce 
ischemia-induced myopathy will be demonstrated. Ultimately, this may lead to 
novel treatments to improve outcomes following revascularisation in patients 
with CLI and/or prevent worsening in those with non-reconstructable disease. 
Targeting the TLR4 pathway may also prevent progression of the myopathy 
in patients with earlier disease. Since TLR4 antagonists are already in clinical 
trials for other indications, this may translate into patient benefit in the near 
future, leading to improved outcomes and better quality of life. 
 
1.3. Aims & Hypothesis  
 
The overall aim of this study was to investigate the potential role of TLR4 in 
skeletal muscle dysfunction in CLI. 
 
Objectives:  
The objectives were: 
1) To investigate expression, distribution and potential activation of TLR4 
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2) To study the functional consequences of TLR4 activation in ischaemic 
myotubes in vitro 




We hypothesized that chronic activation of TLR4 by endogenous ligands 
released by damaged cells within ischaemic skeletal muscle triggers an 
amplifying cascade of downstream pathological mechanisms leading to 
further inflammation and tissue damage.  Identification and understanding of 
early key events in the cascade may allow novel therapies to be developed to 
prevent progressive muscle damage. In particular, modulating TLR4 
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Figure 6 - The TLR signalling pathway 
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Figure 9 – The potential involvement of TLR4 in ischaemia-induced skeletal 




Student Number: 110091643 
 
CHAPTER 2: METHODS AND MATERIALS 
 
2.1. Human tissue collection & preparation 
2.1.1. Ethics and patient groups 
2.1.2. Gastrocnemius muscle biopsy 
2.2. Western blotting 
 2.2.1. Muscle homogenates 
 2.2.2. Preparation of cell lysates 
 2.2.3. Electrophoresis, transfer and developing 
2.3. Immunohistochemistry 
 2.3.1. Biotinylated immunohistochemistry – Paraffin embedded  
 2.3.2. Fluorescent immunohistochemistry – Paraffin embedded  
 2.3.3. Immunocytochemistry 
 2.3.4. Haematoxylin & Eosin staining  
2.4. Human skeletal muscle cell culture 
 2.4.1. Myoblast isolation  
 2.4.2. Myoblast differentiation, cell counting and freezing 
 2.4.3. Protein inhibitors 
 2.4.4. Simulated ischaemia 
 2.4.5. TLR4 antagonism 
2.5. Co-immunoprecipitation  





Student Number: 110091643 
 
 2.6.1. Preparation of supernatants 
 2.6.2 Preparation of blood samples 
2.7. Polymerase chain reaction 
 2.7.1. RNA extraction and quantification 
 2.7.2. Reverse transcription and quantitative PCR 
 2.7.3. ∆∆Ct method and melting peaks  
2.8. Mouse model of hind-limb ischaemia  
 2.8.1. Haemodynamics and Laser Doppler Imaging 
 2.8.2. Blood oxygen pressure and preparation of blood samples 
2.9. Power calculation 























Student Number: 110091643 
 
2.1. Human tissue collection & preparation   
 
2.1.1. Ethics and patient groups 
Local ethics committee approval (REC reference: 29-2000; Royal Free and 
Medical School Local Research Ethics Committee) was obtained to collect 
gastrocnemius biopsies from patients undergoing major lower limb 
amputation for CLI (ischaemic group) and from patients with no PAD 
undergoing saphenous vein harvesting for coronary artery bypass surgery 
(control group). As patients in both groups shared similar risk factors, all 
patients in the control group were reviewed by taking full histories and 
performing clinical examinations to identify and exclude the ones with 
underlying PAD. Baseline data of the 2 groups were collected as follows: sex, 
age, smoking history, eGFR, presence/ absence of hypertension, diabetes, 
hyperlipidaemia, claudication and ABPI. Patients were provided with 
information sheets regarding the project and written consent was taken from 
those who agreed to participate (Appendix 5).  
 
 2.1.2. Gastrocnemius muscle biopsy 
Muscle biopsies taken from the medial head of gastrocnemius muscle, were 
cut into smaller pieces and stored as follows: 
1) Tissue was placed in 10% formalin and stored at room temperature to be 
used for immunohistochemistry. 2) Tissue was placed immediately into 
Eppendorfs in liquid nitrogen and then transferred to -80°C to be used for 
western blot analysis and ELISA. 3) Tissue was placed immediately into 
culture medium for isolation of myoblasts to be used in cell culture 
experiments. 4) Tissue was placed in Eppendorfs containing RNAlater, 
stored at 4°C overnight and then transferred to -80°C within 24 hours to 
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In order to allow blind analysis, all samples were labelled with serial numbers 
prior to storage. The consent forms were placed in the allocated secure place 
after tissue collection. 
 
2.2. Western blotting 
 
 2.2.1. Muscle homogenates 
Snap frozen samples, stored at -80°C, were cut into smaller fragments and 
placed in pre-labelled 2ml Eppendorfs which were filled with 20μl of lysis 
buffer (200μl Triton X100; 1600μl RIPA buffer with added protease inhibitor; 
Thermo Scientific Pierce, UK) per milligram of tissue. The tissue lyser 
machine (TissueLyser II, Qiagen) was programmed for 3 cycles of 3 minutes 
at 30 Hz to achieve adequate lysis. This was followed by centrifugation of the 
samples at 13000 rpm for 5 minutes.  
The BCA (bicinchoninic acid) protein assay kit (Thermo Scientific Pierce) was 
used to measure total protein concentrations of samples. Standard proteins of 
known concentration (Bovine serum albumin, 10μl per well) and protein 
samples of unknown concentration (10μl per well) were added into 96 well 
plates together with the mixed reagents (200μl per well). The first step is the 
chelation of copper with protein in an alkaline environment to form a light blue 
complex. In the second colour development step, BCA reacts with the 
reduced (cuprous) cation which was formed in step one. The plate was 
incubated for 30 minutes at 37°C and then read at light absorbance of 562 
nm to calculate the standard curve and to estimate the protein concentration 
in the samples [Figure 10].  
The final concentration of the proteins was adjusted to about 2000µg per 
millilitre with RIPA buffer. Once the protein concentration was confirmed, 
phosphatase inhibitor (1μl per 1mg of protein; Thermo Scientific Pierce) was 
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proteins.  The samples were exposed to 95°C for 5 minutes before 
transferring back to -80°C for storage.  
 
 2.2.2. Preparation of cell lysates 
Human myotubes were cultured in 6 well plates. Plates were washed 
thoroughly with Phosphate Buffered Saline (PBS; Life Technologies, UK). 
Lysis buffer (120μl RIPA with added protease inhibitor, Thermo Scientific 
Pierce) was added to each plate and mixed using a cell-scraper. Cell lysate 
contents were placed into labelled Eppendorfs and continually aspirated and 
expelled with a fine needle for 2 minutes to enhance cell lysis.  
The BCA protein assay kit was used as described earlier to determine protein 
concentration. Once the protein concentration was confirmed, phosphatase 
inhibitor (1μl per 1 milligram of protein; Thermo Scientific Pierce) was added 
to each Eppendorf to prevent dephosphorylation of transcription proteins.  
The samples were exposed to 95°C for 5 minutes before transferring to -
80°C for storage.  
 
 2.2.3. Electrophoresis, transfer and developing 
Western blotting is a semi-quantitative analysis of a specific protein within a 
heterogeneous mixture of proteins. This technique facilitates the detection 
and comparison of a specific protein expression between different samples 
(130). Polyacrylamide gel electrophoresis (PAGE), describes a technique 
used to separate macromolecules such as proteins according to 
electrophoretic mobility. Mobility is a function of the length, conformation and 
charge of the molecule. In order to separate the proteins of interest (protein 
sizes varied between 15 and 100 kDa), 10% Tris-Glycine gel was made of 
resolving gel (16.7ml of 30% Acrylamide; 12.5ml of 1.5 M Tris PH=8.8; 0.5ml 
of 10% Sodium Dodecyl Sulphate; 19.8ml of dH2O; 0.5ml of 10% Ammonium 
Persulphate; 0.02ml of TEMED) and stacking gel (30% Acrylamide; 0.5 M 
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Dodecyl Sulphate (SDS) is an anionic detergent that linearizes proteins by 
imparting a negative charge (131). The gels were wrapped in wet towel and 
stored in the fridge for no longer than 2-3 days before use.  
Denatured protein samples (thawed adequately and centrifuged at 13000rpm 
for 5 minutes) were loaded onto 10% Tris-Glycin gels. Each lane was loaded 
with total volume of 15μl (10μl / 20µg of protein sample and 5μl of laemmli 
buffer). The laemmli buffer (1 M Tris PH=6.8 / 0.4% SDS (2.4ml), 100% 
Glyceron (4ml), 0.01% Bromphenol blue (2mg), dH2O (2.8ml) and B-
Mercaptoethanol (1ml)) is the standard loading buffer that was first described 
in 1970 (132). One lane in each gel was loaded with 10μl protein ladder 
(SeeBlue Plus, Invitrogen). 
The loaded gels were placed into the central chamber of an XCell Sure Lock 
electrophoresis device [Figure 11] and the central and outer chambers were 
filled with running buffer (100ml of 10 X TrisGlycine Gel diluted in dH2O into 
total volume of 1 litre). The gels were run at 125V until the dye reached the 
bottom of the gels (1.5 – 2 hours). The electroblot was prepared by soaking 
the sponges in transfer buffer (150ml of 15% Methanol and 40ml of 25 X 
TrisGlyc transfer buffer (Novex, Life Technologies, Paisley, UK) diluted with 
dH2O up to 1 litre) for 1 hour. The blotting stack was prepared by expelling air 
bubbles from the sponges by rolling gently with a centrifuge tube, and the 
nitrocellulose membrane (Hybond-C extra; GE Healthcare Life Sciences, 
Buckinghamshire, UK) was sandwiched in the following order: sponge - 
paper filter - gel - membrane - paper filter – sponge. The blotting stack was 
placed in the central chamber of blotting module device which was filled with 
transfer buffer. The outer chambers were filled with cold dH2O and the 
proteins were transferred onto nitrocellulose membrane at 30V for 90 
minutes.  
In order to block non-specific binding sites, the membranes were blocked with 
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Saline (PBS) / 0.1% Tween 20) for 2 hours. This was followed by incubation 
of the membrane at 4°C with the primary antibodies shown in Table 5.  
 
Antibodies Suppliers Concentrations 
TLR1 ab37068; Abcam 1:1000 
TRIF ab13810; Abcam 1:1000 
TLR4 ab22048; Abcam 1:500 
HSP70 sc-373867; Santa Cruz 1:1000 
HSP60 sc-136291; Santa Cruz 1:1000 
MyD88 ab2064; Abcam 1:1000 
P-P38 D3F9; Cell Signalling 1:1000 
P38 9212; Cell Signalling 1:1000 
JNK 9252; Cell Signalling 1:1000 
P-JNK 9251; Cell Signalling 1:1000 
NFkB C22B4; Cell Signalling 1:1000 
P-NFkB 93H1; Cell Signalling 1:2000 
Cleaved Caspase-3 9661; Cell Signalling 1:1000 
β tubulin loading ab4074; Abcam 1:1000 
Table 5 – List of the primary antibodies 
 
The membranes were then washed and incubated with horseradish 
peroxidase-linked corresponding secondary antibody (Anti-Rabbit, Anti-Goat 
or Anti-mouse; Abcam) at room temperature. Both primary and secondary 
antibodies were diluted in 5% milk solution. The membranes were developed 
using chemiluminescent substrate (Amersham ECL Plus™ Western Blotting 
Detection Reagent; GE Healthcare Life Sciences) and the blots were 




Student Number: 110091643 
 
Healthcare Life Sciences). The photographic films were exposed to the 
nitrocellulose membranes in the dark chamber for varying durations from 1 to 
30 minutes to facilitate the best exposure onto the films. The films were then 
placed straight into the developing and fixing solutions. Band intensities were 
determined by densitometry using computer software ImageJ 1.45s (US 
National Institutes of Health, Bethesda, Maryland, USA). The membranes 
were washed with PBS / 0.1% Tween 20 and re-used to measure protein 




Immunohistochemistry (IHC) is a technique to demonstrate the presence and 
location of specific proteins in tissue sections. Although this technique is less 
sensitive quantitatively than western blot and ELISA, it provides more 
information on the distribution and location of the protein. 
Antibodies that recognize the specific target antigens achieve 
immunohistochemical staining. The antibody-antigen complex is then 
visualized using either chromogenic detection or fluorescent detection (133).   
The human and mouse skeletal muscle biopsies were fixed in 10% formalin 
and embedded in paraffin, then cut by microtome to approximate 10-micron 
thickness and affixed onto slides. Slides were left at room temperature 
overnight to dry out. 
Before proceeding with the staining, the slides were washed with xylene and 
ethanol to deparaffinise and rehydrate the sections respectively.  
Fixation in formalin results in formation of methylene bridges, which mask 
antigen sites, and therefore an antigen retrieval step is required to overcome 
this problem. In order to perform antigen retrieval, the slides were placed in 
pre-warmed citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20 PH=6.0) 
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the slides were washed generously with PBS and placed in a humidified 
chamber [Figure 12]. 
 
 2.3.1. Biotinylated immunohistochemistry – Paraffin embedded sections 
Slides were incubated with blocking solution (10% normal serum of the 
species that the secondary antibody was raised in with 1% BSA in PBS / 
0.1% Tween 20) for 2 hours at room temperature to prevent non-specific 
binding of the secondary antibody. 
The primary antibody (TLR4; 1:100; abcam) was then applied, diluted in 1% 
BSA in PBS / 0.1% Tween 20, and incubated overnight at 4°C.  
Blocking of the endogenous peroxidase was performed by incubating the 
slides in 0.3% H2O2 in PBS for 15 minutes. Then, the biotinylated HRP-
conjugated secondary antibody (anti-mouse; 1:200; ab675; abcam) was 
applied, diluted in 1% BSA in PBS / 0.1% Tween 20, and incubated for 30 
minutes at room temperature.   
This was followed by applying Avidin and Biotinylated horseradish 
peroxidase macromolecular Complex (VectaStain Elite ABC kit; Vector 
Laboratories) onto the slides for an additional 30 minutes to amplify the 
signal. Then, the horseradish peroxidase is visualized by the development of 
the peroxidase substrate, 3,3-Diaminobenzidine (DAB), which produces a 
brown colour.  
Further counterstaining with haematoxylin (blue) was performed to observe 
tissue and cell morphology.  The slides were incubated in Mayer’s 
haematoxylin for 5 minutes, and then briefly exposed to acid alcohol followed 
by incubation in blueing solution for 5 minutes.  After further wash with PBS, 
the slides were placed in a rack and washed with ethanol and xylene to 
dehydrate the sections.  The images were viewed using a microscope 
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 2.3.2. Fluorescent immunohistochemistry – Paraffin embedded sections 
In order to examine the co-distribution of two different antigens in the same 
sample, double labelled fluorescent staining was carried out. Sequential 
technique was carried out when primary antibodies were raised in similar 
species, whilst the parallel technique was carried out when primary 
antibodies were raised in different species. TLR1 and TLR4 were stained in 
the muscle sections along with markers for neutrophils (CD34), macrophages 
(CD68) and endothelial cells (CD31) to observe the distribution of TLR 1 and 
4 in the muscle biopsies.  
Similar to biotinylated immunohistochemistry, the human skeletal muscle 
sections were deparaffinised and antigens retrieved with citrate buffer. To 
block the non-specific binding of the antibodies, the slides were incubated in 
1% BSA in PBS / 0.1% Tween 20 for 30 minutes at room temperature. TLR4, 
CD34, CD68 and CD31 antibodies were raised in mouse. Hence, the 
sequential technique was used to examine the co-distribution of these 
antigens in the same samples. TLR1 antibody was raised in rabbit, therefore 
the parallel technique was used to examine the co-distribution of TLR1 and 
TLR4.   
For the sequential technique [Figure 13], slides were blocked with 1% BSA in 
PBS / 0.1% Tween 20 for 30 minutes at room temperature. This was followed 
by incubation of the slides with the primary antibody or their IgG isotype 
control in 1% BSA in PBS / 0.1% Tween 20 for 1 hour at room temperature, 
and then further incubation with the first secondary antibody, labelled with 
flurochrome-1, in 1% BSA in PBS / 0.1% Tween 20 for 1 hour at room 
temperature. After further wash with PBS, the second blocking step was 
performed, and then the second primary antibody and the second secondary 
antibody, labelled with fluorochrome-2, were applied in a similar manner to 
the first step.  The slides were washed with PBS and coverslips were 
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For the parallel technique [Figure 13], slides were incubated with the mixture 
of primary antibodies or their IgG isotype control in 1% BSA in PBS / 0.1% 
Tween 20 for 1 hour at room temperature. After washing with PBS, the slides 
were incubated with a mixture of the two secondary antibodies that were 
raised in different species with two different fluorochromes in 1% BSA in PBS 
/ 0.1% Tween 20 for 1 hour at room temperature. The slides were washed 
with PBS and coverslips were mounted using VECTASHIELD® mounting 
medium containing DAPI. The slides were stored in the dark at -20 °C. 
Cleaved Caspase-3 staining was also performed on paraffin embedded 
ischaemic mouse skeletal muscle sections to assess ischaemia-induced 
apoptosis in muscle. Similarly, the sections were deparaffinised and antigens 
were retrieved using citrate buffer. Sections were blocked with 1% BSA in 
PBS / 0.1% Tween 20 for 30 minutes at room temperature. After incubation 
with the primary antibody (Cleaved Caspase-3; 1:300; rabbit antibody; 9661; 
Cell Signalling) or its IgG isotype control (rabbit IgG) for 1 hour at room 
temperature, the slides were washed with PBS and treated with the 
secondary antibody (Alexa Fluor® 594 Chicken Anti-Rabbit IgG; 1:200; A-
21442; Life Technologies). The slides were washed with PBS and coverslips 
were mounted using VECTASHIELD® mounting medium containing DAPI. 
The images were viewed using a fluorescence microscope (Axioscop 2; Carl 
Zeiss Micro-imaging). 
 
 2.3.3. Immunocytochemistry 
Immunocytochemistry was used to visualize the presence of desmin (marker 
for human skeletal muscle cell) in cultured human myotubes in vitro. There 
are two major types of immunofluorescence staining methods: 1) direct 
immunofluorescence staining in which the primary antibody is labelled with 
fluorescence dye, and 2) indirect immunofluorescence staining in which a 
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The lists of the used primary and secondary antibodies are shown in Table 6 
and Table 7.  
Primary 
antibodies 
Species Suppliers Concentrations 
TLR4 Mouse ab22048; Abcam 1:100 
CD34 Mouse ab9088; Abcam 1:100 
CD68 Mouse M0814; 
DakoCytomation 
1:100 
CD31 Mouse M0823; 
DakoCytomation 
1:20 
TLR1 Rabbit ab37068; Abcam 1:100 




Species Suppliers Concentrations 
Alexa Fluor® 488 
Anti-Rabbit IgG 
Goat A-11008;  
Life Technologies 
1:200 
Alexa Fluor™ 594 
Anti-Rabbit IgG 
 
Goat A-11012;  
Life Technologies 
1:200 
Alexa Fluor® 594   
Anti-Mouse IgG 
 
Chicken A-11032;  
Life Technologies 
1:200 
Alexa Fluor® 488  
Anti-Mouse IgG 
 
Chicken A-1101;  
Life Technologies 
1:200 
Table 7 – List of the secondary antibodies 
 
The indirect immunofluorescence staining was carried out on cultured human 
myotubes fixed on 8 chamber culture slides [Figure 14]. After fixation in ice-
cold acetone for 10 minutes, the slides were placed in a humidifying 
chamber, washed with PBS for 5 minutes, and blocked with 10% chicken 
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(1:200; ab8592; abcam). After incubation with the primary antibody or its IgG 
isotype control (rabbit IgG) for 1 hour at room temperature, the slides were 
washed with PBS and treated for 30 minutes with the secondary antibody 
(Alexa Fluor® 594 Chicken Anti-Rabbit IgG; 1:200; A-21442; Life 
Technologies). The slides were washed with PBS and coverslips were 
mounted using VECTASHIELD® mounting medium containing DAPI. The 
slides were allowed to dry in darkness. Images were captured as soon as 
possible as the fluorescence is unstable and will become less fluorescent 
after a few days. The images were viewed using Axiotop 2 Mot plus 
microscope with Axiovision software and MRm camera (Carl Zeiss, 
Gottingen, Germany). 
 
 2.3.4. Haematoxylin & Eosin staining  
Haematoxylin & Eosin (H&E) staining has been used for over a century and 
is still a recognised technique to observe the histomorphological changes in 
tissue sections. The stain displays a wide range of cytoplasmic, nuclear, and 
extracellular matrix features. Haematoxylin has a deep blue colour and acts 
as a basic dye, while Eosin is pink in colour and acts as an acid dye. In a 
typical tissue, nuclei are stained blue, whereas the cytoplasm and 
extracellular matrix have varying degrees of pink staining (134). The Eosin 
staining will allow the non-nuclear tissue components to be clearly 
differentiated from each other. 
In order to observe the histomorphological changes in gastrocnemius muscle 
in both human and mouse muscle biopsies, H&E staining was carried out on 
paraffin embedded gastrocnemius muscle sections. The ischaemic sections 
were compared with non-ischaemic ones to observe muscle fibre 
degeneration / regeneration, inflammatory cell infiltration, fibrotic tissue / 
adipose tissue replacement and necrosis. 
The slides were placed in a rack and washed with xylene and ethanol to 
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water for 5 minutes, they were stained in Harris’s Haematoxylin (Surgipath 
Europe Ltd, Peterborough, UK) for 6 minutes and washed again in running 
tap water for 20 minutes. The slides were decolorized in 1% acid alcohol for 
1 second and washed in tap water for another 5 minutes. Further treatment 
with Lithium Carbonate for 3 seconds was performed, before washing in tap 
water and counterstaining in 1% Eosin for 15 seconds. Dehydration in 100% 
alcohol and xylene was carried out, before mounting sections with cover slips 
using DPX resin (BDH Guir®). Slides were examined under a light 
microscope and pictures taken with Zeiss Axiotop 2 Mot. 
 
2.4. Human skeletal muscle cell culture 
 
 2.4.1. Myoblast isolation  
Human gastrocnemius muscle was collected in solution A (3.6gr HEPES, 
3.8gr NaCl, 0.112gr KCl, 47gr Glycerin, 500ml dH2O, PH=7.6) at the time of 
biopsy and stored at 4°C for no longer than 24 hours before isolation of 
human myoblasts. 
The samples were transferred to weighing boats in a class II microbiological 
safety cabinet and cut into pieces of < 1mm3. Muscle fragments, mixed with 
solution ATE (4.5ml Trypsin-EDTA in 40.5ml solution A), were aspirated into 
flasks which then were placed in a beaker with water warmed to 37°C on a 
magnetic stirrer for 15 minutes to facilitate myoblast isolation.  
The muscle fragments were allowed to settle at the bottom of the flask and 
only the remaining solution was transferred to 50ml tubes containing 20ml in 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Paisley, Scotland) 
supplemented with 20% foetal calf serum, penicillin (100 U/ml), amphotericin 
B (25 µg/ml), streptomycin (100 µg/ml, all from Gibco). The 50ml tube was 
centrifuged at 13,000 rpm for 5 minutes, before discarding the medium and 
re-suspending the pellet in 1ml Skeletal Muscle Cell Growth Medium (SMM, 
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Factor, Insulin and Dexamethasone; 23060; PromoCell, Germany) 
supplemented with 20% foetal calf serum, penicillin (100 U/ml), amphotericin 
B (25 µg/ml), streptomycin (100 µg/ml) (all from Gibco). The muscle 
fragments were re-suspended in solution ATE and the above steps were 
repeated to isolate more myoblasts in total volume of 3ml (135).  
The cells were strained through the 40-micrometre cell strainer into a fresh 
50ml tube, and were then plated into T12.5cm flasks and incubated at 37°C 
with 5% CO2. By the first 48 hours, extra 1ml of 20% SMM was added to the 
flasks. After a further 48 hours, the flasks were washed with PBS to remove 
erythrocytes and any remaining fragments while the myoblasts adherent to 
the flask were retained. The cells were then provided with fresh 4ml 20% 
SMM every 48 hours.  In case of any contamination with endothelial cells, the 
culture medium was changed to a mixture of 20% DMEM and 20% SMM 
(50:50) for 48 hours, and then 20% DMEM only. The culture medium was 
switched back to 20% SMM when no endothelial cells could be visualized 
under the microscope. 
Within 2 weeks, when cells were approaching 80% confluence, the flasks 
were treated with trypsin for 2 minutes at 37°C to detach the cells, which then 
were counted and plated at approximately 300,000 cells per T175 flask, 
120,000 per T75 flask or 40,000 per T25 flask.  
 
 2.4.2. Myoblast differentiation, cell counting and freezing 
Cells were inspected microscopically every 2-3 days to rule out any possible 
infection, and also to change the culture medium. At 80% confluence, cells 
were trypsinized: culture media was drained and the cells were washed with 
2ml Trypsin-EDTA to neutralise the residual medium. Then, the cells were 
exposed to 5ml Trypsin-EDTA for 2 minutes at 37°C with mild agitation to 
help detach the cells. The contents of the flasks were subsequently 
transferred to a prefilled 50ml centrifuge tube with 20ml of 20% SMM to 
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minutes, the supernatants were discarded and the cell pellets were re-
suspended in 10ml of 20% SMM. These myoblast suspensions were diluted 
to be re-seeded in either another flask or a 6-well plate to proceed with 
differentiation. Myoblasts, which have undergone more than 10 passages, 
were not used in experiments.  
In order to culture the myoblasts to myotubes, the myoblasts were plated 
onto 6 well culture plates (BD Falcon™, cat. no. 351143) or 8-well chamber 
slides (Falcon) and cultured in 20% SMM. At 80% confluence, cells were 
exposed to differentiation medium containing DMEM with 2% horse serum, 
penicillin (100U/ml), streptomycin (100 µg/ml) and amphotericin B (25 µg/ml) 
(all from Gibco). Within 7-10 days, differentiation was confirmed by observing 
the morphological changes under the light microscope at 20X magnification. 
Myotubes were elongated, thickened and multinucleated compared to the 
myoblasts (136). Immunohistochemical staining for desmin was also carried 
out to verify the myogenic phenotype of extracted myoblasts, with reported 
specificity and sensitivity of 99% and 71% respectively (137, 138).   
A haemocytometer was used for cell counting before re-seeding the cells 
onto the flasks or plates. The haemocytometer is a device that can be used 
to count viable cells within a sample [Figure 15]. By knowing the dimensions 
(depth and area) of each segment of the haemocytometer, it is possible to 
calculate the concentration of cells within a known volume and therefore to 
calculate the concentration of cells in the fluid overall. Trypan blue, used to 
selectively colour dead cells that have damaged membranes, is added to the 
cell suspension to calculate the viability count.  
After mixing the cell suspension with trypan blue (100 μl; 50:50), the 
haemocytometer was filled carefully with the mixture of cells and trypan blue, 
allowing capillary action to draw the solution out of the pipette. Only live cells 
were counted as oppose to those that had taken up the trypan blue.   
Total cell count = ((4 corners of 16 squares) / 4) X 2 (dilution factor 1:2) = 
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For the purpose of long-term storage of the myoblasts, cells were trypsinized 
as described above, and centrifuged at 13,000 rpm for 5 minutes to produce 
a pellet. The supernatant was discarded and the pellet re-suspended in the 
18ml of freezing medium (15ml 10% DMEM, 1.5ml Foetal Calf Serum and 
1.5ml of DMSO). The resulting suspension was transferred to cryotubes in 
1ml aliquots that were placed in a suitable freezing container and cooled 
down to -80°C for 24 hours, before being transferred to liquid nitrogen 
storage. In order to re-use the cells, the cryotubes were thawed quickly in a 
warm water bath and washed in culture medium to neutralize the effect of 
DMSO which is toxic to the cells. After centrifuging the suspension, the 
pellets were re-suspended in fresh culture medium and the cells were 
seeded into the flasks accordingly.  
 
 2.4.3. Simulated ischaemia 
In order to investigate the functional consequences of ischaemia in cultured 
human myotubes, a model of simulated ischaemia was adopted from a 
previously published in vitro myotube ischaemia model from our lab (139) 
[Figure 16]. This reproducible model of myotube ischaemia mimics the critical 
parameters that occur in skeletal muscle ischaemia, including changes in the 
level of pH, LDH, pO2 and CO2. Culturing myotubes in depleted media, in a 
gas mixture containing 20% CO2 and 80% N2 for 6–12 h increases the pCO2 
and decreases the pH and pO2 of culture media to similar levels that are 
observed in ischaemic skeletal muscle in vivo.  
The cultured human myotubes in 6-well plates were placed in the sealed 
hypoxic chamber (Modular Incubator Chamber, MIC-101; Billups-
Rothenberg, Del Mar, CA, USA) that was connected to a gas cylinder 
containing 20% CO2 and 80% N2. The chamber was flushed with the gas (10 
litre per minute) for 20 minutes to minimize the amount of O2 left in the 
chamber, before the gas was disconnected and the chamber was sealed 
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hours at 37°C. After microscopic examination of the plates to exclude floating 
cells, the plates were transferred immediately for sample collection for 
experiments. The media was collected in 20ml tubes, labelled and stored at -
20°C for ELISA analysis. Cell lysates were prepared as described earlier for 
western blotting and co-immunoprecipitation.  
 
 2.4.4. Protein inhibitors 
To investigate the TLR4 related downstream signalling pathway in simulated 
ischaemia, protein inhibitors were used to manipulate the signalling pathway 
at the level of both adaptor and transcription proteins in vitro. 
The following inhibitors were added 6 hours prior to exposure to simulated 
ischaemia to inhibit the adaptor proteins: MyD88 inhibitor (20μM; tlrl-pimyd; 
Invivogen) and TRIF inhibitor (20μM; tlrl-pitrif; Invivogen). The following 
inhibitors were used to inhibit the transcription proteins: NF-kB inhibitor 
(10μM; Celastrol ant-cls; Invivogen) was added 6 hours prior to exposure to 
simulated ischaemia; P38 inhibitor (10μM; SB203580; SelleckChem, 
Houston, USA) was added 4 hours prior to exposure to simulated ischaemia; 
JNK inhibitor (20μM; 420119; Merck Chemicals Ltd, Nottingham, UK) was 
added 4 hours prior to exposure to simulated ischaemia. The different doses 
and the duration of the pre-treatment for the various inhibitors prior to the 
simulated ischaemia were adopted from the datasheets (IC50) provided by 
the manufacturers.  
 
 2.4.5. TLR4 antagonism 
To investigate the functional consequences of TLR4 inhibition in ischaemic 
human myotubes, TLR4 was inhibited prior to simulated ischaemia in vitro.  
The following inhibitors were used to inhibit the TLR4 receptor: Anti-human 
TLR4 neutralizing antibody (10 μg/ml; mabg-htlr4; Invivogen) was added 2 
hours prior to exposure to simulated ischaemia and the ultrapure 
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antagonist) (10 μg/ml; tlrl-prslps; Invivogen) was added 4 hours prior to 
exposure to simulated ischaemia. The LPS-RS was also used for the in vivo 
experiments to inhibit TLR4 prior to the hind-limb ischaemia.  
As a positive control, a synthetic TLR4 ligand was used: Synthetic 
Monophosphoryl Lipid A – MPLSs (50μM; tlrl-pimyd; Invivogen) was added 6 




Immunoprecipitation is a technique that enables the purification of a protein. 
The specific antibody against the protein of interest is incubated with the 
mixture of the proteins, and the antigen-antibody complex formed is then 
pulled out of the sample using protein A/G-coupled agarose beads. This 
method helps to physically isolate the protein of interest from the rest of the 
sample. Co-immunoprecipitation (Co-IP) is a similar technique that helps to 
identify physiologically relevant protein–protein interactions by targeting 
protein A with its relevant antibody to indirectly capture protein B which is 
bound to protein A. These protein complexes can be analysed to study the 
possibility of heterodimerisation of the proteins of interest. 
 
2.5.1. Preparation of cell lysates  
Co-IP technique was carried out to investigate the possibility of TLR4 and 
TLR1 heterodimerisation. Ischaemic and control human myotubes were lysed 
with RIPA buffer (25 mM Tris HCL pH 7.6, 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS; Termo Scientific) as described earlier. As 
soon as the lysis process starts, proteolysis, dephosphorylation and 
denaturation happen. Keeping the samples on ice at all times and adding 
fresh protease and phosphatase inhibitors to the lysis buffer, slow down 
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ab22048; abcam) or anti-TLR1 (2μg; ab37068; abcam) at 4oC for 1 hour 
under gentle agitation.  
Meanwhile, protein A-coupled sepharose beads (P9424; Sigma-Aldrich, UK) 
were prepared by incubating 100mg of beads in 1ml 0.1M PBS, then 
centrifuging and discarding the supernatant. After further incubation with 
0.1% BSA in 1ml PBS for 1 hour and the subsequent wash with PBS and 
removal of the supernatant, lysis buffer (400μl RIPA) with added protease 
inhibitors was added to the slurry.  
The slurry was mixed well and incubated with the samples (50μl of the beads 
per sample) for 2 hours at 4oC under gentle agitation. Bound proteins were 
then washed twice with lysis buffer and the supernatant was removed after 
centrifugation. Following the removal of the supernatant after the second 
centrifugation, loading buffer (50μl per sample; Laemlli Blue) was added. 
Finally, the samples were boiled at 95oC for 5 minutes to denature the 
proteins and separate them from the beads. After centrifuging the samples, 
the supernatants (containing the proteins) were collected. The immune 
complexes were then separated on SDS-PAGE gel, and immunoblotted (as 
described earlier) with TLR4 or TLR1 accordingly. Proteins were tagged with 




Enzyme Linked ImmunoSorbent Assay (ELISA), introduced by Engvall and 
Pearmann in 1971 (140), is a biochemical technique that is used mainly to 
detect an antigen or an antibody in a mixture of proteins.  This quantitative 
method provides a useful measurement of antigen or antibody concentration. 
There are two main variations in this technique: an ELISA can be used to 
detect an antigen that is recognised by an antibody (sandwich ELISA), or it 
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The principles of the sandwich ELISA are as follows: the ELISA plate is 
incubated with the antibody of interest over a certain amount of time, and 
then the plate wells are washed and blocked with a blocking solution to 
minimize the non-specific binding. The diluted samples and standards are 
added to the wells and the plate is incubated until the antigen-antibody 
complex is formed. After incubating with the secondary antibody that is 
conjugated with Alkaline Phosphatase (AP) or Horseradish Peroxidase 
(HRP), the plate wells are washed and the substrate is added to produce 
light at a certain wavelength. Finally, the plate is placed into an ELISA 
microplate reader to determine the absorbance based on the wavelength. 
Knowing the concentration of the standards, the absorbance ratios of the 
samples are then calculated to determine the actual concentration [Figure 
18]. 
 
 2.6.1. Preparation of supernatants 
As described earlier, at the time of preparing the cell lysates, the cell culture 
supernatants of the control and ischaemic cultured human myotubes were 
collected, labelled and stored at -20°C.  
 
 2.6.2. Preparation of blood samples  
Whole blood (mouse model of hind-limb ischaemia; chapter 5) was collected 
in anti-coagulant (Sodium Citrate) containing syringes by puncturing the left 
ventricle at the time of sacrificing the animals. After centrifuging the samples 
at 3,000 rpm for 10 minutes, the supernatant (plasma) was collected and 
stored at -80°C. 
 
The sandwich ELISA technique was carried out to detect the presence and to 
quantify the concentration of inflammatory cytokines (IL6, TNFα and INFα) 
and endogenous ligands (HSP60 and HSP70) in the in vitro experiments and 
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following ELISA kits were used and the experiments were carried out as per 
manufacturer’s instructions: Human VeriKineTM INFα (41100; PBL Assay 
Science, USA), Human total HSP60 (1800-2; R&D Systems, USA), Human 
IL6 (D6050; R&D Systems), Human TNFα (DTA00C; R&D Systems), Human 
/ Mouse total HSP70 (DYC1663-2; R&D Systems), Mouse IL6 (M6000B; 
R&D Systems) and Mouse TNFα (MTA00B; R&D Systems).     
 
2.7. Polymerase chain reaction 
 
Polymerase Chain Reaction (PCR) is an important technique that allows 
thermo-enzymatic quantification of DNA, based on the ability of DNA 
polymerase to synthesize new strands of DNA complementary to the offered 
template strand. Because DNA polymerase can add a nucleotide only onto a 
pre-existing 3'-OH group, it is possible to delineate a specific region of 
template sequence to be amplified. This is facilitated by the use of primers, 
also known as qPCR probes, which are short pieces of single stranded DNA 
complementary to the target sequence. The polymerase begins synthesizing 
new DNA from the end of the primer.  
Reverse transcriptase PCR analysis of mRNA, referred as RT-PCR, is one of 
many variants of PCR and is commonly used to detect RNA expression 
levels (141).  Total or specific types of RNA are extracted from the samples, 
and then the RNA is reversed transcribed into single strand DNA, also known 
as complementary DNA or cDNA.  After adding the primers to the transcribed 
cDNA, the PCR takes place and the polymerase carries out the amplification. 
Primers can be labelled with a wide range of fluorochrome tags. The use of 
fluorescence detection offers the advantage of sensitivity and a wide linear 
dynamic range for quantification.  As the cycle number increases, the 
detected fluorescence also increases.  
In order to measure TLR4 gene (507bp) expression in vivo, the mouse 
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chapter 5) were collected in RNAlater at the time of sacrificing the animals at 
days 1, 3 and 21 post operation (hind-limb ischaemia / sham) and stored at -
80o C. 
 2.7.1. RNA extraction and quantification 
RNA was extracted using the RNAeasy mini kit (74106; Qiagen, Germany) 
and a tissue lyser (Qiagen) [Figure 19]. A maximum amount of 20mg of 
RNAlater stabilized tissue was processed from each sample as per capacity 
of RNeasy spin column and the lysing capacity of the Buffer RLT.  The lysis 
buffer (310µl per tube; 10µl 2-Mercaptoethanol in 1ml of RLT) and the 
samples were added into 2ml microcentrifuge tubes containing one stainless 
steel bead. Tubes were placed in the TissueLyser Adapter Set 2 x 24, and 
the TissueLyser was run for 2 x 3 minutes at 20Hz. Tubes were rearranged 
half way through to allow even homogenisation. The homogenate was 
centrifuged at 12,000 rpm for 10 minutes at 40C to remove insoluble material. 
Supernatant was transferred to a new tube and then left at room temperature 
for 5 minutes to promote dissociation of nucleoprotein complexes. After 
adding 70% ethanol (1:1 (v/v)), the total liquid was transferred to an RNeasy 
spin column placed in a 2ml collection tube and centrifuged at 10,000 rpm for 
15 seconds. Further washing and centrifuging were carried out with RW1 and 
RPE buffers respectively. The RNeasy spin column was placed in a new 
1.5ml collection tube and 50µl of RNeasy-free water was added directly to 
the spin column membrane.  
The quantity of the total RNA was measured using a Thermo Scientific 
NanoDrop ND-1000 spectrophotometer (220nm-750nm). Each sample was 
pipetted (1.5l) onto the end of a fibre optic cable in the lower pedestal that 
was brought into contact with the second fibre optic cable, resulting in the 
liquid to bridge the gap between the fibre optic ends. A flash lamp provided 
the light source and a spectrometer was used to analyse the amount of 
ultraviolet irradiation absorbed by the nucleic acid. The NanoDrop 
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blank. Measurements were taken at 260nm and the quantity of extracted 
RNA was calculated in ng/µL. Samples were then stored at -80o C. 
 
 2.7.2. Reverse transcription and quantitative PCR 
QuantiTect Reverse Transcription Kit (205313; Qiagen) was used to perform 
the reverse transcription. After thawing the samples on ice, the genomic DNA 
elimination reaction (2µl of gDNA wipeout buffer and 1µg of template RNA in 
RNase-free water; total volume: 14µl) was carried out for 2 minutes at 42oC. 
Then, the template RNA (14µl) was added to tubes containing reverse 
transcription master mix (1µl of Quantiscript Reverse Transcriptase, 1µl of 
RT Primer Mix and 4µl of Quantiscript RT Buffer; total volume: 6µl) and 
incubated for 15 minutes at 42oC. After further incubation for 3 minutes at 
95oC, the samples were ready for real-time quantitative PCR, also known as 
qPCR. 
SensiMix SYBR HiROX Kit (QT605-02; Bioline Reagents Ltd, London, UK) 
and the 5’ sense and 3’ antisense TLR4 primers, provided with positive 
control double stranded DNA (rtp-mtlr4; Invivogen, USA), were used to carry 
out the real-time PCR. 
In order to normalize the data, it is required to measure an endogenous 
unregulated reference gene, also called a housekeeping gene. This 
measurement enables the calculation of the fold expression in each sample, 
whereas the expression of the target gene is adjusted with its corresponding 
housekeeping gene that acts as a loading control. In this experiment, mouse 
tubulin (350bp), Mm-Tubb4a (251664; Qiagen) was used.  
The PCR cocktails (10µl of Sensi Mix, 2µl of TLR4 or Tubulin primers, 4µl of 
template (cDNA (100 ng per reaction), negative control (PCR water) or 
positive control) and 4µl of PCR water; total volume: 20µl) were placed into 
the Corbett Rotor-Gene 6000 (Qiagen) [Figure 20] that was programmed for 
40 cycles at 95oC for 15 seconds, 60oC for 15 seconds and 72oC for 15 
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calculated using ∆∆Ct technique as described below. Further, the PCR 
products were separated on 2% agarose gel and visualized under UV light 
[Figure 20], to help better understanding of the data.  
 2.7.3. ∆∆Ct method and melting peaks  
Relative expression of the real-time PCR products was determined by using 
the ∆∆Ct method to calculate the fold expression of the target gene that is 
normalized with the housekeeping gene. The positive reaction is detected by 
accumulation of a fluorescent signal. The Ct (cycle threshold) is defined as 
the number of cycles required for the fluorescent signal to cross the threshold 
background level. Ct levels are inversely proportional to the amount of target 
nucleic acid in the sample, i.e., the lower the Ct level the greater the amount 
of target nucleic acid in the sample.  The ∆Ct was calculated by subtracting 
the Ct Tubulin from Ct TLR4 in either treatment or no-treatment group. The 
∆∆Ct was then calculated by subtracting the ∆Ct (no-treatment group) from 
∆Ct (treatment group). The fold expression was calculated as 2-∆∆ct (∆Ct = Ct 
Tubulin – Ct TLR4; ∆∆Ct =∆Ct treatment group – ∆Ct no-treatment group; Fold Expression = 
2-∆∆ct).  
Further, to check that the signal measured was from the cDNA of interest, all 
PCR products for the particular primer pair were expected to have the same 
melting temperature. Therefore, after real-time PCR amplification, a melting 
curve was performed. The temperature was raised by a fraction of a degree 
and the change in fluorescence was measured. At the melting peak 
temperature (Tm), fluorescence rapidly decreases as the two strands of DNA 
separate. 
 
2.8. Mouse model of hind-limb ischaemia 
 
In order to study the therapeutic potential of modulating TLR4 signalling in 
ischaemic skeletal muscle, the mouse model of hind-limb ischaemia was 
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 2.8.1. Haemodynamics and Laser Doppler Imaging 
Laser Doppler Perfusion Imaging (LDPI) is a non-invasive technique 
facilitating the monitoring of tissue perfusion and haemodynamics (142). 
Laser Doppler measures the total local perfusion within capillaries, arterioles, 
venules and shunting vessels.  
The depth of the measurement depends on the structure and density of the 
capillary bed, pigmentation and oxygenation. Further parameters that affect 
the depth of the measurement are the wavelength of the laser light and the 
distance between the sending and receiving fibres in the laser Doppler probe. 
The sending fibre scatters the light waves into the tissue that partly absorbs 
the energy, whilst some light waves are reflected back and detected by the 
returning fibre, converted into an electronic signal and analysed. The light 
hitting moving blood cells undergoes a change in wavelength (Doppler shift), 
while light hitting static objects is unchanged. The magnitude and frequency 
distribution of these changes in wavelength are directly related to the number 
and velocity of the blood cells in the sample volume. 
In order to monitor tissue perfusion in vivo (mouse model of hind-limb 
ischaemia; chapter 5), the anaesthetized mice were positioned under the 
scanner head (Moor FLPI; Moor Instruments Ltd, Devon, UK) on a low 
temperature heating pad to maintain normal body temperature of 37°C, with 
30cm distance between the animal and the scan head. The mice were placed 
in supine position and serial color-coded perfusion images were taken at 
days 1, 3 and 21 post operation (hind-limb ischaemia / sham). The images 
were then analysed using Moor FLPI review V3.0 software [Figure 21].  
 
 2.8.2. Blood oxygen pressure and preparation of blood samples 
Underlying acid-base disturbances are inevitable in tissue ischaemia. Arterial 
blood gas analysis reveals oxygenation status, adequacy of ventilation and 
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Arterial blood samples are used for blood gas analysis to study the 
parameters that can potentially be confounding factors secondary to 
ischaemia, including pH, pO2, pCO2, Hb, SO2, Lactate, Glucose, Sodium and 
Potassium.  
Whole blood (mouse model of hind-limb ischaemia; chapter 5) was collected 
in anti-coagulant (Sodium Citrate) containing syringes by puncturing the left 
ventricle at the time of sacrificing the animals. Air bubbles were removed and 
the needles were sealed with a rubber stopper to prevent the influx of air. 
The samples were kept in ice and transferred to the lab within 30 minutes for 
the analysis (RAPIDPoint 500 Systems; Siemens, Germany).  
 
2.9. Power calculations 
 
For human tissue analyses, sample size calculations were performed using 
the formula: N = 2 x (Zα/2 + Zβ) 2 x σ2/δ2 (N represents the sample size per 
group; Zα/2 and Zβ represents the standard normal deviates for type I and 
type II errors; σ2 represents the squared standard deviation; and δ2 
represents the squared differences between the treatment and control 
groups). From preliminary Western blot results from the human muscle 
biopsies, δ = 0.550 and σ = 0.321, therefore to provide an 80% power of 
detecting a difference between the 2 groups (Zβ=0.84) at 5% significance 
level (Zα/2=1.96), N per group was calculated to be 6.07.  
For in vivo studies, 6 animals of each strain were used for each time point. 
This number was chosen based on published studies of TLR changes in 
ischaemia as well as studies employing similar analyses in mouse hind-limb 
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2.10. Statistical analysis 
 
JMP® 11.0.0 software (SAS institute, NC, USA) was used to present, 
describe and analyse the data from this study. 
The Chi square test was carried out to compare the demographics between 
the patients with CLI and patients with no PAD. In human tissue experiments, 
the data (not normally distributed) was described as medians and ranges and 
compared with the Mann Whitney test. Presenting the in vitro experiments, 
the data (not normally distributed) was described as medians and ranges and 
compared with the Kruskal Wallis test. Presenting the in vivo experiments, 
the data (both normally and not normally distributed) was described as 
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Figure 10 - The graph shows the standard curve (blue line) which is used to 
calculate the protein concentration in the samples (red and green lines), as 
per light absorbance. The picture shows the macroscopic colour differences 
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Figure 13 - A) Mouse-mouse sequential double staining in blue and red - 
step1; B) Mouse-mouse sequential double staining in red and blue - step2; C) 
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Figure 14 - Picture of the 8 chamber culture slides that were used to culture 






Figure 15 - Picture illustrates the haemocytometer device used for the 
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Figure 16 - This picture illustrates the hypoxic chamber used to induce 






Figure 17 - Photographs showing cultured human myotubes placed in the 
hypoxic chamber connected to the gas cylinder for 20 minutes, before 
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Figure 18 - The pictures show the ELISA plate after adding the substrate and 





Figure 19 - The picture shows the tissue lyser used for the extraction of the 
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Figure 20 - The pictures show the 
Rotor-Gene 6000, separation of the 
PCR products on 2% agarose gel and 





Figure 21 – The pictures show the Laser Doppler Perfusion Imager and the 
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CHAPTER 3: EXPRESSION, DISTRIBUTION AND POTENTIAL 
ACTIVATION OF TLR4 AND TLR1 PATHWAY IN CRITICALLY 
ISCHAEMIC HUMAN SKELETAL MUSCLE 
 
3. 1 Introduction 
 
3. 2 Aims   
 
3. 3 Experimental design 
 
3. 4 Results 
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3. 1 Introduction 
There has been a common misunderstanding that CLI simply represents the 
natural progression of IC in patients with PAD. Haemodynamics and blood 
flow are not the only contributing factors in the clinical presentation of PAD 
(144). Lower limb skeletal muscle is an important end organ in the 
pathophysiology of PAD. Ischaemia-induced skeletal muscle damage 
manifests as IC as well as poor functional performance in CLI.    
Skeletal muscle forms the bulk of the lower limbs and play a key part in its 
function. Further, skeletal muscle has a role as a paracrine signalling organ 
and potential source of DAMPs which are host biomolecules that can initiate 
and augment a non-infectious inflammatory response.  Normal physiology of 
the skeletal muscle consists of a stable tissue with very little turnover of 
nuclei, however in the event of any injury, the skeletal muscle has the ability 
to initiate the repair process. The initial phase of muscle repair is 
characterised by necrosis of the damaged tissue and activation of the 
inflammatory response (145).  
The critical consequence of skeletal muscle ischaemia is an inadequate 
oxygen delivery or availability at the cellular level.  Skeletal muscle function 
can be further compromised if exercise takes place during the hypoxic cycle.  
However, in comparison with other tissues such as brain and heart, skeletal 
muscle is relatively tolerant to hypoxia, probably due to the energy buffering 
system. Chronic hypoxia results in reduced fibre area and muscle mass to 
improve oxygen diffusion into muscle cells (146). Further, hypoxia is a trigger 
of oxidative stress due to the increase in the generation of reactive oxygen 
species (ROS) (147).  
Oxidative stress-induced injury and inflammation are important considerations 
in skeletal muscle damage in patients with CLI. Critical reduction in blood flow 
in the lower limb, not only promotes generation of ROS, but also activation of 
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ROS secondary to leakage of electrons. The impairment of the mitochondrial 
respiratory chain increases the leakage of electrons that results in an 
increase in ROS. Decrease in mitochondrial density and impairment of its 
activity associated with increased ROS production, have been observed in 
hypoxic human skeletal muscle (149-151). The ROS released during hypoxia 
act as signalling agents that trigger diverse functional responses, including 
activation of gene expression through the stabilization of the transcription 
factor hypoxia-inducible factor (HIF-α) (151).  ROS can lead to cell damage 
and homeostatic disruption in skeletal muscle, and cause damage through 
lipid oxidation and modification of protein and DNA (152, 153).  
In patients with IC, during exercise induced ischaemia of the lower limbs, 
increased anaerobic metabolism can lead to alteration of pH, muscle cell 
permeability and ultimately result in muscle damage. During the rest period, 
restoration of the blood flow in the ischemic muscle activates inflammation. 
Further, the pro-inflammatory cytokines released from the damaged muscle 
may trigger the systemic inflammatory response.   
The immune system is divided into innate and acquired immunity. The innate 
immune system is primarily a prophylactic system, where toll-like receptors 
(TLR) play a key role in regulating the inflammatory response. The role of 
ROS in the activation of the innate immune system via TLR4 and its NFk-B 
signalling pathway has already been shown (154-156). ROS does not directly 
activate TLR4, but causes several DAMPs which can activate TLR4, resulting 
in the release of pro-inflammatory cytokines. This is a process of sterile 
inflammation.  
TLR4 can recognise specific ligands via its three-dimensional structure. The 
ability to recognise and bind with more ligands is further enhanced by the 
help of co-receptors such as CD14 and MD2, and the ability of the TLRs to 
form heterodimers. Upon recognition of a ligand by TLR4, the adaptor 
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to phosphorylate the transcription proteins such as NFk-B, JNK and P38, 
which then result in production of inflammatory cytokines.  
TLR1, 2 and 6 form heterodimers with TLRs present in the cell membrane 
(38). TLR2 and TLR6 have been shown to form heterodimers with TLR4. It 
has been demonstrated that these heterodimers can initiate a sterile 
inflammatory response in brain tissue in response to endogenous ligands 
(157, 158). The assembly of these heterodimers is regulated by co-receptors 
such as CD36, while the downstream signalling pathway appears to be the 
same as when these receptors are activated individually (158). Although 
TLR1 is known to form heterodimers with other TLRs, it is unclear whether its 
assembly with TLR4 improves the ligand recognition or alters the response. 
The role of TLR4-mediated inflammatory damage in chronic ischaemia has 
been shown in ischaemic myocardial dysfunction. TLR4, expressed by 
cardiomyocytes, mediates post infarct maladaptive left ventricular remodelling 
and impairs cardiac function after myocardial infarction probably via 
inflammatory cytokine production and matrix degradation (159). Further, 
silencing TLR4 in cardiomyocytes improved cell survival following hypoxic 
injury through reduced inflammatory and apoptotic signals (160). In another 
study, it was shown that cardiomyocytes can initiate the inflammatory 
cascade by means of expressing TLR4 that responds to both pathogen and 
damage associated molecular patterns. The binding of TLR4 with Heat Shock 
Protein 60 (HSP60) was also observed in chronic heart failure 
cardiomyocytes. Furthermore, HSP60 induced robust production of 
inflammatory cytokines in chronic heart failure cardiomyocytes, which was 
reduced by TLR4-blocking antibodies. The authors concluded that the 
expression, ligand-binding capacity and pro-inflammatory function of 
cardiomyocyte TLR4 are up-regulated after myocardial infarction, which 
promote inflammation and exacerbate heart failure (161). 
Other studies have shown the expression and upregulation of TLR4 in human 
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chronic kidney disease (162-164). TLR4-mediated inflammation has been 
shown in a mouse model of skeletal muscle ischaemia-reperfusion (165), 
although the mechanism is not fully understood. Preliminary work from our 
group has shown that expression of TLR4 is upregulated in gastrocnemius 
muscle of patients with CLI (38).  
 
3. 2 Aims 
The aims of these experiments were to study in further detail the TLR4 
pathway in skeletal muscle biopsies obtained from patients with CLI and 
those form patients without PAD, and to study the TLR4 distribution in 
critically ischaemic human skeletal muscle.  
Objective:  
The objectives were:  
1) To define changes in TLR4 distribution and protein expression in 
human CLI tissue 




It was hypothesized that TLR4 is upregulated in critically ischaemic human 
skeletal muscle and is activated by endogenous ligands within the ischaemic 
tissue.  
 
3. 3 Experimental design 
Human skeletal muscle biopsies were taken from the medial head of 
gastrocnemius from patients undergoing major lower limb amputation for CLI 
(n=6) and from patients with no PAD undergoing saphenous vein harvesting 
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Sex (male) 4 3 > 0.05 
Age (mean, years) 61.5 64.5 > 0.05 
HTN, 3 4 > 0.05 
Diabetes 4 4 > 0.05 
Smoking 3 2 > 0.05 
eGFR (mean, 
mls/min/1.73m2) 
61 71 > 0.05 
Hyperlipidaemia 5 4 > 0.05 
Symptoms of PAD 6 0 < 0.05* 
ABPI < 0.9 6 0 < 0.05* 
Table 8 – Demographics of the 2 patient groups. The 2 groups differed only in 
terms of the presence of PAD symptoms and reduced ABPI, where p<0.05, Chi 
square test 
 
Immunofluorescence was carried out to study TLR4 and TLR1 expression 
and distribution in human skeletal muscle biopsies including co-location with 
endothelial cells, neutrophils and macrophages [Figure 22].  
Western blot analyses were carried out to study TLR expression and 
activation in human skeletal muscle biopsies. Further western blot analyses 
were carried out to identify the downstream signalling mechanisms 
contributing to cellular damage in ischaemic human skeletal muscle. The 
amount of transcription factors was quantified in the human skeletal biopsies 
utilising western blot analyses [Figure 23]. Western blot images were 
analysed by Image J software (Chapter 2.2) to measure the intensity of the 
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The data were found to be not normally distributed, therefore the Mann-
Whitney U test was used to compare differences between the 2 groups. 
 
The primary antibodies used for the western blotting were as follows:  
Antibodies Suppliers Concentrations 
TLR1 ab37068; Abcam 1:1000 
TRIF ab13810; Abcam 1:1000 
TLR4 ab22048; Abcam 1:500 
HSP70 sc-373867; Santa Cruz 1:1000 
HSP60 sc-136291; Santa Cruz 1:1000 
MyD88 ab2064; Abcam 1:1000 
P-P38 D3F9; Cell Signalling 1:1000 
P38 9212; Cell Signalling 1:1000 
JNK 9252; Cell Signalling 1:1000 
P-JNK 9251; Cell Signalling 1:1000 
NFkB C22B4; Cell Signalling 1:1000 
P-NFkB 93H1; Cell Signalling 1:2000 
Cleaved Caspase-3 9661; Cell Signalling 1:1000 
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The primary antibodies used for the Immunofluorescence were as follows:  
Primary 
antibodies 
Species Suppliers Concentrations 
TLR4 Mouse ab22048; Abcam 1:100 
CD34 Mouse ab9088; Abcam 1:100 
CD68 Mouse M0814; 
DakoCytomation 
1:100 
CD31 Mouse M0823; 
DakoCytomation 
1:20 
TLR1 Rabbit ab37068; Abcam 1:100 
 
The secondary antibodies were as follows:  
Secondary 
antibodies 
Species Suppliers Concentrations 
Alexa Fluor® 488 
Anti-Rabbit IgG 
Goat A-11008;  
Life Technologies 
1:200 
Alexa Fluor™ 594 
Anti-Rabbit IgG 
Goat A-11012;  
Life Technologies 
1:200 
Alexa Fluor® 594   
Anti-Mouse IgG 
Chicken A-11032;  
Life Technologies 
1:200 
Alexa Fluor® 488  
Anti-Mouse IgG 




3. 4 Results 
The immunofluorescence staining demonstrated that both TLR4 and TLR1 
are expressed on endothelium (CD31), neutrophils (CD43) and macrophages 
(CD68) in muscle biopsies from patients with CLI [Figure 24 (a, b)]. TLR4 and 
TLR1 double staining of ischaemic muscle sections showed co-localization of 
these receptors, suggestive of heterodimerisation [Figure 24 (a, b)]. 
To investigate further the potential of TLR4 and TLR1 heterodimerisation, 
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(Chapter 4). Western blot analyses of muscle homogenates showed 
upregulation of TLR4 (median 0.84, range 0.50-1.07) and TLR1 (median 
2.34, range 1.86-3.77) in ischaemic samples versus non-ischaemic samples 
(TLR4, median 0.29, range 0.007-0.57, P<0.05, n=6; TLR1, median 1.23, 
range 0.022-2.72, P<0.05, n=6) [Figure 25]. Transcription factors in human 
muscle biopsies were quantified showing increased phosphorylated NFkB 
(median 0.41, range 0.25-0.85) and phosphorylated JNK (median 0.21, range 
0.12-0.31) in ischaemic samples versus non-ischaemic samples (pNFkB, 
median 0.12, range 0.02-0.25; pJNK, median 0.02, range 0.009-0.05, P<0.05, 
n=4) [Figure 25]. More detailed analyses on the downstream signalling 
mechanism were carried out on cultured human myotubes (Chapter 4).  
Western blot analyses of cleaved caspase 3 expression were performed to 
measure apoptosis within the muscle biopsies and this was found to be 
increased in ischaemic samples (median 0.15; range 0.059-0.387), versus 
non-ischaemic samples (median 0.001, range 0.0007-0.0187, P<0.05, n=4) 
[Figure 26]. Further, protein levels of HSP 60 and 70, potential endogenous 
ligands of TLR4, were found to be elevated in CLI biopsies (HSP60, median 
0.106, range 0.082-0.119; HSP70, median 0.087, range 0.065-0.095) versus 
non-ischaemic biopsies (HSP60, median 0.041, range 0.028-0.044; HSP70, 
median 0.0305, range 0.023-0.038, P<0.05, n=4) [Figure 26]. 
 
3. 5 Discussion 
From analyses of human tissue, it was demonstrated that muscle biopsies 
contained macrophages, neutrophils and endothelial cells in addition to 
muscle fibres. Immunofluorescence staining showed the presence of both 
TLR4 and TLR1 on neutrophils, endothelium and macrophages. The 
presence of TLR4 and TLR1 in these cells have already been shown in 
previous studies (166, 167). These findings confirm wide distribution of both 
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receptors in the ischaemia-induced inflammatory response in patients with 
CLI. Double staining of the sections showed co-localisation of TLR4 and 
TLR1. The potential for heterodimerisation is investigated in more detail in in 
vitro experiments described in Chapter 4.   
TLR4 and TLR1 were found to be present in muscle biopsies from both 
groups, with significant upregulation of these receptors in the ischaemic 
samples. The considerable change in TLR4 expression suggests that it plays 
an important role in critically ischaemic skeletal muscle. The upregulation and 
potential adverse effects of TLR4 in lower limb skeletal muscle have been 
shown in previous studies (168) where TLR4 was upregulated and activated 
by specific ligands to initiate an inflammatory process in skeletal muscle after 
seven consecutive days of bed rest in healthy older adults.  
Phosphorylated NFkB and JNK, activated forms of the key transcription 
proteins (NFkB and JNK) in the TLR4 signalling pathway, were significantly 
upregulated in the ischaemic samples, indicating activation of these pathways 
and is suggestive of functional upregulation of TLR4 in critically ischaemic 
muscle. However further experiments are required to confirm these 
observations and to better understand the downstream signalling involved. 
Joshi et al. showed that cleaved caspase 3 is upregulated in ischaemic 
muscle (139), indicating the activation of the apoptotic caspase 3 pathway. 
The response is dependent on the severity of the ischaemia, suggesting that 
multiple pathways play a role in triggering caspase 3 activation (169). TLR-
induced inflammation and apoptosis has been shown to be associated with 
increased cleaved caspase 3 (170). The increase in cleaved caspase 3 in our 
experiments suggest that TLR4 upregulation and activation in critically 
ischaemic muscle may contribute to the increased apoptosis that occurs.  
The upregulation of HSP60 and 70, potential TLR4 endogenous ligands, were 
shown in the ischaemic samples. Liu et al. showed that HSP70 is increased in 
ischaemic skeletal muscle in patients with chronic lower limb ischaemia while 
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Our findings support the presence and release of potential DAMPs in 
ischaemic muscle which could contribute to chronic activation of TLR4 and 
the resulting tissue damage.   
 
Limitations: 
The control experiments were carried out on skeletal muscle biopsies 
obtained from patients undergoing CABG surgery. Although the patients in 
the control group had no history of arterial claudication, with normal readings 
of ABPI, there is possibility for some underlying PAD as these patients share 
most of the cardiovascular risk factors. Further, presence of potential infection 
in the biopsies is another limitation of these experiments, as infecting 
microorganisms are potent TLR4 activators. To reduce the risk of infection, 
the biopsies were taken away from macroscopically infected areas. Further, 
due to the limited amount of tissue biopsies available from each control 
patients, some experiments were carried out on only 4 patients. Also, we did 
not study specific contribution of TLR4 receptors on various cell types, but 
autocrine/paracrine effect of tissue as a whole. Finally, these experiments 
were observational only but important to study human tissue to understand 
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Figure 22 - CD31, CD43 and CD68 were stained as specific markers for 
endothelial cells, neutrophils and macrophages respectively 









Figure 24 (a) -  H&E and immunohistochemical staining of ischaemic muscle 
sections A) H&E staining of ischaemic muscle section B) Double labelled 
Fluor-IHC-P staining of TLR1 & TLR4 showing co-localisation of TLR1 & TLR4 
C) H&E staining of micro vessel within ischaemic muscle D) Double labelled 
Fluor-IHC-P staining of TLR1 & CD31 showing TLR1 expression by endothelial 
cells E) H&E staining of ischaemic muscle section F) Double labelled Fluor-
IHC-P staining of TLR1 & CD43 showing TLR1 expression by neutrophils G) 
H&E staining of ischaemic muscle section H) Double labelled Fluor-IHC-P of 
TLR1 & CD68 showing TLR1 expression by macrophages (A, C, G: scale bar = 





























































Figure 24 (b) - H&E and immunohistochemical staining of ischaemic muscle 
sections I) H&E staining of micro vessel within ischaemic muscle J) Double 
labelled Fluor-IHC-P staining of TLR4 & CD31 showing expression of TLR4 by 
endothelial cells K) H&E staining of ischaemic muscle section L) Double 
labelled Fluor-IHC-P staining of TLR4 & CD43 showing TLR4 expression by 
neutrophils M) H&E staining of ischaemic muscle section N) Double labelled 
Fluor-IHC-P staining of TLR4 & CD68 showing TLR4 expression by 






















































Figure 25 - A) Representative immunoblots for TLR4 and tubulin loading 
control and densitometric analysis of the TLR4 immunoblots (n=6, P<0.05) B) 
Representative immunoblots for TLR1 and tubulin loading control and 
densitometric analysis of the TLR1 immunoblots (n=6, P<0.05) C) 
Representative immunoblots for P-NFkB, P-JNK and tubulin loading control & 
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Figure 26 - A) Representative immunoblots for cleaved caspase 3 and tubulin 
loading control and densitometric analysis of the cleaved caspase 3 
immunoblots (n=4, P<0.05)  B) Representative immunoblots for HSP70, HSP60 
and tubulin loading control & densitometric analysis of the HSP70 and HSP60 
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CHAPTER 4: FUNCTIONAL CONSEQUENCES OF TLR4 ACTIVATION IN 
ISCHAEMIC HUMAN MYOTUBES  
 
 
4. 1 Introduction 
 
 
4. 2 Aims  
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4. 1. Introduction 
In vitro experiments are beneficial in enhancing our understanding of how a 
specific harmful effect may affect a living system. Further, these experiments 
allow us to study a single effect of an action in isolation and offer high 
sensitivity without interaction from other biological pathways. Moreover, in 
vitro models have the potential to generate reliable data to identify areas 
which can be further investigated in in vivo models enabling the reduction in 
the number of animals required and refinement of animal experiments.    
Human skeletal muscle cell line is a valuable tool to study the 
pathophysiology of the skeletal muscle. Human myotubes have been utilized 
to study muscle physiology, aetiological investigations and therapeutic 
potentials in skeletal muscle related pathologies. Multiple human skeletal 
muscle culture systems have been developed which are mainly based on cell 
isolation from healthy donors or individuals with the relevant disease (172). 
Skeletal muscle has a remarkable ability to regenerate after injury. In the 
event of injury, skeletal muscle undergoes degeneration and regeneration 
process. This regeneration process relies on the interactions between the 
satellite cells and their environment (173). Satellite cells, upon activation, can 
re-enter the cell cycle to proliferate and differentiate into myoblasts where 
further differentiation and proliferation result in formation of myocytes which 
then fuse to form multinucleated myotubes. Myoblasts can be isolated from 
the muscle sample by different approaches: enzymatic digestion or cell 
migration (174, 175).  The in vitro culture of proliferating and differentiating 
myoblasts has been shown to be an effective method in the preparation of 
cell samples suitable for morphological and cytochemical analyses (136). 
The isolated myoblasts are grown to confluence before differentiation 
induction. Activated proliferating myoblasts express MyoD as a myogenic 
marker (176). The full maturation of the human skeletal muscle cells is 
evident when myotubes exhibit striated band pattern. The striated patterns 
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apparatus of skeletal muscle cell, meaning that these myofibres are 
structurally capable of contraction (177). 
Human skeletal muscle fibres express three types of myosin heavy chain 
(MyHC) including MyHC-β, MyHC-2A and MyHC-2X. The expression of the 
MyHC isoform defines the muscle fibre phenotype as slow fibres (type 1 
muscle fibre) or fast fibres (type 2 muscle fibre). Most human muscles consist 
of both fibre types in different degrees based on their functional demand, age 
and gender (178). 
It has been demonstrated that cultured myotubes retain the characteristics of 
their donor, as the donor phenotype is to some extent carried over to 
myotubes in vitro. The retention of the metabolic characteristics of the muscle 
cell donor is not fully understood, however a combination of genetic and 
epigenetic mechanisms are probably involved (179). 
During muscle hypoxia, ATP synthesis is impaired and therefore a mismatch 
of ATP need to ATP production occurs, leading to decreased tissue ATP 
resources and damage to the ATP-dependent enzymes in the skeletal muscle 
cells. The disturbed oxygen homeostasis will result in cell oedema and 
unspecific activation of proteases (180), which results in cell death and 
inflammation which later is followed by repair and formation of new muscle 
fibres (181). In the presence of persistent ischaemia and tissue hypoxia, 
skeletal muscle responds by changes in gene expression. Hypoxia inducible 
factor 1 (HIF-1) coordinates the cellular response in an attempt to recapture 
oxygen homeostasis (182).  
Ischaemia comprises of the accumulation of metabolic waste and nutrition 
depletion in addition to hypoxia. Exposure of cultured myotubes to nutrition 
depletion, hypoxia and hypercapnia is associated with increased HIF-1 levels, 
and simulates certain characteristics of skeletal muscle ischaemia (139). 
These characteristics are described as a fall in the pH of the culture media, 
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increased level of cleaved caspase 3, and increased LDH release by 
myotubes (139).  
The cultured human myotubes from patients with no PAD can provide a 
platform for in vitro experiments to assess the functional consequences of 
ischaemia when the cell lines are exposed to simulated ischaemia. Further 
comparison between the cultured myotubes from patients with no PAD and 
patients with CLI can demonstrate if cultured myotubes from ischaemic 
skeletal muscle retained any memory and behave differently.  
TLR4 has been shown to be up-regulated and activated in cultured human 
endothelial cells when simulated ischaemia is introduced. This up-regulation 
has been associated with activation of the inflammatory system (183).  
The presence of TLR4 in cultured human myotubes can be assessed in cell 
lines obtained from patients with CLI and patients with no CLI. The 
downstream signalling pathway can also be examined when the effect of 
protein inhibitors can be observed at different levels targeting TLR4, and its 
adaptor and transcription proteins.  Further, release of endogenous ligands 
such as HSP 60 and 70 can be examined in the process of hypoxia-related 
skeletal muscle cell damage. 
Intracellular and extracellular physiological cascades are policed by activation 
and inhibition of various biological markers. Natural or synthetic inhibitors 
have become the basis for the development of therapeutic agents.  Protein 
inhibitors are useful tools for research and clinically, for the treatment of 
different medical conditions.  Application of protein inhibitors in in vitro 
experiments has enabled scientists to investigate downstream signalling 
pathways more specifically.  
TLR4 inhibitors have played a pivotal role in the investigation and 
understanding of the role of TLR4 in the pathophysiology of different 
diseases. The impact of TLR4 inhibitors on cardiovascular dysfunction have 
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4. 2. Aims 
The aims of these experiments were to study the role of the TLR4 signalling 
pathway in ischaemia-induced cellular damage and inflammation in human 
skeletal myotubes and to assess for any differential response between 




The objectives were: 
1) To isolate myoblasts from patients with CLI and from patients without 
PAD and to culture them to myotube stage 
2) To compare specific baseline characteristics relating to the TLR4 
pathway in both types of myotubes 
3) To assess the response of these myotubes to ischaemia 
4) To understand the role of TLR4 signalling pathway in ischaemia-
induced apoptosis and cytokine release from myotubes 
5) To explore the role of TLR4 / downstream signalling pathway inhibition 
in ischaemia-induced apoptosis and cytokine release from myotubes  
6) To explore the possibility of heterodimerisation of TLR4 and TLR1 
 
Hypothesis:  
It was hypothesized that: 
1) TLR4 is up-regulated and its signalling pathway activated in cultured 
human myotubes exposed to simulated ischaemia [Figure 27].  
2) TLR4 inhibition attenuates ischaemia-induced damage in cultured 
human myotubes exposed to simulated ischaemia [Figure 28].  
3) MyD88 downstream signalling pathway is involved in regulating 
inflammatory gene transcription in TLR4-induced skeletal muscle 
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4) NFkB, JNK and P38, as transcription proteins, are involved in 
regulating inflammatory gene transcription in TLR4-induced skeletal 
muscle damage in ischaemia [Figure 30].  
5) Simulated ischaemia induces inflammatory cytokine release from 
skeletal myotubes, via a mechanism that involves heat shock protein 
(HSP) 60&70, known endogenous ligands of TLR4 [Figure 31].  
6) Simulated ischaemia results in heterodimerisation of TLR4 and TLR1 
in human myotubes.  
 
4. 3. Experimental design 
The overall experimental design for the in vitro work is illustrated in Figure 32 
and details of experimental techniques are given in Chapter 2. Human 
gastrocnemius muscle biopsies were taken from patients with CLI undergoing 
major lower limb amputation (Group 1; n=6) and from patients with no PAD 
(Group 2; n=6). Human myoblasts were isolated, cultured to myotubes and 
then exposed to simulated ischaemia. The isolated myoblasts were examined 
every 48 hours to monitor for confluence before induction to differentiate into 
myotubes [Figure 33]. Same numbers of cultured cells were placed in culture 
plates to normalise the amount of proteins in all the experiments. Further, 
fluorescent immunohistochemical staining for desmin, a marker of human 
skeletal muscle, was carried out to confirm the presence of myogenic cell 
lines [Figure 34].   
Western blot analyses of TLR4, TLR1 and cleaved caspase 3 were carried 
out on the cell lysates to assess TLR4 expression, signalling activity and 
apoptosis respectively. Further, ELISA quantification of IL-6 and TNFα were 
carried out on supernatants to quantify the inflammatory cytokine response 
after exposure to simulated ischaemia [Figure 32].  
Cultured human myotubes were pre-treated with 1) TLR4 agonist (Synthetic 
Monophosphoryl Lipid A), TLR4 neutralizing antibody or TLR4 antagonist 
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TLR4, P-NFkB (signal-related kinase) and cleaved caspase 3 were carried 
out on cell lysates to assess TLR4 expression, downstream signalling activity 
and apoptosis respectively; 2) MyD88 or TRIF inhibitor prior to exposure to 
simulated ischaemia: ELISA analyses were carried out to quantify IL6 and 
TNFα release, and Western blot was used to assess expression of cleaved 
caspase 3 as a marker of apoptosis; 3) NFkB, JNK or P38 inhibitor prior to 
exposure to simulated ischaemia: ELISA analyses were carried out to 
quantify IL6 and TNFα release, and Western blot was used to assess the 
expression of MyD88, TRIF, NFkB, JNK, P38 and cleaved caspase 3; and 4) 
TLR4 neutralizing antibody prior to exposure to simulated ischaemia: ELISA 
analysis was carried out to quantify HSP60, HSP70, IL6 and TNFα release in 
the supernatants; and Western blot was used to assess expression of 
HSP60, HSP70 and cleaved caspase-3 in the cell lysates. Co-
immunoprecipitation was carried out to assess the potential 
heterodimerisation of TLR4 and TLR1. 
The following inhibitors were used to inhibit adaptor and transcription 
proteins, and TLR4 receptor. All doses were calculated based on the previous 
similar studies or information provided on the datasheet (IC50): 
Inhibitors Suppliers Pre-conditioning 
period  
MyD88 20μM; tlrl-pimyd; Invivogen 6 hours 
TRIF 20μM; tlrl-pitrif; Invivogen 6 hours 
NFkB 10μM; Celastrolant-cls; Invivogen 6 hours 
P38 10μM; SB203580; SelleckChem 4 hours 
JNK 20μM; 420119; Merck Chemicals 4 hours 
TLR4 Neutralizing 
Ab 
10 μg/ml; mabg-htlr4; Invivogen 2 hours 
TLR4 antagonist 
(LPS-RS) 
10 μg/ml; tlrl-prslps; Invivogen 4 hours 
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The following ELISA kits were used and the experiments were carried out as 
per manufacturer’s instructions: 
ELISA kits Suppliers 
Human IL6 D6050; R&D Systems 
Human TNFα DTA00C; R&D Systems 
Human total HSP60 1800-2; R&D Systems 
Human total HSP70 DYC1663-2; R&D Systems 
Human INFα 41100; PBL Assay Science 
  
4. 4. Results 
 
4.4.1  Myotubes derived from patients without PAD  
Western blot analyses of lysates of myotubes derived from patients with no 
PAD showed that TLR4 (median 44; range 26-53) and cleaved caspase 3 
(median 27; range 18-33) were up-regulated after exposure to simulated 
ischaemia (P<0.05; Mann Whitney test) compared to non-ischaemic 
myotubes from the same patient group (TLR4, median 14, range 6-18; 
cleaved caspase 3, median 6, range 4-8) [Figure 35]. 
The ELISA assessment of the supernatants of cultured myotubes derived 
from patients with no PAD showed increased expression of IL-6 (pg/ml) 
(median 178, range 133-269) and TNFα (pg/ml) (median 199, range 174-295) 
after simulated ischaemia (P<0.05; Mann Whitney test) [Figure 35]. Further 
ELISA quantification of the supernatants of myotubes from patients with no 
PAD showed significant increase in both HSP60 and HSP70 (HSP60, median 
1240, range 950-2200 vs median 100, range 50-1000; HSP70, median 5900, 
range 4500-7000 vs median 1900, range 800-3000), when exposed to 
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4.4.2  Myotubes derived from patients with CLI 
The cultured myotubes from patients with CLI showed similar findings in 
terms of up-regulation of TLR4 (median 73; range 55-91 vs median 35, range 
23-52, P<0.05; Mann Whitney test) and cleaved caspase 3 (median 28; range 
21-47 vs median 8.5, range 5-13, P<0.05; Mann Whitney test), and increased 
expression of IL-6 and TNFα after simulated ischaemia (IL-6; median 207, 
range 180-225 vs median 35, range 20-49; TNFα, median 393, range 330-
425 vs median 14, range 8-22, P<0.05; Mann Whitney test) compared to non-
ischaemic myotubes from the same patient group  [Figure 37]. Western blot 
analyses of the cell lysates confirmed the presence of both HSP60 and 
HSP70, and demonstrated up-regulation of these endogenous ligands in 
patients with CLI, when exposed to simulated ischaemia (HSP60, median 15, 
range 13-16 vs median 5, range 2.5-7; HSP70, median 19, range 17-21 vs 
median 11, range 7-14) (P<0.05; Mann Whitney test) [Figure 36]. ELISA 
quantification of the supernatants showed significant increase in both HSP60 
and HSP70 in patients with CLI (HSP60, median 3800, range 2700-4500 vs 
median 1500, range 700-2400; HSP70, median 7000, range 5700-8000 vs 
median 3200, range 2500-4800), when exposed to simulated ischaemia 
(P<0.05; Mann Whitney test) [Figure 36]. 
 
4.4.3  Baseline differences between both groups   
Myotubes from patients with CLI expressed greater levels of TLR4 as 
compared to those from patients with no PAD after exposure to the simulated 
ischaemia. Further, western blot analysis of TLR1 in cell lysates showed up-
regulation in both groups after exposure to the simulated ischaemia (P<0.05; 
Mann Whitney test) [Figure 35, Figure 37]. 
 
4.4.4  TLR4 inhibition in myotubes derived from patients with CLI  
Pre-treatment of myotubes from patients with CLI using TLR4 antagonist (RS-
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(median 20, range 14-31) in ischaemic cell lysates as compared to ischaemic 
cell lysates with no pre-treatment (median 40, range 35-51) (P<0.05; Mann 
Whitney test) [Figure 38]. Pre-treatment of myotubes from patients with CLI 
using TLR4 neutralizing antibody or TLR4 antagonist (RS-LPS) prior to 
simulated ischaemia reduced the expression of cleaved caspase 3 (TLR4 
neutralising Ab, median 100, range 74-141; TLR4 antagonist RS-LPS, 
median 128, range 100-160) in ischaemic cell lysates as compared to 
ischaemic cell lysates with no pre-treatment (median 302, range 259-371) 
(P<0.05; Mann Whitney test) [Figure 39]. Further, pre-treatment with TLR4 
agonist (LPS) was associated with increased expression of P-NFkB (median 
56, range 50-66 vs median 40, range 35-51) (P<0.05; Mann Whitney test) 
[Figure 38].  The amount of P-NFkB, activated form of NFkB, was normalised 
as a ratio to the total levels of NFkB. ELISA quantification of the supernatants 
showed significant decrease in expression of endogenous ligands HSP60 
(median 2230, range 1400-2900 vs median 3700, range 2100-4500) and 
HSP70 (median 3070, range 2500-4250 vs median 7000, range 6250-8100), 
as well as inflammatory markers IL6 (median220, range 200-255 vs median 
105, range 70-155) and TNFα (median 398, range 310-476 vs median 145, 
range 110-245), when the cells are pre-treated with TLR4 neutralizing Ab 
prior to the simulated ischaemia (P<0.05; Mann Whitney test) [Figure 40]. 
 
4.4.5 Inhibition of adaptor proteins in myotubes derived from patients 
 with CLI 
Western blot analyses of the cell lysates from patients with CLI confirmed the 
presence of the adaptor proteins MyD88 and TRIF and their expressions 
were independent to the exposure to simulated ischaemia in culture [Figure 
41]. Pre-treatment of myotubes from patients with CLI with MyD88 inhibitor 
prior to simulated ischaemia resulted in decreased IL6 (pg/ml) (median 59, 
range 40-101 vs median 205, range 180-245) and TNFα (pg/ml) (median 97, 
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myotubes with no pre-treatment before the simulated ischaemia [Figure 42] 
and down-regulation of cleaved caspase-3 (median 56, range 42-78 vs 
median 128, range 102-160) [Figure 43] (P<0.05; Mann Whitney test). 
However, myotubes pre-treated with TRIF inhibitor disclosed no significant 
changes in IL6 and TNFα release or cleaved caspase-3 expression (P>0.05; 
Mann Whitney test). Further, the inhibition of the adaptor proteins prior to 
simulated ischaemia was associated with reduced expression of HSP60 
(median 1600, range 1000-2100 vs median 3800, range 3000-4200) and 
HSP70 (median 3800, range 2700-5000 vs median 7000, range 5400-7800) 
(P<0.05; Mann Whitney test) [Figure 44, Figure 45]. 
   
4.4.6 Inhibition of transcription proteins in myotubes derived from  patients 
 with CLI 
Expression of the activated form of NFkB (median 11, range 8-15 vs median 
3, range 2-12), JNK (median 13, range 10-18 vs median 4, range 2-13) and 
P38 (median 18, range 15-19 vs median 8, range 5-12) were significantly 
increased after exposure to simulated ischaemia (P<0.05; Mann Whitney test) 
[Figure 41]. Pre-treatment of myotubes with NFkB, JNK and P38 inhibitor 
prior to ischaemia resulted in decreased levels of IL6 (pg/ml) (median 55, 
range 40-96 vs median 207, range 180-250) and TNFα release (median 55, 
range 40-96 vs median 493, range 330-425), and down-regulation of cleaved 
caspase-3 (median 23, range 15-43 vs median 140, range 110-146) (P<0.05; 
Mann Whitney test) [Figure 46] [Figure 47].  
Further, the inhibition of the transcription proteins prior to simulated ischaemia 
was associated with reduced expression of HSP60 (median 1500, range 
1100-1900 vs median 3800, range 3000-4200) and HSP70 (median 4200, 
range 3400-4900 vs median 7000, range 5400-7800) (P<0.05; Mann Whitney 
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4.4.6 TLR4 and TLR1 heterodimerisation 
TLR4 and TLR1 co-immunoprecipitation showed heterodimerisation of these 
receptors in cultured human myotubes after exposure to simulated ischaemia 
[Figure 48].  
 
4. 5. Discussion 
In this chapter, functional consequences of TLR4 activation in ischaemic 
human myotubes were examined in vitro. 
It was demonstrated that TLR4 is present in cell lines derived from both 
patients with CLI and patients without PAD. Myotubes from both groups 
showed up-regulation of TLR4 after exposure to simulated ischaemia with the 
response from the CLI group being more pronounced, suggesting that 
cultured myotubes from patients with CLI kept their phenotype. Therefore, 
further work was carried out on the cultured myotubes from patients with CLI. 
Up-regulation of TLR4 after simulated ischaemia is associated with activation 
of its downstream signalling pathway. Both MyD88 and TRIF adaptor proteins 
were found in the cell lysates with no significant changes in their expression 
after simulated ischaemia, although the inhibition of MyD88 was associated 
with reduced inflammatory response as compared to inhibition of the TRIF 
pathway. This suggests that the TLR4 response to simulated ischaemia is 
mainly regulated via the MyD88 signalling pathway rather than the TRIF 
pathway.  
Moreover, the activated transcription proteins (NFkB, JNK and P38) were 
found to be upregulated in the cultured myotubes after exposure to the 
simulated ischaemia, while the inhibition of these regulatory proteins were 
associated with reduced inflammatory response. This suggests that these 
transcription proteins regulate the TLR4-induced inflammatory gene 
transcription. Simulated ischaemia was associated with increased cytokine 
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by the inhibition of TLR4 prior to simulated ischaemia. Investigation of HSP60 
and 70 as potential endogenous ligands for TLR4, showed that these proteins 
are also upregulated in the presence of ischaemia-induced TLR4 activation.     
Increased cytokine release, apoptosis and expression of HSP60 and 70 and 
TLR4 occurred in ischaemic skeletal muscle in vitro. TLR4 antagonism was 
associated with reduced apoptosis and inflammatory cytokine release and 
down-regulation of HSP60 and 70 expressions. This suggests a potential 
pathway where TLR4 and its endogenous ligands contribute to a positive 
feedback loop to maintain a pro-inflammatory environment during ischaemia.  
Hence, there is a potential link between HSP60 and 70-induced inflammatory 
cytokine production and TLR4 activation in ischaemic human myotubes. 
Finally, heterodimerisation of TLR4 and 1 in cultured human myotubes was 
demonstrated after exposure to simulated ischaemia. Further experiments are 
required to investigate the potential downstream signalling pathway after 
activation of heterodimerisation between TLR4 and 1, and whether a different 
downstream signalling pathway is mobilized. 
In this chapter, it was shown that the myoblasts were successfully isolated 
and cultured to myotubes from patients with CLI, and these were different 
from those derived from patients without PAD. This highlights the importance 
of considering relevant cell lines for the study of diseases and their 
treatments. The response of CLI myotubes to further ischaemic insult and the 
effect of TLR4 downstream inhibition in this response demonstrate the 
involvement of the TLR4 pathway and suggests that this pathway may be a 
potential therapeutic target. 
 
Limitations:  
The experiments were carried out on cells isolated from patients with CLI, 
where the process of isolation, culture and differentiation may have affected 
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represent the complex pathophysiological conditions present in in vivo. 
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Figure 27 - TLR4 signalling pathway highlighting the potential up-regulation 
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Figure 28 - TLR4 signalling pathway highlighting the potential effect of TLR4 
inhibition (Neutralizing Ab or RS-LPS) on tissue damage in cultured human 
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Figure 29 - TLR4 signalling pathway highlighting the potential role of MyD88 in 





Student Number: 110091643 
 
 
Figure 30 - TLR4 signalling pathway highlighting the potential roles of P38, 
JNK and NFkB, as transcription proteins, in the downstream signalling 
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Figure 31 - TLR4 signalling pathway highlighting the potential role of HSP60 
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Figure 33 - Cultured human skeletal muscle; A&D) Isolated human myoblasts 
from the skeletal muscle biopsy (1-week-old); B&E) Human myotubes (under 


















Figure 34 - Cultured human skeletal myotubes showing fluorescent 
immunohistochemical staining for desmin (Texas red); A, B & C) Isolated 
human myoblasts from the skeletal muscle biopsy (1-week-old); D) Human 
myotubes (under differentiation); E) Human myotubes (fully differentiated); F) 

















Figure 35 – Effect of ischaemia on myotubes from patients with no PAD A) 
Representative western blots of TLR4, TLR1 and cleaved caspase 3 B-D) 
Densitometric analyses of western blots showing upregulation of TLR4, TLR1 
and cleaved caspase 3 myotubes cultured in ischaemic conditions (n=6, 
p<0.05) E&F) ELISA data showing increased  IL6 and TNFa release by 

























































































Figure 36 – Effect of ischaemia on myotubes from patients with CLI A) 
Representative western blots of HSP60 and HSP70 B&C) Densitometric 
analyses of western blots showing upregulation of HSP60 and HSP70 (n=6, 
p<0.05) D&F) ELISA data showing increased  HSP60 and HSP70 release by 
































































Figure 37 – Effect of ischaemia on myotubes from patients with CLI A) 
Representative western blots of TLR4, TLR1 and cleaved caspase 3 B-D) 
Densitometric analyses of western blots showing upregulation of TLR4, TLR1 
and cleaved caspase 3 myotubes cultured in ischaemic conditions (n=6, 
p<0.05) E&F) ELISA data showing increased  IL6 and TNFa release by 



























































































Figure 38 – A) Representative western blots of P-NFkB with TLR4 agonist 
(synthetic LPS) or TLR4 antagonist (RS-LPS) pre-treatment prior to simulated 
ischaemia in myotubes from patients with CLI B) Densitometric analyses of 
western blots of P-NFkB with TLR4 agonist (synthetic LPS) or TLR4 antagonist 
(RS-LPS) pre-treatment prior to simulated ischaemia in myotubes from 









Figure 39 - Western blot analysis (representative blot and densitometric 
analysis data) of cleaved caspase 3 from patients with CLI which were pre-
treated with TLR4 antagonist (RS-LPS) or TLR4 Neutralising Ab prior to 
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Figure 40 – Effect of TLR4 antagonism and ischaemia on myotubes from 
patients with CLI A) TLR4 antagonist pre-treatment attenuates ischaemia-
induced IL6 and TNFa release (n=6, p<0.05) B) TLR4 antagonist pre-treatment 













Figure 41 – Effect of ischaemia on myotubes from patients with CLI A) 
Representative western blots of MyD88, TRIF, and densitometric analyses of 
western blots showing no significant difference after simulated ischaemia B) 
Representative western blots of P-NFkB, P-JNK, P-P38, and densitometric 
analyses of western blots showing upregulation of P-NFkB, P-JNK and P-P38 








Figure 42 - Representing ELISA analyses of A) IL-6 and B) TNFα in cultured 
myotubes from patients with CLI, with or without pre-treatment with MyD88 















Figure 43 - Effect of ischaemia on myotubes from patients with CLI. 
Representative western blots of Cleaved Caspase 3 after inhibition of adaptor 
proteins and densitometric analyses of western blots showing downregulation 










Figure 44 - Representing ELISA analyses of HSP70 in cultured myotubes from 
patients with CLI, with or without pre-treatment with A) TRIF and MyD88, and 













Figure 45 - Representing ELISA analyses of HSP60 in cultured myotubes from 
patients with critical limb ischaemia, with or without pre-treatment with A) TRIF 










Figure 46 - Effect of ischaemia on myotubes from patients with CLI. 
Representative western blots of Cleaved Caspase 3 after inhibition of 
transcription proteins and densitometric analyses of western blots showing 
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Figure 47 - Representing ELISA analyses of A) IL-6 and B) TNFα in cultured 
myotubes from patients with CLI, with or without pre-treatment with JNK, 
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Figure 48 - A) Co-IP with anti-TLR4 and western blot with anti-TLR1 and anti-
TLR4 suggesting heterodimerisation of TLR4 & TLR1 B) Co-IP with anti-TLR1 
and western blot with anti-TLR4 and anti-TLR1 suggesting heterodimerisation 
of TLR4 & TLR1 C) H&E staining of ischaemic muscle section (scale bar = 
10μm D) Double labelled Fluor-IHC-P staining of TLR1 & TLR4 showing co-
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CHAPTER 5: IN VIVO MODEL OF ISCHAEMIA-INDUCED SKELETAL 
MUSCLE DAMAGE       
 
5. 1 Introduction 
     5.1.1  Techniques of femoral artery disruption 
      5.1.2  Effect of species   
 5.1.3  Effect of age 
 5.1.4  Acute ischaemia vs. chronic ischaemia 
 5.1.5  Limitations of the current models   
 
5. 2 Aims  
 
5. 3 Experimental design 
 
5. 4 Results 
 





















The utilization of animals as models for human anatomy and physiology was 
initiated first in ancient Greece (184).  
“Ought we, for instance (to give an illustration of what I mean), to begin by 
discussing each separate species-man, lion, ox, and the like-taking each kind 
in hand independently of the rest, or ought we rather to deal first with the 
attributes which they have in common in virtue of some common element of 
their nature, and proceed from this as a basis for the consideration of them 
separately?” 
-Aristotle (384 -322 BC) “On the Parts of Animals” 
Although the early animal modelling was completely observational, it soon 
became a strong research tool for studying diseases and their treatments.   
Animal modelling has its own limitations as animals host different diseases 
and different responses, however it allows study of in vivo responses, often in 
controlled conditions before translation of experimental findings into clinical 
trials in humans.  
In clinical physiology and phenotypic mimicry models, the pathogenesis of a 
disease is triggered in an animal model to produce similar phenotypic 
outcome that is seen in clinical scenarios in human. For example, mechanical 
disruption of the vasculature and blood flow in an animal model mimics 
perfusion-related abnormality and dysfunction (185). Further motivation to 
advance animal modelling resulted in the introduction of transgenic and gene 
knockout models to investigate the pathologies which were not available in 
natural models. In transgenic models, an exogenous gene is injected directly 
into cells at early embryonic stage in animal development. Whilst, in gene 
knockout models, an endogenous gene is deleted or modified leading to the 
generation of animals deficient in specific gene of interest. Genetic 
manipulation was initially introduced in a mouse model in 1980s when the 
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Since then, genetic manipulation has been established in different species 
such as rats, cats, dogs, pigs, sheep, goats and chickens, however the 
mouse continues to be the most commonly used for biomedical research. 
Phenotypic mimicry animal models in genetically manipulated animals have 
increased the ability to investigate the therapeutic potentials of novel 
treatments in pre-clinical studies. 
Mice are widely used because they are small, prolific, cost effective, easy to 
maintain and we have the potential to manipulate their genetics. Further, the 
genetic and physiological similarities between mice and human have 
attracted considerable attention on mice as potential models for human health 
and disease (187).    
Many aspects of skeletal muscle biology are remarkably similar between 
mammals (188). In mouse, as in human, skeletal muscle development is the 
result of the activation of different myogenic cells, derived from bone marrow. 
The myogenic cells, myoblasts, undergo myotome formation that is followed 
by fusion of myoblasts to form the primary fibres. Some of the myoblasts 
continue to proliferate and differentiate to form secondary fibres. At the same 
time, a basal lamina begins to form around the fibres and after this stage, the 
myoblasts are known as satellite cells due to their morphological changes. At 
the end of post-natal development, satellite cells enter a phase of quiescence 
but can be activated if the muscle tissue is damaged (189). Satellite cells 
remain associated with muscle fibres after birth and are responsible for 
muscle growth and repair throughout life (190). Muscle regeneration is also 
supported by non-myogenic cells, derived from stem cells. Mesenchymal 
stromal cells and vascular progenitors have been shown to participate in 
muscle regeneration by giving rise to myogenic stem cells or by stimulating 
the activation of the existing satellite cells (191, 192).  
In both human and mouse, there are significant differences between the 
skeletal muscle cells in the head, body and the limbs. This is due to the 
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194). The homeostasis and function of myofibres depend on their size and 
contractile properties, and also vascular supply, extracellular matrix 
composition, and efficacy of neural stimulation. The mechanism to generate 
energy for the contraction of the myofibres depends on the myofibres type: 
fast myofibres mainly rely on glycogen metabolism, while slow myofibres 
depends on mitochondria and lipid oxidation. Thus, the number of healthy 
mitochondria is essential to maintain muscle function.  
Healthy blood supply and capillary network is an imperative factor in skeletal 
muscle homeostasis to deliver oxygen and nutrients and also to remove 
waste products. Interruption in blood supply will affect skeletal muscle cell 
functionality and severe ischaemia will result in cell death and necrosis (195).  
The ratio between the slow and the fast fibres in skeletal muscle has a 
significant role in determining the nature of ischaemia-induced skeletal 
muscle damage. Slow fibre containing muscle, such as soleus, is more 
sensitive to ischaemia compared to muscle with predominantly fast fibres, 
such as gastrocnemius. Gastrocnemius has both oxidative and glycogen 
metabolism which makes it more suitable for the study of ischaemia-induced 
damage in skeletal muscle damage in the chronic setting (196). 
Another essential element in skeletal muscle homeostasis is the extracellular 
matrix that plays a key role in the transmission of the contractile 
characteristics of myofibres to move parts of the body. The generated force 
within myofibres is transferred across the sarcolemma to the basement 
membrane and then to the interstitial connective tissue where collagen is  
responsible for contraction (197).  
Following skeletal muscle damage in mouse, as in human, inflammation and 
myogenesis are required for resolution and healing. The process of 
regeneration starts soon after the infiltration of inflammatory cells and 
production of cytokines and enzymes. The inflammatory mediators activate 
the satellite cells which play a key role in the process of regeneration (192). 
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within 24 hours with peak activity on day 3-4. Their activity reduces 
significantly by day 7-10. By the end of the third week, the damaged 
innervation is restored with myofibres increased in size (198).  
Ischaemia-induced skeletal muscle damage in mouse, shows similar 
morphological changes to ischaemic human skeletal muscle. The 
histomorphological changes include increased disruption of inter-myofibres 
network, oedema and migration of polymorphonuclear neutrophils and 
phagocytic invasion (199). 
Many murine models of hind-limb ischaemia have been described in the 
literature. Most of these were developed for the assessment of ischaemia-
induced angiogenesis, and to understand the pathophysiology of blood flow 
recovery after ischaemic insult to the hind-limb. Studies generally involved 
disruption of blood flow to the hind-limb using a range of techniques to ligate 
+/- excise segments of the hind-limb arterial tree. Tissue perfusion assessed 
by laser Doppler, and histological assessment of muscle sections and 
assessment of necrosis were main techniques of post-surgical assessment. 
Mice developed reduced perfusion in ischaemic limbs but in general, limb 
perfusion returned to normal by 4-6 weeks at the latest due to effective 
collateralisation in mice. Here, a range of models described in the literature 
will be summarised. 
 
5.1.1  Techniques of femoral artery disruption 
 
A. Simple ligation / electrocoagulation 
 
Limbourg et al. described a protocol in 10-12 weeks old BALB/c mice for the 
assessment of ischaemia-induced angiogenesis. They used adult mice as 
they have fully developed arterial networks and exclusively used male mice to 
exclude the confounding effects of cyclic oestrogen on the cardiovascular 
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ligated immediately distal to the origin of the deep femoral branch to redirect 
blood flow to the collateral arteries. Although this model is suitable for 
studying angiogenesis, the extent of ischaemia induced by this procedure 
was insufficient to cause severe functional or histological changes. 
Mulkern et al. used C57BL/6 mice with ligation of the unilateral hind-limb 
vessel under general anaesthesia to induce hind-limb ischaemia. The primary 
endpoint was to assess if the resultant gait can be validated as a surrogate 
marker for angiogenesis. The animals underwent gait assessment at day 3, 5, 
7, 10, 14, 21 and 28 post surgery. Gait analysis was performed using a 
Plexiglass tube. Angiography was performed at each time point to image the 
arterial tree and the corresponding collateral formation. To calculate the 
amount of collateralization, pixel count measurement was done after the 
angiography. The results showed significant correlation between 
collateralization and gait improvement, with mice showing complete recovery 
from the ischaemic insult within 21 to 28 days (201). Although this model of 
ischaemia showed reduced limb perfusion, the focus was on ischaemia-
induced collateralization and the associated ischaemia-induced muscle 
damage was not studied. In this publication, no data was provided regarding 
the age and gender of the mice, and no details regarding the level of arterial 
ligation and whether the vein was ligated or not were available. 
Desposito et al. used 10 weeks old male C57BL/6 mice with ligation of right 
femoral artery under general anaesthesia. The ischaemic changes were 
assessed at day 3, 7 and 14 post surgery, by quantification of 
neovascularization. Capillary density was measured by fluorescent staining of 
endothelial cells in muscle biopsies from gastrocnemius muscle, and was 
expressed as a percentage of pixels per image occupied by blood vessels. 
Tissue perfusion was assessed by laser Doppler. The results showed 
reduction of tissue perfusion, followed by significant improvement in the 
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technique caused significant interruption to the hind-limb perfusion, the post-
operative ischaemic changes were only observed for a short period of time.  
Borne et al. used 10-12 weeks old male C57BL/6 mice with unilateral double 
electrocoagulation of both femoral artery and iliac artery. The hind-limb 
perfusion was assessed at day 3, 5, 7, 10, 14, 21 and 28 post surgery. A 
systemic inflammatory response was demonstrated by increased circulating 
TNF levels 24-hour post surgery. Perfusion of the hind-limb almost returned 
to baseline by day 7 (203).  Although the level of ligation was high, up to the 
iliac artery, the mice only showed reduced perfusion for 7 days before 
recovering to base line tissue perfusion. 
Ouma et al. used male BALB/c mice weighing between 20 to 25 grams. The 
left femoral artery was exposed, isolated from the femoral nerve and vein, 
and ligated distal to the origin of the deep femoral artery, using a 6.0 silk 
sutures. Tissue perfusion was monitored with laser Doppler, and muscle 
necrosis was assessed by H&E staining of adductor muscle biopsies (204). 
Although the interruption to the hind-limb artery was only by ligation of the 
femoral artery with no excision, the perfusion ratio was still well below the 
base line on day 28. The histomorphological changes were only assessed on 
day 21 when necrosis and inflammatory cell infiltration were observed. The 
authors did not provide details regarding the age of the mice.  
Zhang et al. used 8 weeks old female C57BL/6 mice with ligation of the 
femoral artery proximal to origin of profunda. Tissue perfusion was monitored 
by laser Doppler, and skeletal muscle damage was examined histologically by 
identifying apoptotic cells (205). The results showed significant reduction in 
tissue perfusion post surgery, however muscle damage was only assessed 
histologically on day 21 post surgery, showing increased apoptosis within the 
ischaemic skeletal muscle.   
Kim et al. used 8 weeks old male BALB/c mice. The proximal portion of the 
femoral artery including the superficial and deep branches were ligated twice 
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in perfusion post-surgery with some degree of recovery by day 14 (206). 
Although reduction in tissue perfusion was shown in this study, the follow up 
period was only until day 14 post surgery, and there was no assessment of 
the histomorphological changes included.  
Aitsebaomo et al. used 10 weeks old Sv129 mice, widely used in the 
production of targeted mutations due to the availability of multiple embryonic 
stem cell lines derived from them. The femoral artery was exposed and two 7-
0 sutures placed proximal to the origin of the lateral caudal femoral artery. 
Perfusion was reduced post-surgery with foot and thigh perfusion recovering 
to its base line by day 8. However adductor muscle perfusion continued to 
increase over its base line by day 14 (207). H&E assessment of biopsies from 
the adductor muscles showed inflammatory cell infiltration at day 8 and 21.  
Jiang et al. used 8-10 weeks old female C56BL/6 mice with ligation of the 
proximal portion of the left femoral artery and vein including the superficial 
and the deep branches as well as the distal portion of the saphenous artery 
with 7-0 silk sutures. All arterial branches between the ligations were ligated. 
Ischaemic damage was assessed by calculating the ischaemic score (0 = no 
change, 1 = mild discoloration, 2 = moderate to severe discoloration, 3 = 
necrosis, 4 = amputation), and perfusion was measured by laser Doppler. 
Perfusion showed full recovery by day 21 post surgery. The ischaemic score 
was only calculated until day 7 post surgery, and significantly increased at 
day 1 with continued gradual increase until day 7 (208). The effect of venous 
congestion on the outcome was not discussed in this study.  
Hourde et al. established a mouse model of hind-limb ischaemia where the 
femoral artery was ligated immediately proximal to the bifurcation from the 
superficial epigastric artery (209). No evidence of toe, foot, leg necrosis, or 
toe amputation was observed.  Electric nerve stimulation of gastrocnemius 
muscles showed notable changes as the tetanic forces were significantly 
reduced by day 7, with significant recovery by day 28 post surgery. 
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showed some centrally nucleated muscle fibres (10% of the muscle cross-
sectional area), as evidence for regenerating muscle fibres [Figure 49]. 
Tekabe et al. used 6 weeks old male C57BL/6 mice. The femoral artery was 
ligated with two sterile 8/0 non-absorbable silk sutures below the inguinal 
ligament proximally and just above the bifurcation into the superficial and 
deep femoral arteries distally (210).  Biopsies of anterior tibialis muscle were 
stained for H&E on day 5 post-surgery, and showed significant infiltration of 
the inflammatory cells [Figure 50].  
 
B. Ligation and excision 
 
Thompson et al.  ligated and excised the left femoral artery, vein, and nerve 
proximal from just distal to the inguinal ligament to the level of the popliteal 
bifurcation in 8-12 weeks old male C57BL/6 mice. Limb perfusion was 
assessed by laser Doppler. The angiogenesis characteristics were assessed 
by quantification of CD31, a marker for endothelial cells, in muscle biopsies 
(211). This model resulted in significant ischaemia in the hind- limb up until 
day 28 post surgery. However, it was not clear if any animals were lost due to 
extensive tissue necrosis. Further, the ligation of the nerve along with the 
vessels was not justified in this technique. The potential changes due to 
nerve damage, or venous congestion following excision of the vein were not 
discussed.  
Takeda et al. used 10-12 weeks old male C57BL/6 mice with the femoral 
artery ligated distal to the inguinal ligament and proximal to the saphenous-
popliteal bifurcation. After all side branches were occluded by electrical 
cautery, the femoral artery was isolated and the ligated segment excised. 
Laser Doppler showed significant reduction in tissue perfusion with recovery 
to base line by day 28 post surgery. H&E staining of the gastrocnemius 
muscle showed a mixture of necrotic and fibrotic changes associated with 
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necrosis described as black toes (212). This model showed ischaemia-
induced morphological changes in the gastrocnemius muscle similar to those 
seen in ischaemic human skeletal muscle.  
Reis et al. used BALB/c male mice weighing between 20 to 25 grams. The 
femoral, deep femoral, and popliteal arteries were ligated. The femoral 
arteries were resected at their origin, just below the inguinal ligament, without 
injuring veins or the femoral nerve. The mice showed extensive tissue 
necrosis: in some mice involving the whole limb. H&E staining and 
morphological assessment of the gastrocnemius muscle showed muscle 
degeneration and infiltration of adipocytes similar to the changes in patients 
with CLI (213). This model resulted in extensive tissue damage in some mice 
but no clear details about the age of the animals were given.  
Huang et al. used adult male C57BL/6 mice weighing between 18 to 22 
grams.  The left femoral artery was ligated and excised between the inguinal 
ligament and its bifurcation into the saphenous and popliteal artery using 7-0 
propylene sutures (214). This led to significant ischaemia with tissue loss and 
foot necrosis in some of the animals, however the experiments were only 
examined until day 14 post surgery with no histological examination to 
observe the inflammatory changes. The average score of tissue necrosis was 
presented as 2.2 where 2 represented below ankle amputation and 3 
represented above ankle amputation. Again, the age of the mice was not 
clear in this study.   
Nakamura et al. used 10 weeks old male BALB/c mice. The entire left deep 
femoral artery and vein were ligated at two points with surgical 5-0 silk. The 
vessels were excised between the two points. The mice were sacrificed at 
day 3, 7, 14, 21 and 1 year and assessed for capillary density and necrosis. 
This model of ischaemia was associated with some degree of tissue loss and 
foot necrosis in most animals. H&E staining showed necrotic changes in 
adductor muscle biopsies up to day 21 post surgery (215). At 1 year follow 
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showed normal tissue along with some fibrotic and adipose tissue [Figure 51]. 
The potential effect of venous congestion after excision of the femoral vein 
was not discussed in this study.  
Park et al. used adult male C57BL/6 mice, with ligation and excision of the 
femoral artery. The mice were assessed on day 1, 3 and 21 with laser 
Doppler showing significant reduction in perfusion and almost full recovery by 
day 21. The mice showed some toe necrosis. No histomorphological 
assessment of muscle changes was done (216). The authors did not provide 
details regarding the age of the mice. 
Hellingman et al. investigated different surgical techniques to compare the 
effect of surgical variations on collateral formation (217). Adult male C57BL/6 
mice (10-12 weeks old) were used. They compared four different techniques: 
1- Ischaemia was induced by electrocoagulation of the left femoral artery, 
proximal to the superficial epigastric artery which resulted in complete 
transaction of the artery and retracting of the two ends 2- Electrocoagulation 
of the common iliac artery 3- Ligation and excision of the common femoral 
artery from the inguinal ligament to the popliteal artery with electrocoagulation 
of side branches. 4- Electrocoagulation of the common iliac followed by the 
femoral artery [Figure 52]. Tissue perfusion was assessed by laser Doppler 
and angiogenesis was assessed by immuno-staining of the muscle biopsies 
for CD31.  Blood flow restoration was significantly reduced to 54% after 28 
days in the group which had double electrocoagulation of both femoral and 
iliac artery. This was compared to 100% restoration of the blood flow on day 7 
post surgery in the groups with single electrocoagulation of femoral artery or 
iliac artery.  After total excision of the femoral artery, mice had 100% recovery 
of perfusion after 28 days, whilst those who underwent electrocoagulation of 
the femoral artery had 100% blood flow recovery within 14 days. Single 
electrocoagulation of the femoral artery or iliac artery, did not result in any 
distal necrosis, whilst the double ligation model resulted in three out of 10 
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extent of injury to the vascular tree (single ligation of artery, total excision of 
artery or double ligation) had greater influence on the pattern of blood flow 
restoration, than the level of arterial occlusion.  
Asano et al. used 7 weeks old male BALB/c mice. The proximal left femoral 
artery was ligated at 2 points 3 mm apart, and the artery between the 
ligatures was excised. Blood flow was measured with laser Doppler. The 
functional recovery assessment scored 1 and 2 on day 7 and 14 post surgery, 
respectively (0=lack of any visible mobility, and 3=mobility equal to non-
ischaemic hind limbs, with scores 1 and 2 in between). Histological 
examination showed that gastrocnemius muscles were atrophic, and the 
number of nuclei of both muscles and pericytes was decreased. The 
extracellular space had widened, and capillaries were barely observed [Figure 
53]. No apparent necrosis was observed in this model (218).  
In conclusion, the above studies suggest that the extent in length of the 
disruption to the hind-limb arterial tree has more impact on the severity of 
tissue perfusion reduction and ischaemia-induced tissue damage, than the 
level of the disruption. Further, the recovery period to restore the baseline 
tissue perfusion is longer in models with more extensive disruption, providing 
a longer period for investigators to study the ischaemic changes.   
 
5.1.2  Effect of species  
 
Schaper et al. used 11-13 week old male C57BL/6 and BALB/c mice to 
induce hind-limb ischaemia to compare the collateral vasculature between the 
two strains. The femoral artery was ligated and limb perfusion was assessed 
by laser Doppler imaging, visible light oximetry, treadmill testing, electron 
paramagnetic resonance (EPR) oximetry, x-ray angiography, and histology. 
Assessment of the tissue perfusion showed less initial ischaemia and then 
complete recovery in C57BL/6 mice, compared to BALB/c mice that showed 
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surgery. The histological examination of thigh muscles showed more 
prominent ischaemia-induced muscle damage in BALB/c mice described as 
multiple necrotic and regenerating areas with destroyed myofibres, and 
myofibres with central nuclei (219). 
Scholz et al. used 11 week old male BLAB/c and C57BL/6 mice to examine 
the mechanisms of restoration of the tissue perfusion in hind-limb ischaemia. 
The femoral artery was ligated and the tissue perfusion was assessed by 
laser Doppler at day 3, 7 and 21 post surgery. The perfusion recovery was 
quicker in the C57Bl/6 group, where it reached more than 80% of control 
values at day 7 post surgery. At that time BALB/c mice showed only 20% 
recovery. Cell damage in the gastrocnemius muscle was assessed as the 
number of nuclei that had taken up propidium iodide per 100 muscle fibres. It 
was 15+/- 5 in C57BL/6 mice and 71+/-14 in BALB/c mice (P<0.01). In non-
operated hind-limbs it was less than 1 for both groups (220).   
The above studies highlight the importance of the genetic background and 
the existing collateral circulation when designing a model of hind-limb 
ischaemia. C57BL/6 mice showed less severe reduction in tissue perfusion 
post surgery, but severe enough to cause ischaemia-induced inflammatory 
changes in the skeletal muscle, compared to BALB/c mice which showed 
more severe tissue damage with poorer tissue perfusion recovery.  
 
5.1.3  Effect of age 
 
Rey et al.  used male C57BL/6 mice to induce ischaemia by complete ligation 
and excision of the left femoral artery and its branches. Limb perfusion was 
assessed by laser Doppler, and compared in two groups of mice aged 12 
weeks and 13 months. The younger mice showed complete blood flow 
recovery by day 14 post surgery, whereas the older mice did not show 
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motor impairment scores and limb necrosis rates than the younger mice 
(221). 
Bosch-Marce et al. used male C57BL/6 mice. After ligating the proximal end 
of the femoral artery, the distal portion of the saphenous artery was ligated, 
and the artery and all the side branches were dissected free; after this, the 
femoral artery and attached side branches were then excised. Blood flow 
recovery in the ischaemic limb was compared in 2, 8 and 20 months old mice 
for a period of 35 days post-surgery. The blood flow recovery was most 
impaired in 20 months old mice followed by 8 months old mice, when 
compared to the young 2 months old mice. Further, the older mice showed 
less HIF-1 levels in the ischaemic limb compared to the younger mice (222). 
The results of the above studies suggest that aging is associated with 
impaired tissue perfusion recovery and increased ischaemia-induced tissue 
damage. Unlike younger mice, which recover spontaneously with no 
permanent damage, the older mice may represent a better model of hind-limb 
ischaemia more similar to patients with CLI. However, aging is a multifactorial 
component which can be a confounding factor in the overall physiology of the 
animal.   
 
5.1.4  Acute ischaemia vs. chronic ischaemia 
 
Yang et al. described a mouse model of hind-limb ischaemia with gradual 
arterial occlusion. The authors argued that acute arterial occlusion results in 
sudden increase of shear stress within the existing collaterals. The 
upregulation of shear stress responsive and inflammatory genes in the region 
of collaterals promote the process of angiogenesis, compromising the study 
of tissue response to ischaemia only. In this study, 3-5 months old C57BL/6 
mice were used. Acute ischaemia was induced by excision of femoral artery 
and ligation of the side branches, whilst the gradual ischaemia was induced 
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constrictors (0.25 mm internal diameter) around the proximal and distal 
femoral artery. Ameroid constrictors have an outer metal sleeve encasing an 
inner layer of a hygroscopic material which induce gradual vessel occlusion 
as they absorb moisture from the surrounding tissues. The tissue perfusion 
recovery was assessed by laser Doppler at day 1, 7, 14 and 35 post surgery, 
and the H&E staining was carried out to assess the muscle necrosis and 
inflammatory cell infiltration at day 3 post surgery. The analysis of tissue 
perfusion results showed rapid deterioration in the acute model soon after the 
surgery with faster recovery to almost baseline at day 35, compared to more 
gradual decrease in tissue perfusion after surgery with slower recovery rate 
even at day 35 post surgery. The H&E examination of the ischaemic 
gastrocnemius muscle showed greater necrosis with infiltration of 
inflammatory cells in the acute model, compared with no significant necrosis 
or inflammatory cell infiltration in the gradual model (223). In this study, the 
ischaemia-induced morphological changes in the skeletal muscle was only 
assessed at day 3 post surgery. Further, the lack of significant inflammatory 
cell infiltration in the gradual model may suggest that the induced-ischaemia 
is not severe enough to mimic the skeletal muscle damage observed in 
patients with CLI.   
Padgett et al. recently described another model of gradual ischaemia in 
BALB/c mice, compared to a model of acute ischaemia. In this study, the 
acute ischaemia was induced by double ligation of the femoral artery, whilst 
the gradual ischaemia was induced by placing ameroid constrictors at 
proximal and distal parts of the femoral artery, with side branches left intact. 
The authors showed less disruption in tissue perfusion in the gradual model 
post surgery (224). However, the perfusion was only assessed immediately 
post surgery with no further follow up. Further, there was no histological 
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The above studies suggest that models of gradual ischaemia represent 
changes more similar to the changes in CLI. Gradual ischaemia avoids the 
unnecessary activation of shear stress-induced genes, hence less extensive 
inflammatory response in the skeletal muscle. However, the application of 
these gradual models is more challenging technically and less cost effective.  
 
5.1.5  Limitations of the current models   
 
Most of the current hind-limb ischaemia models are designed to represent 
and assess the changes in the haemodynamics with primary endpoint of 
blood flow restoration after the induced ischaemia. We know from clinical 
studies that the functional outcomes in patients with CLI is not only 
dependent on blood flow restoration (225, 226). An animal model of hind-limb 
ischaemia which recapitulates the changes in skeletal muscle similar to the 
changes in CLI, is required for testing strategies to improve muscle 
dysfunction.  
Results from the different studies are not comparable due to differences in 
technique, species and age. Some studies did not give clear information on 
age, species, or the number of animals that did not survive or experienced 
severe ischaemia. Also, in some studies, lack of clear information on the 
surgical procedure regarding the instruments, sutures, dressing, type of 
anaesthesia or the post operative management render them less 
reproducible. Most models only induce a short period of ischaemia, providing 
a limited period to study the ischaemia-induced changes. Further, early tissue 
perfusion recovery compromises the investigators ability to study the chronic 
effects of -ischaemia. This can be the result of recruitment of existing 
collateral vessels, and the ability to do so shows inter-strain and inter-animal 
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5.2 Aims  
 
The aim of this chapter was to develop a model of hind-limb ischaemia that 
induced changes of the affected muscle which were more comparable to the 
changes in chronic limb ischaemia in patients with CLI, to aid further studies 
in this area and to evaluate potential novel therapies.  
 
Objectives: 
The objectives were: 
1) To assess histomorphological changes in critically ischaemic human 
skeletal muscle  
2) To develop a murine model of hind-limb ischaemia which 
demonstrates changes similar to those that occur in skeletal muscle of 
patients with CLI.  
Hypothesis:  
It was hypothesized that: 
 Excision of common and superficial femoral artery with ligation of the 
side branches in mice of different strain/ age would alter the resulting 
muscle changes.  
 
5.3  Experimental design 
 
Changes in critically ischaemic human skeletal muscle were assessed in 
gastrocnemius biopsies taken from patients undergoing major lower limb 
amputation due to CLI (n=4). Histomorphological changes were assessed 
using H&E staining.  
In order to identify a murine model which best recapitulates these changes, 
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femoral artery and ligation of the side branches (Appendix 1) in BALB/c and 
C57BL/6 mice of 6 and 12 weeks of age (n=10 in each group) [Figure 54]. We 
only used male mice to exclude the confounding factor of cyclic oestrogen. To 
investigate the muscle damage, gastrocnemius and tibialis anterior muscles 
were biopsied. These muscles are both distal enough to sustain severe 
ischaemia, and consist of both slow and fast fibres which respond to the 
ischaemia with both aerobic and anaerobic mechanisms.  
All procedures were performed in accordance to Home Office legislation, 
under Project Licence number 70/7087. ARRIVE guidelines were considered 
and followed to improve the design, analysis and reporting of the in vivo 
experiments (229).  
The mice were kept pathogen-free in groups of 6 in a strict 12-hour night and 
day cycle.  They were fed standard chow with free access to water. Animals 
were anesthetized by intraperitoneal injection of 2% Avertin, 2, 2, 2-
Tribromoethanol, (0.25 ml/g). To maintain the anaesthesia, 1% isoflurane 
mixed in 100% oxygen with flow of 0.8 l/min was used during the procedure 
[Figure 55].  All the operations were done over two consequent days during 
the day time by same operator. 
After the mouse was anaesthetized, the hair on the abdominal wall, pelvis 
and the upper legs was shaved using an electronic shaver. The skin was 
cleaned using alcohol spray. A skin incision was made on the upper thigh of 
the mouse. The inguinal ligament and the upper half of the femoral artery 
were exposed using sharp and blunt dissection. The femoral artery was 
ligated with sterile 7-0 Prolene suture at the level of inguinal ligament 
proximally and just above the popliteal artery distally. All the side branches 
were ligated with 7-0 Prolene suture [Figure 56]. The skin incision was closed 
with 5-0 silk suture. Animals were nursed for a period of one hour post 
surgery in a recovery area on a 370C warming pad, with buprenorphine (0.1 
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Tissue perfusion and evidence of morphological changes and damage within 
the ischaemic muscle were assessed at days 1, 3, 7, 14 and 21 by laser 
Doppler (Moor Instruments) and H&E staining, respectively (Chapter 2).  The 
ischaemic hind-limb perfusion was described as a ratio of the color-coded 
perfusion image of the ischaemic limb to the non-ischaemic one.   
Further, H&E staining of harvested lung, liver, heart and kidney were carried 
out to investigate the associated systemic inflammatory response. 
Inflammatory cell quantification was carried out using ImageJ 1.4s (US 
National Institutes of Health) on H&E stained paraffin embedded left hind-limb 




Consistent with previous reports, muscle sections from patients with CLI 
demonstrated features of muscle fibre injury, including loss of muscle fibres 
with concomitant fibroadipocytic changes, as well as variation in muscle fibre 
size and evidence of degeneration and necrosis [Figure 57].   
Laser Doppler images of the ischaemic hind-limb showed reduced perfusion 
soon after surgery, with blood flow restoration near to baseline by day 21 in 
all three groups (BALB/c 12 weeks old, day 1, median 0.15, range 0.10-0.18; 
day 21, median 1.08, range 0.95-1.15; BALB/c 6 weeks old, day 1, median 
0.18, range 0.12-0.20, day 21, median 1.05, range 0.90-1.10; C57BL/6 12 
weeks old, day 1, median 0.10, range 0.08-0.18, day 21, median 1.10, range 
0.99-1.18) [Figure 58].  
Histological assessment of the muscle biopsies demonstrated a similar 
pattern of histomorphological changes in both C57BL/6 and BALB/c strains at 
day 7, 14 and 21 including inflammation, degeneration, fibrosis, adiposis and 
necrosis. However younger animals showed less severe muscle damage, and 




Student Number: 110091643 
 
The inflammatory cell infiltration was significantly less in younger mice at day 
21 post-surgery (BALB/c 6 weeks old, median 9%, range 4-14%; BALB/c 12 
weeks old, median 14%, range 9-19%; C57BL/6 12 weeks old, median 15%, 
range 12-19%) (P value < 0.05, oneway ANOVA test). [Figure 59, Figure 60, 
Figure 61, Figure 62]. 
The H&E staining of the gastrocnemius and tibilais anterior muscle sections 
were found to be similar in terms of demonstrating the features of ischaemia-
induced skeletal muscle damage: degeneration, regeneration, fibrotic tissue, 
adipose tissue and necrosis [Figure 59, Figure 60, Figure 61, Figure 62]. 
Further, H&E analyses of the lung biopsies showed inflammatory cell 
infiltration in the lung tissue suggesting systemic inflammatory response; 
however there was no obvious inflammatory changes observed in biopsies 
from heart, kidney and liver [Figure 63, Figure 64, Figure 65]. 
 
5.5 Discussion 
The previously established mouse models of hind-limb ischaemia were mainly 
focused on the effect of blood flow interruption and perfusion changes on the 
arterial tree and angiogenesis.  
The role of ischaemia-induced myopathy in the poor functional outcomes of 
patients with CLI is increasingly recognised, however, the detailed 
mechanisms involved are not fully understood. Accordingly, for the purpose of 
this study, we required a mouse model that mimicked the skeletal muscle 
changes seen in ischaemic human muscle. 
The extent of the arterial injury is associated with different patterns of 
perfusion restoration (230). Excision of common and superficial femoral 
arteries with ligation of the side branches in our model in male C57BL/6 mice 
of 12 weeks of age resulted in reproducible ischaemia-induced skeletal 
muscle changes that closely mimicked those that occur in human skeletal 
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affected the post-surgery angiogenesis, but in terms of the skeletal muscle 
damage, it was more desirable.  
Westvik et al. showed that young adult and aged mice had a similar degree of 
decreased perfusion soon after interruption of the lower limb arterial tree, 
however the young mice recovered faster whilst the aged mice had worse 
functional recovery (231). Genetic differences in pre-existent collateral 
vasculature can profoundly affect outcomes by compensatory collateral artery 
growth in different mouse strains (219). McClung et al. showed that C57BL/6 
and BALB/c mice displayed strain-specific differences in myofibres responses 
after hind-limb ischaemia, with significantly greater myofibre atrophy, greater 
apoptosis, and attenuated myogenic regulatory gene expression and stress-
responsive signalling in BALB/c mice (232).  
In agreement with our findings, previous reports showed that the severity of 
the ischaemia increases with the age of the mouse, whilst BALB/c strain 
manifests more tissue necrosis after the same experimental procedure, 
compared to C57BL/6 mice (219).  
In our observations, the ischaemia-induced histomorphological changes in 
skeletal muscle in 12 weeks old mice were more similar to what we observed 
in skeletal muscle from patients with CLI, compared to those in 6 weeks old 
mice. C57BL/6 mice showed more reliable pattern of tissue perfusion 
restoration which may be the result of variations in pre-existing collateral 
vasculature in the BALB/c strain mice (233). Further, we did not observe any 
obvious histological difference between gastrocnemius and tibialis anterior 
muscle, in terms of the response to the induced ischaemia. Based on our 
findings we decided to proceed with our in vivo work by excising the common 
and superficial femoral artery and ligating the side branches in 12 weeks old 
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Limitations:  
The chronic models of ischaemia with gradual occlusion were not tried in our 
experiments, partly due to limitations in financial resources and time but also 
limitations imposed by our project licence.  
Since patients with CLI are usually elderly, it might worth considering the 
model of hind-limb ischaemia in elder mice; however, again it would be 
expensive and also difficult to maintain.  
Further, in our experiments, we did not perform physiological assessments, 
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Figure 49 – H&E staining of gastrocnemius muscle biopsies from Hourde et al. 









Figure 50 - H&E staining of gastrocnemius muscle biopsies from Tekabe et al. 
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Figure 51 – From Nakamura et al. showing fibrotic and adipose tissue in 
muscle biopsies one year post excision of the femoral artery and vein (215)  
 
 
Figure 52 – Hellingman et al. compared 4 different surgical approaches of 







Student Number: 110091643 
 
 
Figure 53 – Hematoxylin-eosin (H&E) stained gastrocnemius muscle from 
Asano et al’s model A) normal muscle B) ischaemic muscle (218)  
 
Figure 54 – Illustrating the mouse model of hind-limb ischaemia used in this 
study where excising the common and superficial femoral artery were excised 
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Figure 56 – A) Demonstrating the anatomy of the left mouse hind limb, supine 
position. Extensive dissection of the skin and fascia is for the purpose of 
demonstration. Common femoral artery appears below the inguinal ligament 
and gives off two main branches of epigastric and profunda before it forms the 
superficial femoral artery. B) Demonstrating the anatomy of the left mouse 
hind-limb after ligation of the femoral artery at the proximal and distal sites 
before the excision of the femoral artery. C) Showing the excised artery. D) 
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Figure 57 – H&E staining of gastrocnemius muscle from a patient with CLI 
demonstrating A) Inflammatory cell infiltration and degeneration and atrophic 
fibres, B) Fibrosis and regeneration with central nuclei C) Adipose tissue 
replacement, myophagocytosis and necrosis (nuclear clumps); D) H&E 
staining of gastrocnemius muscle from a patient with no PAD demonstrating 
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Figure 58 - Laser Doppler imaging perfusion measurements of the mice 
positioned supine under the scan head on a low temperature heating pad. 
Serial colour-coded perfusion images A) before and B) immediately after 
surgery. 12 weeks old male BALB/c mouse C) Day 1, D) Day 3, E) Day7, F) 
Day14, G) Day 21 after surgery. 12 weeks old male C57BL/6 mouse H) Day 1, I) 
Day 3, J) Day 7, K) Day 14, L) Day 21 after surgery. 6 weeks old male BALB/c 


























Figure 59 – Gastrocnemius muscle biopsy (Ischaemic limb); day 1, 3, 7, 14, 21 
in C57BL/6-12 weeks old, BALBc-12 weeks old and BALBc-6 weeks old (scale 



















Figure 60 – Gastrocnemius muscle biopsy (non-Ischaemic limb); day 1, 3, 7, 
14, 21 in C57BL/6-12 weeks old, BALBc-12 weeks old and BALBc-6 weeks old 
























Figure 61 - Tibialis anterior muscle biopsy (ischaemic limb); day 1, 3, 7, 14, 21 
in C57BL/6-12 weeks old, BALBc-12 weeks old and BALBc-6 weeks old (scale 



















Figure 62- Tibialis anterior muscle biopsy (non-ischaemic limb); day 1, 3, 7, 14, 
21 in C57BL/6-12 weeks old, BALBc-12 weeks old and BALBc-6 weeks old 






















Figure 63 – H&E staining of lung biopsies; day 1, 3, 7, 14, 21 in C57BL/6-12 



















Figure 64 – H&E staining of liver biopsies; day 1, 3, 7, 14, 21 in C57BL/6-12 


























Figure 65 – H&E staining of liver, heart and kidney biopsies; day 1, 3, 7, 14, 21 
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CHAPTER 6: THERAPUTIC ROLE OF TLR4 INHIBITION IN MOUSE MODEL OF 
HIND-LIMB ISCHAEMIA  
 
6. 1 Introduction 
 
6. 2 Aims  
 
6. 3 Experimental design 
 
6. 4 Results 
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6. 1. Introduction 
 
TLR antagonists and inhibitors are currently in various stages of development 
from pre-clinical evaluations to clinical trials. TLR4 antagonists are being 
developed and tested with the objective to inhibit acute exacerbation of organ 
damaging immune responses. The TLR4 antagonist Eritoran, showed 
positive results in the treatment of critically ill septic patients in a randomized, 
double-blind, multicentre phase II clinical trial (NCT00046072), however in 
phase III studies Eritoran did not perform better than existing treatments for 
the treatment of sepsis. Another TLR4 antagonist, TAK242, has also 
progressed to two phase III clinical trials (NCT00143611 and NCT00633477) 
(234). 
Although TLR4 has a pathogen detection role, as previously discussed, it can 
act as a monitoring receptor in the detection of tissue injury. Endogenous 
ligands such as HSPs and HMBG1 are up-regulated during ischaemia-
induced tissue damage. The release of TLR4 endogenous ligands is 
associated with TLR4 activation and the corresponding inflammatory 
response can lead to excessive tissue damage. Thus, pharmacological 
inhibition of TLR4 can be of potential therapeutic benefit. 
Zhao et al. showed that TLR4 has a detrimental role in renal transplant 
ischaemic reperfusion injury as it prompts maladaptive immune response that 
results in excess tissue damage.  The authors argued that TLR4 inhibition 
could serve as a target for pharmacological agents directed toward optimizing 
renal graft survival (235).   
Nace et al. investigated the role of TLR4 in liver ischaemia using TLR4 knock 
out mice. The exposure of TLR4 knock out mice to liver ischaemia was 
associated with reduced phosphorylation of NFkB, JNK and P38, as 
compared to wild type mice. The endogenous inhibition of TLR4 was 
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Suzuki et al. examined the role of pharmacological inhibition of TLR4 in 
neuronal death in transient brain ischaemia. The exogenous inhibition of 
TLR4 in a mouse model of transient brain ischaemia, just before reperfusion, 
was associated with less cerebral ischemia-induced oxidative stress and 
reduced production of the reactive oxygen species (237). The effect of 
exogenous TLR4 inhibition has also been found to improve neurological 
function in a mouse model of middle cerebral artery occlusion (238). 
Shimamoto et al. investigated the role of TLR4 inhibition in attenuation of 
myocardial ischaemia reperfusion injury. Exogenous inhibition of TLR4 in a 
mouse model of myocardial ischaemia was associated with reduced 
ischaemia-induced injury and markers of inflammatory response. This was 
evidenced by reduced infarct size, TNFα and IL-6 levels (48). 
TLR4-induced inflammatory response has been shown to encourage 
angiogenesis and collateral artery formation in various ischaemic reperfusion 
models suggesting the dual role of TLR4 in inflammation and angiogenesis. 
However, it has been reasoned that fine tuning of TLR4 and its associated 
signalling pathway can eliminate the undesired effect of TLR4 inhibition on 
collateral artery formation (239).  
Borne et al. studied the effect of systemic inhibition of TLR4 on perfusion 
recovery in a mouse model for angiogenesis. They found that inhibition of 
TLR4 by TAK-242 in a mouse model of hind-limb ischaemia did not negatively 
influence perfusion recovery following the ischemia, despite its potential 
inhibitory effects on angiogenesis (240).  
If TLR4 inhibition is able to reduce ischaemia-induced skeletal muscle 
damage effectively, targeting the TLR4 pathway could provide an additional / 
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6. 2. Aims 
 
In vitro TLR inhibition reduced apoptotic changes in human myotubes 
cultured in ischaemic conditions. Here, the aim was to investigate the 
therapeutic potential of modulating TLR4 signalling in vivo.  
Objectives:  
The objective was:  
 To assess the effect of TLR4 inhibition on skeletal muscle damage in a 
mouse model of hind-limb ischaemia 
 
Hypothesis:  
It was hypothesized that: 
 Hind-limb ischaemia will result in TLR4 upregulation and activation 
whilst endogenous deletion and exogenous inhibition of TLR4 will 
attenuate tissue damage following hind-limb ischaemia. 
 
6. 3. Experimental design 
 
Hind-limb ischaemia was induced by excision of the common and superficial 
femoral arteries and ligation of the side branches [Figure 66] in male C57BL/6 
mice of 12 weeks of age, as described in chapter 5. The animals were split 
into three groups:  
• Group 1: Endogenously deleted TLR4 (TLR4-/-); n=18 
• Group 2: Exogenously inhibited TLR4 (LPS-RS); n=18 
• Group 3: Vehicle; n=18 
Nine animals per group were sham operated [Figure 67]. Mice in group 1 
were kindly gifted by Dr Nathan Davies, Institute for Liver & Digestive Health, 
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TLR4lps-del spontaneous mutation had a 7-kb deletion in the TLR4 gene 
(Jackson Laboratory, United States). Two breeding pairs of TLR4-knockout 
mice were purchased from the Jackson Laboratory and bred in house. Mice in 
groups 2 and 3 were purchased from the UCL Biological Services (Royal Free 
Campus).  
Mice in group 2 were treated by intraperitoneal administration of LPS-RS (1μg 
per mouse (40μg/kg) in saline, twice a week; first injection at the time of 
induction for surgery; InvivoGen). This dose of LPS-RS was reported to be 
effective in blocking TLR4 in previous studies (242-244). Laser Doppler (Moor 
FLPI; Moor Instruments Ltd) was used to measure changes in perfusion. The 
overall well-being of animals was checked daily with specific assessment of 
function performed on post surgical day 3, 7 and 21. Tissue necrosis, limping 
and muscle flexion were recorded to calculate the post-operative functional 
scores. The Tarlov and Modified Ischaemia scoring systems were used for 
this purpose (243) [Table 9]. 
Animals were sacrificed (n=6 per ischaemic group and n=3 per sham group at 
each time point) and hind-limb tissue and serum samples were collected at 
day 3, 7 and 21. Blood samples were taken via cardiac puncture at the time 
of sacrificing the animals.  
TLR4 mRNA expression was examined by RT-PCR, as previously described 
in chapter 2. 5’ sense and 3’ antisense TLR4 primers, provided with positive 
control double stranded DNA were used for real-time PCR (rtp-mtlr4; 
InvivoGen). Systemic levels of IL-6 & TNFα were examined by ELISA (Mouse 
IL6, M6000B, R&D Systems; Mouse TNFα, MTA00B, R&D Systems). 
Expression of cleaved caspase-3 in the ischaemic skeletal muscle was 
examined by Fluorescent IHC-P (Mouse Cleaved Caspase-3, rabbit antibody, 
9661; Cell Signalling; Alexa Fluor® 594 Chicken Anti-Rabbit IgG, A-21442, 
Life Technologies). Inflammatory damage was assessed by H&E staining 
[Figure 68]. Inflammatory cell quantification was carried out using Image J 
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Further, blood gas analysis was carried out at each time point to measure the 
following: pO2, pH, pCO2, haemoglobin (Hb), lactate, Sodium (Na), Potassium 
(K), glucose and SO2.   
ARRIVE guidelines were followed during the design and analysis of the in 
vivo experiments (245).  
 
Score Tarlov scoring 
0 No Movement 
1 Barely perceptible movement, non-weight-bearing 
2 Frequent movement, non-weight-bearing 
3 Supports weight, partial weight-bearing 
4 Walks with mild deficit 
5 Normal but slow walking 
6 Full and fast walking 
 
Score Modified ischaemia scoring 
0 Auto-amputation of leg 
1 Leg necrosis 
2 Foot necrosis 
3 Discoloration of > 2 toes 
4 Discoloration of 1 toe 
5 Discoloration of > 2 nails 
6 Discoloration of 1 nail 
7 No necrosis 
Table 9 – Recognised functional and ischaemia scoring based on mobility/ 
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6. 4. Results 
 
There was upregulation of TLR4 mRNA in gastrocnemius muscle of mice who 
underwent hind-limb ischaemia compared with that of sham operated mice 
(group 3) at day 3 (ΔCt: median 9, range 2.7-16 vs.  median 2, range 1-2.6) 
and day 21 (ΔCt: median 10, range 9-11 vs. median 1, range 1-1) [Figure 69]. 
Analysis of the laser Doppler images showed significant reduction in 
perfusion in the operated hind-limb at day 3 post surgery in all groups 
(perfusion unit rate: vehicle (n=6), median 0.38; TLR4 -/- (n=6), median 0.2; 
LPS-RS (n=6), median 0.41), with the reduction being more significant in the 
TLR4-/- group when compared to vehicle and LPS-RS groups at this time 
point (P<0.05, Mann Whitney test) [Figure 70, Figure 72]. The perfusion in the 
sham operated groups showed no significant differences between the groups 
at all time points [Figure 71]. Slower blood flow recovery was observed in 
vehicle group in comparison to TLR4-/- and LPS-RS groups at day 3 
(perfusion unit rate: vehicle (n=6), median 0.38; TLR4 -/- (n=6), median 0.2; 
LPS-RS (n=6), median 0.41), day 7 (perfusion unit rate: vehicle (n=6), median 
0.51; TLR4 -/- (n=6), median  0.79; LPS-RS (n=6), median 0.61), and day 21 
(perfusion unit rate: vehicle (n=6), median 0.84; TLR4 -/- (n=6), median 1.1; 
LPS-RS (n=6), median 0.90) (P<0.05, Kruskal Wallis test) [Figure 72]. 
 
The functional status of the mice was assessed at day 3, 7 and 21 post 
surgery [Table 10] [Figure 73]. 
 
Day 3 Tarlov score (median) Modified ischaemia score (median) 
Vehicle (n=6) 1.0 3.1 
TLR4 -/- (n=6) 3.0 3.6 
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Day 7 Tarlov score (median) Modified ischaemia score (median) 
Vehicle (n=6) 3.9 5.5 
TLR4 -/- (n=6) 5.2 5.5 
LPS-RS (n=6) 4.9 5.5 
 
Day 21 Tarlov score (median) Modified ischaemia score (median) 
Vehicle (n=6) 4.9 5.4 
TLR4 -/- (n=6) 5.9 7 
LPS-RS (n=6) 5.8 6.9 
Table 10 - The functional status of the mice was assessed at day 3, 7 and 21 
post surgery. 
 
 All mice showed low functional performance post surgery with gradual 
improvement by day 21. Mice in TLR4-/- and LPS-RS groups restored their 
functional status to the near base line by day 21, whereas the vehicle group 
had lower performance even at day 21 (P<0.05; Kruskal Wallis test) [Figure 
73, Figure 74].   
The blood gas analysis of blood samples taken via cardiac puncture at the 
time of sacrificing the animals, showed no significant differences between the 
ischaemic and sham operated mice in both vehicle and TLR4 -/- groups when 
the following parameters were quantified: pH, pO2, pCO2, Hb, lactate, Na, K 
and SO2. The random blood glucose levels in ischaemic and sham operated 
TLR4 -/- groups were significantly higher compared to ischaemic and sham 
operated vehicle groups at day -1, 3, 7 and 21 (P<0.05; Kruskal Wallis test) 
[Figure 75, Figure 76].  
The ELISA quantification of IL-6 showed significantly increased levels in the 
vehicle group compared to TLR4-/- and LPS-RS groups at day 3, 7 and 21 
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Day 3 IL-6 (pg/ml) 
Vehicle (n=6) 20 
TLR4 -/- (n=6) 9 
LPS-RS (n=6) 11 
 
Day 7 IL-6 (pg/ml) 
Vehicle (n=6) 26 
TLR4 -/- (n=6) 11 
LPS-RS (n=6) 20 
 
Day 21 IL-6 (pg/ml) 
Vehicle (n=6) 35 
TLR4 -/- (n=6) 20 
LPS-RS (n=6) 22 
Table 11 - ELISA quantification of IL-6 at day 3, 7 and 21 post surgery 
 
Similarly, ELISA quantification of TNFα showed significantly increased levels 
in the vehicle group in compare to TLR4-/- and LPS-RS groups at day 3, 7, 
21 post surgery (P<0.05; Kruskal Wallis test) [Table 12] [Figure 77]. 
 
Day 3 TNFα (pg/ml) 
Vehicle (n=6) 280 
TLR4 -/- (n=6) 30 
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Day 7 TNFα (pg/ml) 
Vehicle (n=6) 310 
TLR4 -/- (n=6) 90 
LPS-RS (n=6) 150 
 
Day 21 TNFα (pg/ml) 
Vehicle (n=6) 360 
TLR4 -/- (n=6) 119 
LPS-RS (n=6) 160 
Table 12 - ELISA quantification of TNFα at day 3, 7 and 21 post surgery 
 
TLR4-/- mice and mice given LPS-RS, demonstrated diminished apoptosis in 
ischaemic skeletal muscle following hind-limb ischaemia as compared to 
vehicle mice at day 21 [Figure 78]. Fluorescent immunohistochemical staining 
for cleaved-caspase 3 showed less expression of this protein in TLR4 
inhibited groups at day 21.  
Inflammatory cell quantification in H&E stained paraffin embedded ischaemic 
gastrocnemius muscle sections post surgery showed less inflammatory cell 
infiltration in both TLR4 -/- and LPS-RS groups when compared to vehicle 
group at each time point (P<0.05; Kruskal Wallis test) [Figure 79]. The 
median percentages of inflammatory cell infiltration in vehicle, TLR4 -/- and 
LPS-RS groups were calculated as 19%, 7% and 10.5% respectively at day 
3; 21%, 10% and 14% respectively at day 7, and 14%, 8% and 10.5 % 
respectively at day 21.  
TLR4-/- mice and mice given LPS-RS demonstrated attenuated histological 
evidence of ischaemia-induced inflammation following hind-limb ischaemia as 
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The H&E examination of the hind-limb skeletal muscles in sham groups 
showed no obvious histological differences between vehicle, TLR4 -/- and 
LPS-RS groups at day 3, 7 and 21 [Figure 82, Figure 83].   
 
6. 5. Discussion 
 
In this chapter, the role of TLR4 inhibition in vivo was examined in a murine 
model of hind-limb ischaemia. TLR4 up-regulation occurred in ischaemic 
skeletal muscle (group 3) with increased TLR4 mRNA expression in 
ischaemic gastrocnemius muscle post surgery at day 3 and 21, however the 
sample size was small.   
Tissue perfusion was significantly interrupted after the excision and ligation of 
the femoral artery and its side branches. This was followed by recovery of 
tissue perfusion in all experimental groups, however the mice with 
compromised TLR4 function showed faster recovery when compared to the 
vehicle group. Functional assessment of the mice showed reduced function in 
all three groups post surgery, however the functional performance was 
superior in TLR4 inhibited groups at day 21.  
Blood gas analyses showed no significant differences in the measurements of 
pO2, pH, SO2 and Hb between the vehicle and TLR4-/- groups. These 
markers could potentially act as confounding factors by influencing the 
oxygen delivery equation. The random blood glucose levels were higher in 
TLR4-/- groups (both ischaemic and sham) even prior to the surgery; 
however, if hyperglycaemia was a potential confounding factor, it would be 
expected to perhaps worsen recovery in this group. These findings are 
consistent with previously published data suggesting that TLR4 controls the 
development of autoimmune diabetes in TLR4-/- mice by affecting the activity 
of regulatory T-cells (247).   
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ischaemia in human myotubes was associated with reduced inflammatory 
cytokine production, endogenous deletion and exogenous inhibition of TLR4 
in vivo were associated with reduced systemic IL6 and TNFα levels following 
hind-limb ischaemia. Further experiments showed that TLR4-/- mice and mice 
given LPS-RS, exhibited reduced ischaemia-induced apoptosis similar to that 
observed in in vitro experiments.   
In addition, TLR4 inhibition was associated with diminished inflammatory cell 
infiltration in the ischaemic limb as compared to mice treated with vehicle at 
different time points. Endogenous deletion and exogenous inhibition of TLR4 
were associated with reduced damage to the skeletal muscle after the 
ischaemic insult. These findings suggest that TLR4 plays a key role in 
ischaemia-induced skeletal muscle damage [Figure 84]. 
 
Limitations: 
The upregulation of TLR4 mRNA in ischaemic skeletal muscle was only 
examined in limited number of experiments (n=2 per group at day 3 and 21 
post surgery). Further, the potential increase in other TLRs, as compensatory 
increase, was not examined in these experiments. The other limitation is that 
the animal model does not include the other cardiovascular risk factors that 
CLI patient experience. Furthermore, the effect of concomitant medications 
such as statins and anti-platelets is not observed. 
Furthermore, many findings in animal models are not translated into the 
clinical setting, such as therapeutic angiogenesis that has shown more 
impressive results in preclinical studies than in clinical trials. This might be 
due to more complex systems along with more advanced diseases in human. 
Finally, the experimental drugs in animals undergo different pharmacokinetics 
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Figure 66 - The arterial tree was excised proximally above the inguinal 
ligament, and distally at the level of popliteal artery. The side branches were 
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Figure 69 - RT-PCR quantification of TLR4 in mouse gastrocnemius muscle. 
Data has been normalized to endogenous housekeeping gene (tubulin). 
Vehicle group: CLI (n=2), Sham (n=2) on day 3 and 21 post operation. A) Fold 
expression of TLR4 across the groups at different time points (ΔCt analysis) B) 
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Figure 70  – Ischaemic groups - Representative Laser Doppler 
perfusion images obtained with mice positioned supine under the 
scan head on a low temperature heating pad. Serial colour-coded 
perfusion images A), B) & C) 12 weeks old C57BL/6, post operation 
on day 3, 7 & 21 respectively. D), E) & F) 12 weeks old C57BL/6 with 
genetically deleted TLR4, post operation on day 3, 7 & 21 
respectively. G), H) & I) 12 weeks old C57BL/6 treated with 












Student Number: 110091643 
 
 
Figure 71 - Representative Laser Doppler perfusion images of mice 
positioned supine under the scan head on a low temperature 
heating pad. Serial colour-coded perfusion images A), B) & C) 12 
weeks old C57BL/6, post Sham operation on day 3, 7 & 21 
respectively. D), E) & F) 12 weeks old C57BL/6 with genetically 
deleted TLR4, post sham operation on day 3, 7 & 21 respectively. 
G), H) & I) 12 weeks old C67BL/6 treated with exogenous TLR4 
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Figure 72 - Perfusion recovery post surgery. The ischaemic / non-ischaemic 
lower limb perfusion ratio showed significant difference on day 3, 7 and 21 
between TLR4-/- group and Vehicle / LPS-RS groups (*P<0.001 at day 3 and 7; 
**P=001 at day 21; Kruskal Wallis test). The difference between each group 
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Figure 73 - Representative photographs of mice from all three groups that 
underwent hind-limb ischaemia at day -1, 3, 7 and 21. Tissue necrosis, limping 
and muscle flexion were recorded to calculate the functional and ischaemia 
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Figure 74 - Functional and ischaemia scoring of the mice in all groups showed 
faster recovery in TLR4-/- and LPS-RS groups compared to vehicle group 
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Figure 75 - Blood gas analysis of vehicle and TLR4-/- mice pre and post left 
hind-limb ischaemia and sham operation on day -1, 3, 7 and 21. Random blood 
glucose was significantly higher in TLR4-/- than CL57BL group (*P<0.05; 
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Figure 76 - Blood gas analysis of vehicle and TLR4-/- mice pre and post left 
hind-limb ischaemia and sham operation on day 3, 7 and 21 (No significant 












Figure 77 - IL-6 and TNFα levels in serum from vehicle, TLR4-/- and LPS-RS 
groups on day 7, 14 and 21 post operation. The IL-6 and TNFα levels were 
significantly different at each time point between the three groups (*P<0.05; 
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Figure 78 Fluorescent immunohistochemical staining for cleaved-caspase 3 in 
C57BL/6 mouse gastrocnemius muscle, post hind-limb ischaemia day 21 
(Paraffin embedded, DAPI and AlexaFluor 647 stains, 3-micron thick section, 
x40 fluorescence); representative from A) Vehicle group; B) LPS-RS group; C) 
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Figure 79 - Inflammatory cell quantification in H&E stained ischaemic 
gastrocnemius muscle showed less inflammatory cell infiltration in both TLR4 
-/- and LPS-RS groups when compared to vehicle group at each time point 





























































Figure 80 - Representative H&E staining of, ischaemic (top) and, non-
ischaemic (bottom) gastrocnemius muscle post surgery day 3, 7 & 21 (scale 








































Figure 81 - Representative H&E staining of, ischaemic (top) and, non-
ischaemic (bottom) tibialis anterior muscle post surgery day 3, 7 & 21 (scale 












































Figure 82 - Representative H&E staining of, sham operated (top) and, non-
ischaemic (bottom) gastrocnemius muscle post sham surgery day 3, 7 & 21 



































Figure 83 - Representative H&E staining of, sham operated (top) and, non-
ischaemic (bottom) tibialis anterior muscle post sham surgery day 3, 7 & 21 








Figure 84 – Diagram suggesting the potential role of TLR4 in ischaemia-
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CHAPTER 7: GENERAL DISCUSSION 
 
7. 1 Summary and discussion 
 
7. 2 Limitations 
 
7. 3 Future directions 
 
7. 4 Potential clinical application 
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7.1. Summary and discussion 
 
The prevalence of CLI, impending limb loss that is caused by severe 
compromise of blood flow, is reported to be as high as 0.24% in the 
population aged between 40 and 69 years in Western society (248).The 
Vascular Society for Great Britain and Ireland estimated that 40 per 100,000 
population experience CLI per year in the UK. An ageing population and 
improved survival from ischaemic heart disease and cerebrovascular events 
suggest that this incidence may be increasing. It has been reported that 
patients with CLI have mortality rates of 20% and 50% within one and five 
year respectively (249). More recent meta-analysis of mortality rates in 
patients with CLI estimated that probability of mortality was 3·7% at 30 days, 
17·5% at 1 year, 35·1% at 3 years and 46·2% at 5 years (250). Another 
retrospective cohort study of patients who underwent a first major lower limb 
amputation showed frailty of this population, with almost 25% of patients 
dying within 30 days, and almost 50% at 1 year (251).  
The main treatment options for patients with CLI remain limited to 
revascularisation, or amputation if the arterial tree is not re-constructible or 
tissue loss too severe. Advances in surgical technology has amplified the 
revascularization options by both open and endovascular approaches, 
however even revascularisation in critically ischaemic limbs is often not 
associated with significant improvement in functional status. These patients 
continue to have poor lower limb function and quality of life even though the 
distal blood flow is restored (252, 253). The poor functional outcomes have 
highlighted the need for consideration of other contributory factors involved in 
the pathophysiology of the CLI. 
Primary amputation is considered for up to 20% of patients with CLI who have 
extensive tissue loss, or non-reconstructable disease. The European 
Consensus Document recommends primary amputation if it is deemed that 
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25% (249). It has been shown that only 4% of patients who were in a 
dependent living situation preoperatively went on to live independently at 6 
months, and only 21% who did not ambulate preoperatively were 
independently ambulatory 6 months after surgery (254).  
Understanding the pathophysiology of the ischaemia-induced inflammatory 
damage in CLI may provide a potential missing link in improving functional 
outcomes along with successful revascularization. It is thought that the 
muscle dysfunction in CLI is potentially due to the ischaemia-induced skeletal 
muscle damage, in which inflammation plays a central role (18, 255).  
The most common underlying aetiology of CLI is atherosclerosis, an 
inflammatory condition that increases the risk of cardiovascular events. The 
systemic levels of inflammatory cytokines have been shown to be increased 
in patients with CLI (256).  
Vascular function is regulated by the endothelium and inflammatory-induced 
endothelial dysfunction is associated with increased risk of cardiovascular 
events. Inflammation is now a recognised risk factor for endothelial 
dysfunction: it increases oxidative stress, which is the common underlying 
factor of many of the known cardiovascular risk factors (257).   
Hence, the systemic inflammatory response in patients with CLI can 
contribute to the higher prevalence of cardiovascular disease in this group of 
patients. Patients with PAD are six times more likely to die from 
cardiovascular event over 10 years than patients with no PAD (258). 
The recent and intense interest around TLRs, has revealed that the innate 
immune system makes important contribution to the development of 
cardiovascular diseases, which are now recognized as chronic inflammatory 
conditions (259). TLRs are one of the key pattern recognition receptors in the 
innate immune system, and they have been shown to play an important role 
in ischaemia-induced inflammatory responses. There is mounting evidence 
that TLRs from both immune and non-immune cell origin are involved in the 
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has been widely investigated to explore the therapeutic potentials in 
pharmacological modulation of TLRs (42).  
The indispensable role of TLR4-induced tissue damage in ischaemia has 
been shown in different organs such as brain, kidney, liver and myocardium 
(48, 238, 240, 242, 260). Earlier work by our group demonstrated the 
expression of TLRs in ischaemic muscle. TLR4 is also expressed in skeletal 
muscle where ischaemia-induced myopathy is associated with activation of 
the adaptive immune system (38).  
In this work, expression of TLR4 was shown in both ischaemic and non-
ischaemic human skeletal muscle, with increased expression in the ischaemic 
samples. The upregulation of TLR4 is in support of a notable role of TLR4 in 
the process of ischaemia-induced tissue damage. NFkB and JNK are key 
transcription factors in TLR4-mediated MyD88-dependent signalling pathway. 
TLR4-mediated NFkB and JNK pathways are shown to be involved in 
myocardium ischaemia (45, 261). Here it was shown that phosphorylated 
NFkB and JNK, activated forms of NFkB and JNK, were significantly up-
regulated in the ischaemic samples. The high expression of these 
transcription proteins suggests that TLR4 is not only up-regulated but also 
activated. Further, the increase in cleaved caspase 3, a marker for apoptosis, 
suggests that significant tissue damage occurs even within clinically viable 
lower limb muscle in patients with CLI. This is in support of previous studies 
implicating TLR-induced apoptotic cell death in the pathophysiology of 
ischaemia-induced cell damage (38). Immunofluorescence staining of the 
muscle biopsies revealed the presence of TLR4 on neutrophils, endothelium 
and macrophages. These findings suggest wide distribution of TLR4 in the 
lower limb which may emphasis the role of these receptors in ischaemia-
induced inflammatory response in patients with CLI.  
To assess the significance of these findings in supporting the hypothesis, and 
to understand the downstream signalling pathway better, an in vitro model of 
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developed by our group, showed that exposure of mature myotubes to 
nutrition depletion, hypoxia and hypercapnia simulated certain changes 
similar to skeletal muscle ischaemia in vivo. The overall effect of these 
changes was a significant time-dependent increase in the percentage of 
apoptotic cells and inflammatory cytokine release, which are features of 
skeletal muscle ischemia. This model is reproducible, easy to use and 
considers main characteristics of chronic ischaemia, including apoptosis, pO2, 
pCO2 and pH (139).  
Using this model, simulated ischaemia in cultured human myotubes led to 
upregulation of TLR4 and activation of its downstream signalling pathway with 
increased cytokine release and apoptosis in the ischaemic human myotubes.  
Further, inhibition of TLR4 prior to ischaemia was associated with inhibition of 
the signalling pathway and reduced ischaemia-induced apoptosis. Moreover, 
amplified cytokine release and increased expression of HSP60 and 70 was 
demonstrated in ischaemic skeletal muscle in vitro. Inhibition of the MyD88-
dependent signalling pathway attenuated inflammatory cytokine production in 
the presence of ischaemia-induced TLR4 activation. This data is in keeping 
with previous findings of accelerated muscle regeneration in hind-limb 
ischaemia in MyD88 knock out mice as described previously (262) and 
supports the involvement of MyD88 in the inflammatory response to 
ischaemia, which may be a critical step in the development of skeletal muscle 
damage. Furthermore, TLR4 antagonism was associated with reduced 
inflammatory cytokine release and down-regulation of HSP60 and 70 
expressions. This suggests a potential pathway where TLR4 and its 
endogenous ligands contribute to a positive feedback loop to maintain a pro-
inflammatory environment during ischaemia.  
The murine model of hind-limb ischaemia used in this work involved the 
excision of the common and superficial femoral arteries with ligation of the 
side branches in male C57BL/6 mice of 12 weeks of age, which resulted in 
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those that occur in patients with CLI. This provides a useful pre-clinical model 
for further work including the assessment of novel muscle-protective 
adjunctive therapies for the treatment of CLI. In this in vivo model, it was 
shown that TLR4 is up-regulated in ischaemic skeletal muscle. TLR4-/- mice 
and mice given LPS-RS, a TLR4 antagonist, exhibited reduced systemic IL6 
and TNFα levels following hind-limb ischaemia, implicating the role of TLR4 in 
ischaemia-induced systemic inflammatory cytokine production. Both 
endogenous and exogenous inhibition of TLR4 were associated with reduced 
inflammatory cell infiltration and diminished apoptosis in the ischaemic limb 
as compared to the control group. These findings suggest that TLR4 plays a 
key role in ischaemia-induced skeletal muscle damage. In previous studies, it 
has been argued that the TLR-induced inflammatory response plays a critical 
role in angiogenesis in tissue ischaemia, however the lack of TLR4 has been 
shown to have no negative effect on this process in this model (262, 263). 
Patients with PAD have two to three fold increase risk of five to ten year 
cardiovascular related mortality. PAD appears to increase the risk of 
myocardial infarction and perhaps stroke (264). This increased risk might be 
due to systemic inflammatory response induced by PAD, with lower limbs as 
the main source.  
 
7.2. Limitations 
Muscle biopsies in the control group (No PAD) were obtained from patients 
undergoing CABG. Since coronary artery disease shares the roots of its 
pathophysiology with PAD, the patients were selected only if they had no 
history of lower limb arterial claudication with normal ABPI measurements. It 
is still possible for the patients in the control group to have subclinical PAD 
affecting the results of the human tissue experiments. Further, the number of 
human tissue biopsies was limited by time and resources. 




Student Number: 110091643 
 
enzymatic digestion are myogenic cells and muscle-derived fibroblasts. In our 
experiments, we used muscle homogenates to quantify the proteins. This 
approach does not allow identification of the cell types associated with the 
relevant proteins. Therefore, the results indicated protein expression in tissue 
rather than specific cell types involved. The presence of potential infection in 
the biopsied skeletal muscle is another limitation of our experiments. Infecting 
microorganisms are potent TLR4 activators (265) and therefore the presence 
of any infection could have interfered with the results. To minimize the 
potential infection-related bias, all the ischaemic biopsies were taken from 
sites away from ulcers and grossly necrotic tissue.  
Although the activation of NFkB and JNK is in favour of TLR4 activation, 
many other immune receptors share these proteins in their downstream 
signalling pathways (266) and therefore more detailed experiments are 
required to confirm the implications of these findings and indeed this needs to 
be considered in the development of potential therapeutic strategies.  
In the in vitro experiments, despite regular observations of the cell lines and 
application of antibiotics, the possibility of contamination of the cultured 
muscle cells with other cell lines or infective microorganisms, could have 
affected the results.   
In the in vivo experiments, the limited number of RNA experiments made it 
difficult to confirm the statistical significance in the RNA work, however the 
results showed clear up-regulation of the TLR4 in the control group with 
induced hind-limb ischaemia. In addition, the overall sample size was kept to 
minimum to reduce the number of required animals.  
The laser Doppler imaging allows quantitative analysis of functional blood 
flow, while it lacks anatomical information. The new advances in small animal 
imaging such as micro-CT provides the opportunity to achieve more 
anatomical information while the animal can be imaged multiple times non-
invasively over the period of the study (267).  
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signalling pathways and mechanisms involved, as the crosstalk between 
different signalling pathways can affect the final response. Also, additional 
work is needed to investigate the optimal time and delivery method of the 
TLR4 inhibition in more detail.      
 
7.3. Future directions  
 
Although our model of hind-limb ischaemia closely mimics the skeletal muscle 
changes which occur in patients with CLI, further work is required to optimise 
the model to exhibit more chronically induced changes. This will also allow 
the assessment of the pathophysiological changes in more detail with longer 
follow up. This can also be developed in other species for further validation of 
the results before the translation of the outcomes into human trials.   
Further studies are required to explore different routes and timing of drug 
delivery and the dose response effect of TLR4 antagonists. Considering the 
positive effects of TLR4 activation in stimulating the necessary inflammatory 
response, the aim would be to only control the unnecessary immune 
response or to prevent the ongoing inflammatory damage without affecting 
the protective aspects of the process.  Although TLR antagonists have clearly 
been shown to be protective by directly inhibiting inflammatory gene 
transcription and reducing secretion of inflammatory cytokines in several 
conditions, the preconditioning with low dose TLR agonists may also be an 
effective strategy to protect tissue against subsequent detrimental insults 
such as reperfusion injury. This highlights the importance of administering 
specific TLR agonists and antagonists during the relevant phase of the 
pathological process in order to achieve an optimal balance of TLR activation 
and inhibition (42).  
TLR4 can interplay with other inflammatory signalling pathways to balance 
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regeneration and angiogenesis, however, a regulated balance is required to 
prevent unnecessary inflammation-induced tissue damage, while preserving 
the positive effects. It has been reported that unopposed TLR4 activation in 
skeletal muscle ischaemia slows regeneration and also angiogenesis; while 
TLR2, which is simultaneously up-regulated by TLR4, plays a protective role 
to modify the TLR4 effect (183). Further, the potential of TLR4 and TLR1 
heterodimerisation needs to be explored, where TLR1 activation may affect 
the final response to the tissue ischaemia and confers a degree of specificity 
in the response.  
TLR4 response to simulated ischaemia is mainly regulated via MyD88 
signalling pathway, which results in activation of transcription proteins (NFkB, 
JNK and P38). The inhibition of these regulatory proteins is associated with 
less inflammatory response. Hence, pharmacological interruption of the 
signalling pathway further downstream can be of clinical significance. 
However, this needs careful evaluation as these regulatory proteins are 
shared between many other signalling pathways, and therefore their inhibition 
can be associated with some adverse effects.      
Moreover, the other routes of adaptive immune system such as T-cell 
mediated response are further potential areas of future research to explore 
the possible interactions with TLR4 signalling pathway.  
 
7.4. Potential clinical application 
 
Revascularisation, as per current practice, offers the best option for limb 
salvage. The poor functional outcomes, even after successful 
revascularization, highlight the clinical need to developing adjuvant therapies 
alongside surgical intervention.  
Therapeutic angiogenesis is another novel concept to treat patients with CLI.  
This involves the use of angiogenic growth factors or stem cells, in order to 
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application of angiogenic growth factors have showed potential to promote 
tissue angiogenesis in limb musculature in patients with CLI. However, this 
requires multiple treatments over months.  Also, therapeutic outcomes are still 
limited and further improvements are required for extensive clinical 
applications (268). There are a number of pre-clinical studies showing 
beneficial effects of vascular stem cell therapy in ischaemic disease, however 
translation of these findings to the clinic is challenging. Cell therapy products 
are manufactured under strict, centralized procedures resulting in extra costs 
and more complex regulatory pathway than synthetic drugs (269). 
Our study suggests that ischaemia induces an inflammatory response in 
skeletal muscle, which then contributes to the underlying skeletal muscle 
dysfunction. Hence, pharmaceutical inhibition of TLR4 might be of clinical 
significance in patients with CLI. The TLR4 inhibition can also be considered 
for the management of earlier stages of PAD when patients present with 
claudication. The reversal of the ischaemia-induced myopathy might be more 
feasible in the earlier stages of the disease.  
The inhibition of TLR4 can also be considered in adjunction with other novel 
strategies. Reducing the ischaemia-induced inflammatory response may 
improve the environment/ niche to enable growth factors or stem cells to 




This study investigated the role of TLR4-mediated inflammatory response in 
critically ischaemic skeletal muscle. Human myotubes derived from patients 
with and without PAD were successfully cultured in vitro and a mouse model 
of hind-limb ischaemia suitable for evaluating ischaemic muscle damage was 
developed. TLR4 was found to be up-regulated and activated in ischaemic 
skeletal muscle in patients with CLI, and TLR4 signalling contributed to 




Student Number: 110091643 
 
Modulating TLR4 signalling in vivo was associated with attenuation of skeletal 
muscle damage. This work highlights the potential therapeutic role of TLR4 
inhibition in patients with CLI.  
It is conceivable that pharmacological targeting of TLR4 in patients with CLI 
along with improving the haemodynamics may improve both functional and 
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1. Visiting scholarship at Yale University 
 
Based on the work for this thesis, I was granted a Bogue Fellowship for a 4-
week-visit to Prof Alan Dardik’s lab at Yale University, New Haven, USA.  
This was complimented by a one day visit to Dr Louis Messina’s lab at 
University of Massachusetts Medical School. The purpose of this visit was to 
observe the locally developed models of hind-limb ischaemia.  
The Bogue Fellowship is provided by a bequest from the late James Yule 
Bogue, a former Research Fellow in the UCL Department of Physiology and 
one time Deputy Chairman of the Pharmaceuticals Division of ICI. The 
fellowship supports visits to carry out research in laboratories in the USA and 
Canada in order ‘to enrich the research experience and help develop the 
scientific career of the Fellow’. 
Professor Dardik is a surgeon-scientist who seeks to use the basic science 
laboratory to perform cutting edge research to ultimately benefit patients with 
vascular disease. 
 
▪ Acute model of hind-limb ischaemia 
Alan Dardik developed a mouse model of hind-limb ischaemia to study 
therapeutic angiogenesis (246). In this model, unilateral high femoral artery 
ligation and superficial femoral artery excision were performed on 6-8 weeks 
old male C57BL/6 mice [Figure 85]. Intraperitoneal anaesthesia was 
administered using ketamine (100 mg/ kg) and xylazine (5 mg/kg). Mice were 
positioned in dorsal recumbency with their hind limbs externally rotated. A 
skin incision was made over the femoral artery beginning at the inguinal 
ligament and continued caudally to the popliteal bifurcation. The femoral 
artery was isolated above the level of the profunda and epigastric arterial 
branches, doubly ligated using 7-0 Prolene suture, and transected. The 
superficial femoral artery caudal to the major branch points was dissected, 
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This model closely resembles diseases in humans. In comparison to other 
models, the common femoral artery and its proximal deeper branches in this 
model are occluded but still present. Extensive excision of the arterial tree 
can adversely affect the angiogenesis.  This model resulted in signs ranging 
from no necrosis to toe necrosis, in comparison to the models with more 
severe ischaemic damage with profound necrosis.  
By visiting Dardik’s lab, further experience was gained in application of 
Duplex technology to assess haemodynamics post surgery.  However, this 
was not translated into our project due to logistical problems [Figure 88].   
Louis Messina investigated the effect of gradual or acute arterial occlusion on 
skeletal muscle blood flow, arteriogenesis, and inflammation in rat hind-limb 
ischaemia model (270), It is argued that sudden interruption in the blood flow 
will result in increased shear forces proximal to the ligation, and this will 
directly affects collateral formation. Also, it is argued that acute ischaemia is 
associated with more tissue necrosis and aggravated inflammatory response 
which again contributes to the angiogenesis. In the Messina’s rat model of 
acute ischaemia, hind-limb ischaemia was created by ligation of the left 
common iliac artery and left femoral artery and all their branches [Figure 89].  
 
 Chronic model of hind-limb ischaemia 
In the rat model of chronic ischaemia, a similar operation to the acute model 
was performed in Messina’s lab, but instead of ligating the left common iliac 
artery at the aortic bifurcation and the left femoral artery above the 
saphenopopliteal bifurcation, a 0.75-mm internal diameter ameroid constrictor 
was placed around the artery at each location. Ameroid constrictors have an 
outer metal sleeve encasing an inner layer of a hygroscopic material, usually 
casein, and when placed around an artery they induce gradual vessel 
occlusion over 2-3 days as they absorb moisture from the surrounding 
tissues. These custom ameroid constrictors were sterilized with ethylene gas 
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The model of gradual ischaemia showed signs of chronic ischaemia but failed 
to reproduce critical limb ischaemia. In this group, rats showed muscle 
atrophy, but no evidence of necrosis or limping, when compared to Messina’s 
acute model.  
The chronic model of ischaemia was associated with reduction in the blood 
flow, with less inflammatory changes in the skeletal muscle. The rats that 
were treated by gradual arterial occlusion showed preserved muscle mass 
and architecture without muscle necrosis or late fibrosis. 
2. Search strategy  
 
Developing a well-built research question is fundamental to retrieving the 
relevant research literature. It is advocated that a well-built question should 
include four parts, referred to as PICO that identify the patient problem or 
population (P), intervention (I), comparison (C) and outcome (O) (271). The 





Patients / In vitro / In Vivo 
 




Induced Ischaemia / Systemic deficiency OR 
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The primary search was performed by considering the first two elements of 
PICO (Patients and Interventions). As per result of the primary search, further 
components of PICO were added to refine the search. 
Literature was reviewed by searching the following databases: MEDLINE, 
EMBASE, Cochrane Library and Google search. OvidSP and PubMed were 
used as database gateways. All the relevant research literature can be 
retrieved from electronic databases with close to perfect sensitivity or 
specificity, or with high precision, by using comprehensive search strategies. 
To construct a comprehensive set of search terms, a combination of MeSH 
terms and free texts referring to subject headings and subheadings, is 
advocated (272). Therefore, multiple Mesh terms and free texts referring to 
the subject headings and subheadings were used to identify the relevant 
evidences as below:   
 
The search strategy 




3. In vivo 
4. Mouse module 
5. Chronic limb 
Ischaemia 
6. Critical limb 
ischaemia 
7. Induced ischaemia 














9. 2001 - 2017 
English 
language 
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The above keywords will be used in different combinations to increase the 
both sensitivity and specificity of the search. In order to include more 
evidence, articles published within the last 10 years are considered. Also, 
only the articles written in English are included to refine the search. Back 
chaining retrieval through the references of the electronically obtained 
evidences was applied to include more articles.  
The grey literature was not searched as a major limitation of the grey 
literature is that many of the studies reported are initiated in response to a 
political problem but with inadequate funding and unavoidable limitations that 
seriously undermine the credibility and value of the final product (Committee 
on Environmental Epidemiology, National Research Council. 1997). 
 
3. List of Awards, Publications and Presentations 
 
Awards 
 PVD Travel Award ($500) - Awarded by American Heart Association (AHA); 
Arteriosclerosis, Thrombosis  and Vascular Biology (ATVB) conference in 
Toronto; May 2014 
 
 Travel bursary (£100) - Awarded by Society of Academic & Research 
Surgery; SARS annual meeting in  Cambridge;  January 2014  
 
 Travel Scholarship ($1000) - Awarded by Society for Vascular Surgery (SVS) 
Research and Education  Committee;  Vascular Research Initiatives 
Conference and the  Arteriosclerosis, Thrombosis and  Vascular Biology 
meeting in Orlando;  April  2013 
 
 Bogue Research Fellowship (£2,500) - Awarded by University College 





Student Number: 110091643 
 
Publications 
 Navi A, Patel H, Shaw S, Baker D, Tsui J. Therapeutic Role of Toll-Like 
Receptor Modification in Cardiovascular Dysfunction. Vascular 
Pharmacology. 2012: 58(3): 231-9. [23070056] 
 
Published abstract  
 Navi A, Yu R, Abraham D, Shi-Wen X, Baker, Tsui J, Mouse Model of 
Ischaemia-induced Skeletal Muscle Damage. European Journal of Vascular 
and Endovascular Surgery, 2014; In Press 
 
 Navi A, Abraham D,  Shi-Wen X, Hamilton G,  Baker D, Tsui J. Critical Role of 
Toll-like Receptor 4 (TLR4) in Ischaemia-induced Skeletal Muscle Damage. 
ATVB. 2014; In Press 
 
 Navi  A, Abraham  D,  Shi-Wen X, Shaw S,  Baker D, Tsui J. Role of Toll-like 
receptor 4 (TLR4) inhibition in ischaemia-induced systemic inflammatory 
response and skeletal muscle damage. British Journal of Surgery, 2014; 100: 
31 
 
 Navi A, Abraham D,  Shi-Wen X, Shaw S,  Baker D, Tsui J.  Toll-like receptor 
4 (TLR4) inhibition reduces ischaemia-induced skeletal muscle damage. 
British Journal of Surgery, 2013 
 
 Navi A, Yu R, Shi-wen X, Shaw S, Hamilton G, Baker D, Tsui J. Detrimental 
role of  Heat  Shock  Protein  60&70  and  Toll-like  Receptor  4  in  skeletal 
muscle ischaemia in vitro. Journal of Vascular Surgery. 2013; 57(5): 77 
 
 Navi A, Shi-wen X, Shaw S, Hamilton G, Tsui J. Emerging Role of Toll-like 
Receptor 4 and Heat Shock Protein 60&70 in Ischaemia-Induced Skeletal 
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 Navi A, Yu R, Shi-wen X, Shaw S, Baker D, Tsui J. Detrimental role of 
MyD88-dependent signaling and Toll-like receptor 4 in ischaemia induced 
skeletal muscle damage in vitro. European Journal of Vascular and 
Endovascular Surgery, 2013; In Press 
 
 Navi A,  Patel H, Abraham  D,  Shi-Wen X,  Baker D, Tsui J.  Functional 
consequences of ischaemia-induced Toll-like Receptor 4 (TLR4) activation in 
skeletal muscle. British Journal of Surgery, 2013; 100: 15 
 
 Navi A, Abraham D, Shi-Wen X, Shaw S, Baker D, Tsui J. Functional up- 
regulation of toll-like receptor 4 and 1 in ischaemic skeletal muscle. 
Cardiovascular Pathology, 2013; 22(3): 31 
 
 Patel H, Navi A, Shi-Wen X, Abraham D, Baker D,, Shaw S, Tsui J. Toll-like 
receptor (TLR) 2 and 6 ligands and heat shock proteins 60 and 70 may play a 
role in the pathogenesis of skeletal muscle damage in critical limb ischaemia. 
Cardiovascular Pathology, 2013; 22(3): 3 
 
Oral Presentations 
 Critical Role of Toll-like Receptor 4 (TLR4) in Ischaemia-induced Skeletal 
Muscle Damage. Society for Vascular Surgery (SVS) Vascular Research 
Initiatives Conference, Toronto, Canada, April 2014 
 
 Role of Toll-like receptor 4 (TLR4) inhibition in ischaemia-induced systemic 
inflammatory response and skeletal muscle damage. Society of Academic 
and Research Surgery (SARS), Cambridge, January 2014 
 
 Detrimental role of MyD88-dependent signaling and Toll-like receptor 4 in 
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Vascular Surgery, Frankfurt, Germany, May 2013 
 
 Emerging Role of Toll-like Receptor 4 and Heat Shock Protein 60&70 in 
Ischaemia-Induced Skeletal Muscle Damage In Vitro. Society for Vascular 
Surgery (SVS) Vascular Research Initiatives Conference, Florida, USA, April 
2013 
 Functional consequences of ischaemia-induced Toll-like Receptor 4 (TLR4) 




 Mouse Model of Ischaemia-induced Skeletal Muscle Damage. European 
Society for Vascular Surgery, London, May 2014 
 
 Critical Role of Toll-like Receptor 4 (TLR4) in Ischaemia-induced Skeletal 
Muscle Damage. Arteriosclerosis, Thrombosis, and Vascular Biology 
Scientific Sessions Toronto, Canada, April 2014 
 
 Toll-like receptor 4 (TLR4) inhibition reduces ischaemia-induced skeletal 
muscle damage. Vascular Society (AGM), Manchester, November 2013 
 
 Detrimental role of Heat Shock Protein 60&70 and Toll-like Receptor 4 in 
skeletal muscle ischaemia in vitro. Society for Vascular Surgery (SVS) annual 
meeting, San Francisco, USA, June 2013 
 
 Emerging role of  Toll-like  Receptor  4  and  Heat  Shock  Protein  60&70  in 
ischaemia-induced skeletal muscle damage in vitro. Arteriosclerosis, 
Thrombosis, and Vascular Biology Scientific Sessions, Florida, May 2013 
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Muscle. International Society of Applied Cardiovascular Biology (ISACB), 
London, September 2012. 
 The Toll-like Receptor (TLR) 2 and 6 ligands Heat shock proteins (HSP) 60 
and 70 may play a role in the pathogenesis of skeletal muscle damage in 
critical limb ischaemia (CLI). International Society of Applied Cardiovascular 
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Functional upregulation of Toll-like Receptor 4 and 1 in Ischaemic 
Skeletal Muscle 
Ali Navi, Division of Surgery and Interventional Science, Royal Free Campus, 
UCL, London, UK; David Abraham, Centre for Rheumatology and 
Connective Tissue Disease, University College London, Royal Free Campus, 
London, UK; Xu Shi-Wen, Centre for Rheumatology and Connective Tissue 
Disease, University College London, Royal Free Campus, London, UK; 
Sidney G. Shaw, Department of Clinical Experimental Research, University 
of Bern, 3010 Bern, Switzerland; Daryll M. Baker, Division of Surgery and 
Interventional Science, Royal Free Campus, UCL, London, UK; Janice Tsui, 
Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK; 
Purpose: It has been suggested that the inflammation induced by ischaemia 
in peripheral arterial disease (PAD) has a key role in damaging lower limb 
skeletal muscle. TLR4 has been implicated in ischaemia and has been shown 
to form heterodimers with TLR 1. We aimed to study expression, activation 
and distribution of TLR4&1 in human critical limb ischaemia (CLI). Methods: 
Human skeletal muscle biopsies were taken from the medial head of 
gastrocnemius from patients undergoing major lower limb amputation due to 
CLI (n=6) and from patients with no PAD undergoing saphenous vein 
harvesting for CABG surgery (n=6). We carried out western blot analyses and 
immunofluorescence to study the TLR expression, activation and distribution 
in human skeletal muscle biopsy. Results: Western blot analyses on muscle 
homogenates showed upregulation of TLR4&1 in CLI (P<0.05); Furthermore, 
phosphorylated NFkB and JNK as key known signaling pathways were found 
to be increased in ischaemic samples (P<0.05) [Figure1]. TLR4&1 double 
staining of ischaemic muscle sections demonstrated co-localization of these 
receptors, suggestive of heterodimerisation. Also, we demonstrated TLR1 is 
expressed on endothelium (CD31), neutrophils (CD43) and macrophages 
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CLI. Also, Our study suggests that upregulated TLR4&1 are functional in CLI.  
Further studies are required to understand the downstream signalling, which 
may lead to the development of novel therapies. 
 
Expression and Distribution of Toll-like Receptor 4 and 1 in Ischaemic 
Skeletal Muscle 
Ali Navi, Division of Surgery and Interventional Science, Royal Free Campus, 
UCL, London, UK; David Abraham, Centre for Rheumatology and 
Connective Tissue Disease, University College London, Royal Free Campus, 
London, UK; Xu Shi-Wen, Centre for Rheumatology and Connective Tissue 
Disease, University College London, Royal Free Campus, London, UK; 
Sidney G. Shaw, Department of Clinical Experimental Research, University 
of Bern, 3010 Bern, Switzerland; Daryll M. Baker, Division of Surgery and 
Interventional Science, Royal Free Campus, UCL, London, UK; Janice Tsui, 
Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK; 
Purpose: It has been suggested that the inflammation induced by ischaemia 
in peripheral arterial disease (PAD) has a key role in damaging lower limb 
skeletal muscle. Toll-like receptors (TLRs) are key pattern recognition 
receptors in the innate immune system. TLR4 has been implicated in 
ischaemia. Also, TLR4 has been shown to form heterodimers with TLR1 in 
animal model. We aimed to define the changes in TLR4&1 expression and 
distribution in human critical limb ischaemia (CLI). Methods: We collected 
human skeletal muscle biopsies from the medial head of gastrocnemius from 
patients undergoing major lower limb amputation due to CLI (n=6) and from 
patients with no PAD undergoing saphenous vein harvesting for CABG 
surgery (n=6). We carried out western blot analyses and immunofluorescence 
to study the TLR expression and distribution in human skeletal muscle biopsy 
respectively. Results: Western blot analyses on muscle homogenates 
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double staining of ischaemic muscle sections demonstrated co-localization of 
these receptors, suggestive of TLR4&1 heterodimerisation. Furthermore, we 
demonstrated that the TLR1 is expressed on endothelium (CD31), neutrophils 
(CD43) and macrophages (CD68) in CLI. Conclusions: We showed that 
TLR4&1 are upregulated in CLI. Further studies are required to understand 
the downstream signalling, which may lead to the development of novel 
therapies aimed at reducing muscle damage. 
 
Downstream Signaling Pathway of Toll-like Receptor 4 and 1 in 
Ischaemic Skeletal Muscle 
Ali Navi, Division of Surgery and Interventional Science, Royal Free Campus, 
UCL, London, UK; David Abraham, Centre for Rheumatology and 
Connective Tissue Disease, University College London, Royal Free Campus, 
London, UK; Xu Shi-Wen, Centre for Rheumatology and Connective Tissue 
Disease, University College London, Royal Free Campus, London, UK; 
Sidney G. Shaw, Department of Clinical Experimental Research, University 
of Bern, 3010 Bern, Switzerland; Daryll M. Baker, Division of Surgery and 
Interventional Science, Royal Free Campus, UCL, London, UK; Janice Tsui, 
Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK; 
Purpose: The inflammation induced by ischaemia in peripheral arterial 
disease (PAD) has significant role in damaging lower limb skeletal muscle. 
Toll-like receptors (TLRs) are key pattern recognition receptors in the innate 
immune system. Whilst the upregulation of TLR4&1 has been shown in 
critical limb ischaemia (CLI), the activation of the related transcription factors 
has not been demonstrated. We aimed to identify the downstream signalling 
mechanisms contributing to cellular damage in ischaemic human skeletal 
muscle. Methods: We collected human skeletal muscle biopsies from the 
medial head of gastrocnemius from patients undergoing major lower limb 
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saphenous vein harvesting for CABG surgery (n=4). We carried out western 
blot analyses to quantify the amount of transcription factors in the human 
muscle biopsies. Results: Western blot analyses on muscle homogenates 
showed increased phosphorylated NFkB and phosphorylated JNK in CLI 
(P<0.05). Furthermore, western blot analyses of cleaved caspase 3 
expression was also performed to measure apoptosis within the muscle 
biopsies and this was found to be increased in the ischaemic samples 
(P<0.05) [Figure 1]. Conclusions: Our results suggest that both NFkB and 
JNK are activated in CLI. Further studies are required to establish the link 
between TLR4&1 and these transcription factors, which may lead to develop 
novel therapies aimed at reducing muscle damage. 
 
Functional consequences of ischaemia-induced Toll-like Receptor 4 
(TLR4) activation in skeletal muscle 
Ali Navi, Division of Surgery and Interventional Science, Royal Free Campus, 
UCL, London, UK; Hemanshu Patel, Division of Surgery and Interventional 
Science, Royal Free Campus, UCL, London, UK, David Abraham, Centre for 
Rheumatology and Connective Tissue Disease, University College London, 
Royal Free Campus, London, UK; Xu Shi-Wen, Centre for Rheumatology 
and Connective Tissue Disease, University College London, Royal Free 
Campus, London, UK; Daryll M. Baker, Division of Surgery and 
Interventional Science, Royal Free Campus, UCL, London, UK; Janice Tsui, 
Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK; 
Objectives: Inflammation contributes to ischaemia-induced myopathy in 
patients with peripheral arterial disease (PAD). TLR4 is a well-recognized 
pattern recognition receptor that has been implicated in ischaemia-induced 
tissue injury. We hypothesize that TLR4 is upregulated and its signalling 
pathway activated in cultured human myotubes exposed to simulated 
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from patients with critical limb ischaemia undergoing major lower limb 
amputation (Group 1) and from patients with no PAD (Group 2). Human 
myoblasts were isolated, cultured to myotubes and then pre-treated with 
TLR4 neutralizing antibody prior to exposure to simulated ischaemia. Western 
blot analysis of TLR4, P-NFkB (signal-related kinase) and cleaved caspase III 
were carried out on the cell lysates to assess TLR4 expression, downstream 
signalling activity and apoptosis respectively. Results: Upregulation of TLR4, 
P-NFkB and cleaved caspase III was observed after simulated ischaemia in 
both groups (P<0.05). Further, pre-treatment with TLR4 neutralizing antibody 
prior to simulated ischaemia reduced the expression of P-NFkB and cleaved 
caspase III in ischaemic cell lysates as compared to ischaemic cell lysates 
with no pre-treatment (P<0.05). Conclusion: TLR4 is upregulated and its 
downstream signalling pathway is activated in the ischaemic human 
myotubes in vitro. Further, inhibition of TLR4 prior to ischaemia was 
associated with inhibition of the signalling pathway and reduced ischaemia-
induced apoptosis. Further studies are required to understand the 
downstream signaling, which may lead to the development of novel therapies 
aimed at reducing muscle damage in patients with CLI. 
 
Emerging role of Toll-like Receptor 4 and Heat Shock Protein 60&70 in 
ischaemia-induced skeletal muscle damage in vitro 
Navi, A.1 Yu, R.1 Shi-wen, X.2 Shaw, S.3 Baker, D.1 Tsui, J.1 
1Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK. 2Centre for Rheumatology & Connective Tissue Disease, UCL, 
Royal Free Campus, UK. 3Department of Clinical Research, University of 
Bern, Switzerland 
OBJECTIVES: The innate immune response contributes to the skeletal 
muscle damage in patients with critical limb ischaemia (CLI); however, the 
detailed signaling mechanisms are not fully understood. We hypothesized 
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myotubes, via a mechanism that involves heat shock protein (HSP) 60&70, 
known endogenous ligands of Toll-like receptor 4 (TLR4), in vitro. 
METHODS: Human gastrocnemius muscle biopsies were taken from patients 
with CLI undergoing major lower limb amputation and from patients with no 
peripheral arterial disease (PAD). Human myoblasts were isolated, cultured to 
myotubes and then pre-treated with TLR4 neutralizing antibody prior to 
exposure to simulated ischaemia. Fluorescent immunostaining was carried 
out to confirm cell differentiation; ELISA analysis were carried out to quantify 
IL6 and TNFα release; and Western blot was used to assess expression of 
HSP60&70, TLR4 and cleaved caspase-3 as a marker of apoptosis. 
RESULTS: Myotubes from patients with CLI expressed greater levels of 
cleaved caspase-3 and TLR4 as compared to those from patients with no 
PAD. When exposed to ischaemic conditions, increased IL6 and TNFα 
release and upregulation of HSP60&70, cleaved caspase-3 and TLR4 were 
observed in myotubes from both groups of patients compared to culturing in 
normoxic conditions (P<0.05). Pre-treatment of myotubes from patients with 
CLI with TLR4 neutralizing antibody prior to simulated ischaemia was 
associated with reduced expression of HSP60&70, IL6, TNFα and cleaved 
caspase-3 (P<0.05). CONCLUSIONS: Increased cytokine release, apoptosis 
and expression of HSP60&70 and TLR4 occur in ischaemic skeletal muscle in 
vitro. TLR4 antagonism was associated with reduced apoptosis and 
inflammatory cytokine release and down-regulation of HSP60&70 expression. 
This suggests a potential pathway where TLR4 and its endogenous ligands 
contribute to a positive feedback loop to maintain a proinflammatory 
environment during ischaemia. 
 
Detrimental role of MyD88-dependent signaling and Toll-like receptor 4 
in ischaemia induced skeletal muscle damage in vitro. 
Navi, A.1 Shi-wen, X.2 Shaw, S.3 Baker, D.1 Tsui, J.1 
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London, UK. 2Centre for Rheumatology & Connective Tissue Disease, UCL, 
Royal Free Campus, UK. 3Department of Clinical Research, University of 
Bern, Switzerland 
Background: Mounting evidence supports a detrimental role of the innate 
immune system in the pathophysiology of skeletal muscle damage in patients 
with peripheral arterial disease (PAD); however, the downstream signaling 
pathway is poorly understood. Toll-like receptor 4 (TLR4) is a well-recognized 
pattern recognition receptor that has been implicated in ischaemia-induced 
skeletal muscle damage. We hypothesized that the MyD88 downstream 
signaling pathway is involved in regulating inflammatory gene transcription in 
TLR4-induced skeletal muscle damage in ischaemia. Methods: Human 
gastrocnemius muscle biopsies were taken from patients with critical limb 
ischaemia (CLI) undergoing major lower limb amputation and from patients 
with no PAD. Human myoblasts were isolated, cultured to myotubes and then 
pre-treated with MyD88 or TRIF inhibitor prior to exposure to simulated 
ischaemia. Fluorescent immunostaining was carried out to confirm cell 
differentiation; ELISA analyses were carried out to quantify IL6 and TNFα 
release; and Western blot was used to assess expression of TLR4, P-NFkB 
(transcription protein) and cleaved caspase-3 as a marker of apoptosis. 
Results: Increased IL6 and TNFα release and upregulation of TLR4, P-NFkB 
and cleaved caspase-3 were observed after simulated ischaemia in myotubes 
from both groups (P<0.05); however, myotubes from patients with CLI 
expressed greater levels as compared to those from patients with no PAD 
(P<0.05). Pre-treatment of myotubes from patients with CLI with MyD88 
inhibitor prior to ischaemia showed decreased IL6 and TNF-α release and 
down-regulation of cleaved caspase-3 (P<0.05). However, myotubes pre-
treated with TRIF inhibitor disclosed no significant changes in IL6 and TNFα 
release or cleaved caspase-3 expression. Conclusion: TLR4 is upregulated 
and its downstream signaling pathway is activated with increased cytokine 
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MyD88-dependent signaling pathway constrains inflammatory cytokine 
production in the presence of ischaemia-induced TLR4-activation. Further 
studies are required to understand the downstream signaling, which may lead 
to the development of novel therapies aimed at reducing muscle damage in 
patients with CLI. 
 
Detrimental role of Heat Shock Protein 60&70 and Toll-like Receptor 4 in 
skeletal muscle ischaemia in vitro 
Navi, A.1 Yu, R.1 Shi-wen, X.2 Shaw, S.3 Baker, D.1 Tsui, J.1 
1Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London 
2Centre for Rheumatology & Connective Tissue Disease, UCL, Royal Free 
Campus, UK 
3Department of Clinical Research, University of Bern, Switzerlan 
Objectives: The innate immune response contributes to the skeletal muscle 
damage in patients with critical limb ischaemia (CLI); however, the detailed 
signalling mechanisms are not fully understood. We hypothesised that 
simulated ischaemia induces inflammatory cytokine release from skeletal 
myotubes, via a mechanism that involves heat shock protein (HSP) 60&70, 
known endogenous ligands of Toll-like receptor 4 (TLR4), in vitro. Methods: 
Human gastrocnemius muscle biopsies were taken from patients with CLI 
undergoing major lower limb amputation and from patients with no peripheral 
arterial disease (PAD). Human myoblasts were isolated, cultured to myotubes 
and then pre-treated with TLR4 neutralizing antibody prior to exposure to 
simulated ischaemia. Fluorescent immunostaining was carried out to confirm 
cell differentiation; ELISA analysis were carried out to quantify IL6 and TNFα 
release; and Western blot was used to assess expression of HSP60&70, 
TLR4 and cleaved caspase-3 as a marker of apoptosis. Results: Myotubes 
from patients with CLI expressed greater levels of cleaved caspase-3 and 
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ischaemic conditions, increased IL6 and TNFα release and upregulation of 
HSP60&70, cleaved caspase-3 and TLR4 were observed in myotubes from 
both groups of patients compared to culturing in normoxic conditions 
(P<0.05). Pre-treatment of myotubes from patients with CLI with TLR4 
neutralizing antibody prior to simulated ischaemia was associated with 
reduced expression of HSP60&70, IL6, TNFα and cleaved caspase-3 
(P<0.05). Conclusion: Increased cytokine release, apoptosis and expression 
of HSP60&70 and TLR4 occur in ischaemic skeletal muscle in vitro. TLR4 
antagonism was associated with reduced apoptosis and inflammatory 
cytokine release and down-regulation of HSP60&70 expression. Here we 
report an intimate link between HSP60&70-induced inflammatory cytokine 
production and TLR4 inhibition in ischaemic human myotubes.  
 
Mouse Model of Ischaemia-induced Skeletal Muscle Damage 
*Navi, A.1 *Yu, R.1 Abraham, D.2 Shi-Wen, X.2 Baker, D.1 Tsui, J.1 
1Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK 
2Centre for Rheumatology & Connective Tissue Disease, UCL, Royal Free 
Campus, UK 
* Joint first authors 
Objectives: The role of ischaemia-induced myopathy in the poor functional 
outcomes of patients with critical limb ischaemia (CLI) is increasingly 
recognised, however, the detailed mechanisms involved are not fully 
understood. Accordingly, we aimed to develop a murine model of hind-limb 
ischaemia which recapitulates the pathophysiological changes seen in human 
CLI muscle to aid further studies in this area and to evaluate potential novel 
therapies. Methods: Firstly, changes in critically ischaemic human skeletal 
muscle were assessed in gastrocnemius biopsies taken from patients 
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changes were assessed using H&E staining. In order to identify a murine 
model which best recapitulates these changes, hindlimb ischaemia was 
induced by excision of common and superficial femoral artery and ligation of 
the side branches in BALB/c and C57BL/6 mice of 6 and 12 weeks of age. 
Tissue perfusion and evidence of morphological changes and damage within 
the ischaemic muscle were assessed at days 1, 3, 7, 14 and 21 by laser 
Doppler and H&E staining, respectively. Results: In line with previous 
reports, we demonstrated features of significant muscle fibre injury in muscle 
sections from CLI patients compared to non-ischaemic control donors.  These 
included loss of muscle fibres with concomitant fibroadipocytic changes, as 
well as variation in muscle fibre size and evidence of degeneration and 
necrosis.  Analysis of muscle biopsies from in vivo studies demonstrated a 
similar pattern of histomorphological changes in both C57BL/6 and BALB/c 
strains at day 7, 14 and 21.  However younger animals showed less severe 
muscle damage, and faster resolution of muscle injury (resolution by day 21). 
Conclusion: Excision of common and superficial femoral artery with ligation 
of the side branches in 12 week old mice resulted in reproducible ischaemia-
induced skeletal muscle changes that closely mimicked those that occur in 
human CLI.  This provides a useful pre-clinical model for further work 
including the assessment of novel muscle-protective adjunctive therapies for 
the treatment of CLI. 
 
Toll-like receptor 4 (TLR4) inhibition reduces skeletal muscle damage in 
critical limb ischaemia. 
Ali Navi, Division of Surgery and Interventional Science, Royal Free Campus, 
UCL, London, UK; David Abraham, Centre for Rheumatology and 
Connective Tissue Disease, University College London, Royal Free Campus, 
London, UK; Xu Shi-Wen, Centre for Rheumatology and Connective Tissue 
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Sidney G. Shaw, Department of Clinical Experimental Research, University 
of Bern, 3010 Bern, Switzerland; Daryll M. Baker, Division of Surgery and 
Interventional Science, Royal Free Campus, UCL, London, UK; Janice Tsui, 
Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London, UK; 
Objective: The innate immune response has emerging role in skeletal 
muscle damage in patients with critical limb ischaemia. We have previously 
shown that TLR4, a well-recognized pattern recognition receptor, is 
upregulated and functional in cultured human myotubes exposed to simulated 
ischaemia. We show herein that inhibition of TLR4 enhanced recovery from 
ischaemia-induced damage in skeletal muscle, in vivo. Methods: The hind-
limb ischaemia was induced by excision of common and superficial femoral 
arteries in wild-type (WT), endogenously deleted (TLR4-/-) and exogenously 
inhibited TLR4 (LPS-RS) mice (CL57/BL6, n=18 per group, 12 weeks old), 
while 9 animals per group were sham operated. The hind-limb tissue and 
serum samples were collected at day 3, 7 and 21, when laser Doppler and 
H&E staining were applied to measure haemodynamics and the inflammatory 
damage. TLR4 mRNA expression and systemic levels of IL-6 & TNFα were 
also examined by RT-PCR and ELISA, respectively. Results: Hind–limb 
ischaemia of WT mice demonstrated significant up-regulation of TLR4 mRNA 
expression when compared with sham operated WT mice (P=0.013). In 
addition, marked increase in the level of IL6 & TNFα (P<0.05) and slower 
blood flow recovery (P<0.05) were observed in WT mice in comparison with 
TLR4-/- and LPS-RS groups at day 3, 7 and 21. Further, WT mice displayed 
more severe ischaemia-induced inflammatory damage in the skeletal muscle 
after hind-limb ischaemia. Conclusion: TLR4 inhibition was associated with 
significant reduced damage to the skeletal muscle after the ischaemic insult. 
Here we report an intimate link between TLR4 signalling and ischaemia-
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Role of Toll-like receptor 4 (TLR4) inhibition in ischaemia-induced 
systemic inflammatory response and skeletal muscle damage 
Ali Navi, Royal Free London Vascular, London, UK; David Abraham, Centre 
for Rheumatology and Connective Tissue Disease, University College 
London, Royal Free Campus, London, UK; Xu Shi-Wen, Centre for 
Rheumatology and Connective Tissue Disease, University College London, 
Royal Free Campus, London, UK; Sidney G. Shaw, Department of Clinical 
Experimental Research, University of Bern, 3010 Bern, Switzerland; Daryll M. 
Baker, Royal Free London Vascular, London, UK; Janice Tsui, Royal Free 
London Vascular,  London, UK 
Introduction: The innate immune response plays an important role in 
skeletal muscle damage in hind-limb ischaemia, however the mechanism is 
not fully understood. Previously, we showed less apoptotic changes in 
cultured human myotubes in simulated ischaemia when TLR4, a pattern 
recognition receptor, was inhibited. Herein, we investigated whether TLR4 
inhibition reduces the ischaemia-induced skeletal muscle damage, via a 
mechanism that involves systemic IL6 and TNFα, in vivo. Methods: Hind-limb 
ischaemia was induced by excision of femoral artery in 12-week-old wild-type 
(WT) and TLR4-/- mice. Further, a group of CL57/BL6 mice received the 
TLR4 antagonist, LPS-RS (n=18 per group plus 9 sham operated per group). 
Laser Doppler was used to measure haemodynamic changes. Tissue 
collection and serum samples were obtained at day 3, 7 and 21. Systemic 
levels of IL-6 & TNFα, cleaved caspase-3 (marker of apoptosis) and 
inflammatory damage were examined by ELISA, Fluorescent IHC-P and H&E 
staining, respectively. Results: TLR4-/- mice and mice given LPS-RS, 
demonstrated reduced systemic IL6 & TNFα levels (P<0.05). This was 
associated with significant improved blood flow recovery (P<0.05), diminished 
apoptosis and attenuated inflammatory cell infiltration (P<0.05) in the skeletal 
muscle following hind-limb ischaemia as compared to WT mice at day 3, 7 
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TLR4 were associated with reduced systemic IL6 & TNFα levels and skeletal 
muscle damage following hind-limb ischaemia. Here we report an intimate link 
between ischaemia-induced systemic inflammatory cytokine production and 
TLR4 inhibition. 
 
Toll-like receptor 4 (TLR4) inhibition reduces ischaemia-induced skeletal 
muscle damage. 
Ali Navi, Royal Free London Vascular, London, UK; David Abraham, Centre 
for Rheumatology and Connective Tissue Disease, University College 
London, Royal Free Campus, London, UK; Xu Shi-Wen, Centre for 
Rheumatology and Connective Tissue Disease, University College London, 
Royal Free Campus, London, UK; Sidney G. Shaw, Department of Clinical 
Experimental Research, University of Bern, 3010 Bern, Switzerland; Daryll M. 
Baker, Royal Free London Vascular, London, UK; Janice Tsui, Royal Free 
London Vascular,  London, UK 
Objective: There is an emerging role for the innate immune response in 
skeletal muscle damage in critical limb ischaemia. We have shown that TLR4, 
a pattern recognition receptor, is upregulated and functional in cultured 
human myotubes exposed to simulated ischaemia. This study investigates 
the effect of TLR4 inhibition on ischaemia-induced skeletal muscle damage in 
vivo. Methods: Hindlimb ischaemia was induced by excision of femoral artery 
in 12 week old wild-type (WT) and TLR4-/- mice. In addition, a group of 
CL57/BL6 mice received the TLR4 antagonist LPS-RS (n=18 per group plus 9 
sham operated per group). Laser Doppler was used to measure 
haemodynamic changes. Tissue collection and serum samples were obtained 
at day 3, 7 and 21. TLR4 mRNA expression, systemic levels of IL-6 & TNFα 
and inflammatory damage were examined by RT-PCR, ELISA and H&E 
staining, respectively. Results: TLR4 mRNA was upregulated in ischaemic 
skeletal muscle of WT mice (P<0.05 compared to sham operated controls). 
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recovery (P<0.05), reduced systemic IL6 & TNFα levels (P<0.05) and 
attenuated histological evidence of ischaemia-induced inflammation following 
hindlimb ischaemia as compared to WT mice at days 3, 7 and 21. 
Conclusion: TLR4 upregulation occurs in ischaemic skeletal muscle in vivo. 
Furthermore, endogenous deletion and exogenous inhibition of this receptor 
were associated with reduced skeletal muscle damage and systemic 
inflammatory markers following hindlimb ischaemia, implicating its role in 
ischaemic skeletal muscle damage. 
 
Critical Role of Toll-like Receptor 4 (TLR4) in Ischaemia-induced 
Skeletal Muscle Damage 
Navi, A.1 Abraham, D.2 Shi-wen, X.2 Hamilton G. 1 Baker, D.1 Tsui, J.1 
1Division of Surgery and Interventional Science, Royal Free Campus, UCL, 
London 
2Centre for Rheumatology & Connective Tissue Disease, UCL, Royal Free 
Campus, UK 
Objectives: Inflammation contributes to skeletal muscle damage in patients 
with critical limb ischaemia (CLI), in whom patient oriented functional 
outcomes are poor. Previously, we showed that TLR4, a pattern recognition 
receptor, is upregulated and activated in skeletal muscle of patients with CLI. 
This study aimed to investigate whether the TLR4 pathway contributes to 
skeletal muscle damage in CLI, using in vitro and in vivo models. Methods: 
Human myoblasts, isolated from skeletal muscle biopsies, were cultured to 
myotubes and exposed to simulated ischaemia, with or without TLR4 inhibitor 
pre-treatment. Western blot analyses of P-NFkB (signal-related kinase) and 
cleaved caspase-3 were carried out on cell lysates to assess downstream 
signalling activity and apoptosis respectively. Further, hind-limb ischaemia by 
excision of femoral artery was induced in 12-week old TLR4-/- and wild-type 
(WT) mice with and without administration of the TLR4 antagonist, LPS-RS 
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inflammatory damage and apoptosis within the ischaemic muscle were 
assessed at days 3, 7 and 21 by ELISA, laser Doppler, H&E staining and 
Fluorescent IHC-P, respectively. Results: Simulated ischaemia in cultured 
human myotubes was associated with upregulation of TLR4, P-NFkB and 
cleaved caspase-3. Pre-treatment with TLR4 inhibitor reduced P-NFkB and 
cleaved caspase-3 expression (P<0.05). In in vivo studies, TLR4-/- mice and 
mice given LPS-RS exhibited reduced systemic IL6 & TNFα levels (P<0.05) 
following hind-limb ischaemia. This was associated with improved tissue 
perfusion recovery (P<0.05), reduced inflammatory cell infiltration and 
diminished apoptosis (P<0.05) in the ischaemic limb as compared to 
untreated WT mice at days 3, 7 and 21. Conclusion: TLR4 inhibition prior to 
ischaemia in human myotubes in vitro, was associated with inhibition of the 
signalling pathway and reduced ischaemia-induced apoptosis. Further, 
endogenous deletion and exogenous inhibition of TLR4 in vivo were 
associated with reduced systemic IL6 & TNFα levels and skeletal muscle 
damage following hind-limb ischaemia. These findings suggest that TLR4 
plays a key role in ischaemia-induced skeletal muscle damage. 
 
Role of Toll-like receptor 4 (TLR4) inhibition in ischaemia-induced 
systemic inflammatory response and skeletal muscle damage 
Ali Navi, Royal Free London Vascular, London, UK; David Abraham, Centre 
for Rheumatology and Connective Tissue Disease, University College 
London, Royal Free Campus, London, UK; Xu Shi-Wen, Centre for 
Rheumatology and Connective Tissue Disease, University College London, 
Royal Free Campus, London, UK; Sidney G. Shaw, Department of Clinical 
Experimental Research, University of Bern, 3010 Bern, Switzerland; Daryll M. 
Baker, Royal Free London Vascular, London, UK; Janice Tsui, Royal Free 
London Vascular,  London, UK 
Introduction: The innate immune response plays an important role in 
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not fully understood. Previously, we showed less apoptotic changes in 
cultured human myotubes in simulated ischaemia when TLR4, a pattern 
recognition receptor, was inhibited. Herein, we investigated whether TLR4 
inhibition reduces the ischaemia-induced skeletal muscle damage, via a 
mechanism that involves systemic IL6 and TNFα, in vivo. Methods: Hind-limb 
ischaemia was induced by excision of femoral artery in 12-week-old wild-type 
(WT) and TLR4-/- mice. Further, a group of CL57/BL6 mice received the 
TLR4 antagonist, LPS-RS (n=18 per group plus 9 sham operated per group). 
Laser Doppler was used to measure haemodynamic changes. Tissue 
collection and serum samples were obtained at day 3, 7 and 21. Systemic 
levels of IL-6 & TNFα, cleaved caspase-3 (marker of apoptosis) and 
inflammatory damage were examined by ELISA, Fluorescent IHC-P and H&E 
staining, respectively. Results: TLR4-/- mice and mice given LPS-RS, 
demonstrated reduced systemic IL6 & TNFα levels (P<0.05). This was 
associated with significant improved blood flow recovery (P<0.05), diminished 
apoptosis and attenuated inflammatory cell infiltration (P<0.05) in the skeletal 
muscle following hind-limb ischaemia as compared to WT mice at day 3, 7 
and 21. Conclusions: Endogenous deletion and exogenous inhibition of 
TLR4 were associated with reduced systemic IL6 & TNFα levels and skeletal 
muscle damage following hind-limb ischaemia. Here we report an intimate link 
between ischaemia-induced systemic inflammatory cytokine production and 
TLR4 inhibition. 
 
Toll-like receptor 4 (TLR4) inhibition reduces ischaemia-induced skeletal 
muscle damage. 
Ali Navi, Royal Free London Vascular, London, UK; David Abraham, Centre 
for Rheumatology and Connective Tissue Disease, University College 
London, Royal Free Campus, London, UK; Xu Shi-Wen, Centre for 
Rheumatology and Connective Tissue Disease, University College London, 
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Experimental Research, University of Bern, 3010 Bern, Switzerland; Daryll M. 
Baker, Royal Free London Vascular, London, UK; Janice Tsui, Royal Free 
London Vascular,  London, UK 
Objective: There is an emerging role for the innate immune response in 
skeletal muscle damage in critical limb ischaemia. We have shown that TLR4, 
a pattern recognition receptor, is upregulated and functional in cultured 
human myotubes exposed to simulated ischaemia. This study investigates 
the effect of TLR4 inhibition on ischaemia-induced skeletal muscle damage in 
vivo. Methods: Hindlimb ischaemia was induced by excision of femoral artery 
in 12 weeks old wild-type (WT) and TLR4-/- mice. In addition, a group of 
CL57/BL6 mice received the TLR4 antagonist LPS-RS (n=18 per group plus 9 
sham operated per group). Laser Doppler was used to measure 
haemodynamic changes. Tissue collection and serum samples were obtained 
at day 3, 7 and 21. TLR4 mRNA expression, systemic levels of IL-6 & TNF-α 
and inflammatory damage were examined by RT-PCR, ELISA and H&E 
staining, respectively. Results: TLR4 mRNA was upregulated in ischaemic 
skeletal muscle of WT mice (P<0.05 compared to sham operated controls). 
TLR4-/- mice and mice given LPS-RS demonstrated improved blood flow 
recovery (P<0.05), reduced systemic IL6 & TNFα levels (P<0.05) and 
attenuated histological evidence of ischaemia-induced inflammation following 
hindlimb ischaemia as compared to WT mice at days 3, 7 and 21. 
Conclusion: TLR4 upregulation occurs in ischaemic skeletal muscle in vivo. 
Furthermore, endogenous deletion and exogenous inhibition of this receptor 
were associated with reduced skeletal muscle damage and systemic 
inflammatory markers following hindlimb ischaemia, implicating its role in 
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5. Patient information sheet, consent form and data collection form 
 
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON  
Address for Correspondence:  
University Department of Surgery 
Royal Free Campus 
The Royal Free Hospital  
Pond Street, 
London NW3 2QG 
Telephone: 020 77940500 
 Facsimile: 02074726711 
 
PATIENT INFORMATION SHEET  
Study Title: A study of muscle injury in peripheral vascular disease 
You are invited to participate in a research study. This information sheet 
explains why we are conducting this study and how it is being done. Please 
take some time to read the information carefully and to decide whether you 
would like to take part or not. Please discuss it with your  family and friends 
as you wish and ask us if you have any questions.  
What is the purpose of this study?  
The aim of this project is to study some aspects of peripheral vascular 
disease which are not well understood. Peripheral vascular disease is a 
common condition where the blood supply to the legs is impaired and the leg 
muscles are damaged. At present, treatment includes bypass surgery to 
improve the circulation. We aim to study the mechanisms that are involved in 
causing muscle damage secondary to peripheral vascular disease. A better 
understanding of these mechanisms may improve treatment for this disease 
in the future.  
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You have been invited to take part either because you suffer from peripheral 
vascular disease or because the operation you will be undergoing is similar in 
many ways to that done for peripheral vascular disease. This allows us to 
collect suitable samples for analyses and make appropriate comparisons.  
Do I have to take part?  
You do not have to take part in this study if you do not want to. If you decide 
to take part you may withdraw at any time without giving a reason. Your 
decision to take part or not will not affect your care in any way.  
What will happen to me if I take part?  
Up to 2 calf muscle samples, each the size of a small pea, will be taken 
during the operation. These are for the study and not part of the treatment. 
None of these should cause any ill effect or additional discomfort and will not 
affect your recovery from your operation.  
What do I have to do?  
You do not have to do anything more than you need to for your operation. 
What are the possible disadvantages and risks in taking part?  
You will have small samples of your calf muscle taken. However, these will 
be done during the operation when you are asleep and so will not cause any 
discomfort. Your treatment and recovery will not be affected.  
What are the possible benefits of taking part?  
This study will help us improve treatment for this condition in the future. 
However, at this stage, there will be no immediate benefits to you.  
What if something goes wrong?  
This study does not involve any extra treatment or any high-risk procedures 
so nothing is likely to go wrong. However, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms may 
be available to you.  
Will taking part in this study be kept confidential?  
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kept strictly confidential.  
What happens to the results of the research study?  
Results from this study will be published in a medical journal in approximately 
a year's time. However you will not be identified in any report or publication. If 
you wish to know the outcome of the study, you can do so by contacting us.  
Who is organizing and funding the research?  
This study is organised and funded by the Vascular Unit of the Department of 
Surgery.  
Who has reviewed the study?  
The Research Ethics Committee of the Royal Free Hospital has reviewed this 
study. If you have any questions or queries at any stage, please contact: 
Miss Janice Tsui 
University Department of Surgery 
Royal Free Hospital 
Pond Street 
London NW3 2QG 
Tel: 020-7794-0500 Ext 33938  
You will be given a copy of the information sheet and a signed consent form 



















Project Title: Study of Muscle Injury in Peripheral Vascular Disease 
Researcher: Miss Janice Tsui & _______________________ 
1. I confirm that I have read and understood the information sheet provided 
for the above study and have had the opportunity to ask questions. 
2. I confirm that I have had sufficient time to consider whether or not I want to 
be included with the study 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reasons, without my medical care or 
legal rights being affected. 
4. I understand that sections of my medical notes may be looked at by 
responsible individuals from NHS or from regulatory authorities where it is 
relevant to my taking part in the research. I understand that samples of my 
muscle may be kept up to 6 months for other studies. 
5. I agree to take part in the above study 
 
Name of patient      Date 
Signature 




















Sample Type:  













Date of Birth: 
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6. Ethics approval and personal licence 
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7. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 
2009) 
Level Therapy / 
Prevention, 
Aetiology / Harm 
















Level 1 diagnostic 
studies; CDR with 












cohort study with > 
80% follow-up; 
CDR validated in a 
single population 
Validating cohort 
study with good 
reference 
standards; or CDR 
tested within one 
clinical centre 
Prospective cohort 
study with good 
follow-up 




All or none case-
series 






cohort studies or 
untreated control 
groups in RCTs 
SR (with 
homogeneity) of 




2b and better 
studies 
2b Individual cohort 
study (including 




cohort study or 
follow-up of 
untreated control 
patients in an RCT; 
Derivation of CDR 






after derivation, or 











 Ecological studies 




 SR (with 
homogeneity) of 3b 
and better studies 
SR (with 
homogeneity) of 
3b and better 
studies 








cohort study, or 
very limited 
population 
4 Case-series (and 















5 Expert opinion 
without explicit 
critical appraisal, 
or based on 
physiology, bench 





or based on 
physiology, bench 




critical appraisal, or 
based on 
physiology, bench 





or based on 
physiology, bench 
research or “first 
principles” 
 
Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon 
Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy 
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Figure 86 - Dardik model of hind-limb ischaemia 
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Figure 87 - A) Demonstrating the anatomy of the mouse hind limb, supine 
position. Extensive dissection of the skin and fascia is for the purpose of 
demonstration. Common femoral artery appears below the inguinal ligament 
and gives off two main branches of epigastric and profunda before it forms 
superficial femoral artery. B) Demonstrating the anatomy of the left mouse 
hindlimb after ligation of the femoral artery at the proximal and distal sites 
before the excision of the superficial femoral artery. Tissue necrosis on C) day 
7, D) Day 14 after surgery in 11 weeks old male BALB/c mouse. 
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Figure 88 - A, B) Duplex machine with the probe suitable for very small vessels; 
C,D) Duplex images of proximal and distal aorta; E,F) Duplex images of 
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Figure 89 -  Messina model of acute limb ischaemia 
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